Abstract
Caregivers, employment, and healthcare utilization
P001
Caregiver’s burden in multiple sclerosis is higher in Mexican population
1CMN 20 de Noviembre, Neurology, Mexico, Mexico
P002
How do MS patients’ sickness absence and disability pension trajectories develop over time? A nationwide cohort study of 3 543 MS patients
1Karolinska Institutet, Stockholm, Sweden
Characterize MS patients’ SA/DP trajectory from five years before to five years after diagnosis and compare this with matched controls,
Explore if the progression of MS patients’ SA/DP trajectories are associated with socio-demographics.
P003
Knowledge and attitude towards multiple sclerosis in Turkey
1Dumlupınar University Faculty of Medicine, Department of Neurology, Kutahya, Turkey, 2Çanakkale 18 Mart University Faculty of Medicine, Department of Neurology, Çanakkale, Turkey
The number of participants who would allow their child marrying someone with MS was significantly higher in MS patient group than control group (p < 0.05). Of the patient and relatives groups 4(%5.6) and 6(%13) had decided to use alternative herbal medicine in addition to medical treatment, respectively.
In the control group 7(17.5%) of them thought not to employ a MS patient, while 27 (67%) of them thought to employ a MS patient for only easy works.
P004
Early loss of working capability in a Swiss cohort of patients with multiple sclerosis
1Inselspital, University Hospital Bern and University of Bern, Neurology, Bern, Switzerland, 2Christian-Doppler-Klinik, Paracelsus Medical University, Neurology, Salzburg, Austria, 3Klinikum rechts der Isar, Technische Universität München, Neurology, München, Germany
P005
Profile of social participation of multiple sclerosis adults in Québec city
1Université Laval, CIRRIS (Center for Interdisciplinary Research in Rehabilitation and Social Integration), Quebec, QC, Canada, 2Université Laval, School of Social Work, Quebec, QC, Canada
Describe the social participation of people living with MS, and
determine what personal factors may influence it.
balance problems and leg weakness explained variance in Mobility scores,
depression and sexual problems in Interpersonal relationship scores, and
leg weakness and cognitive changes in Leisure scores.
P006
Determinants of stigma experienced by patients suffering from multiple sclerosis. A Hellenic population study
1Medical School of National and Kapodistrian University, 1st Dept of Neurology, Athens, Greece, 2Medical School of National and Kapodistrian University, 1st Dept of Psychiatry, Athens, Greece
P007
A 10-year longitudinal study of use of and satisfaction with health care in a population-based sample of people with MS
1Karolinska Institute, Neurobiology, Care Science and Society, Stockholm, Sweden, 2Karolinska University Hospital, Department of Physiotherapy, Stockholm, Sweden, 3Karolinska Institutet, Neurobiology, Care Science and Society, Division of Nursing, Huddinge, Sweden
P008
Differences in health care utilization over 10 years between people with MS who entered a nursing home and those who did not
M Finlayson1,
1Queen’s University, Kingston, ON, Canada, 2University of Manitoba, Winnipeg, ON, Canada, 3Manitoba Centre for Health Policy, Winnipeg, ON, Canada
For ambulatory physician visits, the 10-year trajectories were similar across the cases and controls up until the 9th year, when the cases experienced an increase in visits in the year before NH entry.
Days in hospital remained relatively stable over time for controls but began to increase at year 5 for cases with a more marked increase in the two years prior to NH entry.
For the number of prescription medications, the 10-year trajectories for the controls saw increases of 1-3 prescriptions versus 1-7 prescriptions for cases.
P009
Multiple sclerosis relapses: economic impact of oral high-dosecorticosteroids
1Rennes University Hospital, Epidemiology and Public Health, Rennes, France, 2Rennes University Hospital, Neurology, Rennes, France
Patients inclusion and exclusion : cf COPOUSEP trial
Points of view : societal and health insurance perspectives
Primary endpoint : Incremental Cost-Effectiveness Ratio (ICER): cost for one more patient improved by the treatment
Time horizon: 28 days after the beginning of treatment for the main analysis and 90 days for the second analysis
Acquisition of data : Direct costs (medical, non-medical) and indirect costs are collected by loading patients’ data from the French national health insurance database linked to the national hospital discharge database[1]
Costs valuation : Medical costs are recovered from the rate of reimbursement for health insurance and patient financial contribution for medical costs. Indirect costs are valued by the method of human capital (productivity loss) from daily allowance reimbursed by health insurance. Non-medical costs are valued at average cost of an equivalent resource on the market (replacement cost) taking into account frequency and duration.
1 http://www.ameli.fr/fileadmin/user_upload/documents/SNIIRAM_database_at_a_glance.pdf
Clinical trial results are now available (cf Dr E Le Page abstract). Economic analysis is being process. Following results, will be available in June: total costs, part of each item of expenditure, average cost per patient in each treatment group, and globally ICER (cost per patient improved).
P010
Treatment patterns and budget impact of dalfampridine in multiple sclerosis: a retrospective claims database analysis
S Palli1,
1HealthCore, Inc., Wilmington, DE, United States, 2Acorda Therapeutics, Inc., Ardsley, NY, United States
P011
Greater cost savings associated with disability improvement in patients treated with alemtuzumab versus interferon beta-1a
1Stanford University School of Medicine, Stanford, CA, United States, 2Express Scripts, Waldwick, NJ, United States, 3Genzyme, a Sanofi Company, Cambridge, MA, United States, 4Sanofi R & D, Bridgewater, NJ, United States
disability costs associated with EDSS score distribution at the study end, and
net change in disability costs from baseline weighted by probability of EDSS improvement or worsening from baseline EDSS score.
Yearly disability costs adjusted for inflation were estimated and the United Kingdom (UK) disability cost estimates were applied as a sensitivity analysis.
P012
Economic burden of multiple sclerosis: a systematic review of the literature
AO Ashaye1, S Cadarette1,
1Evidera, Lexington, MA, United States, 2Biogen Idec Inc., Cambridge, MA, United States
P013
Cost-effectiveness of alemtuzumab vs subcutaneous interferon beta-1a for treatment of active relapsing-remitting multiple sclerosis: payer perspective
1Genzyme, a Sanofi Company, Cambridge, MA, United States, 2University of Alabama at Birmingham, Department of Biostatistics, Birmingham, AL, United States, 3University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, 4Genzyme, a Sanofi Company, Stockholm, Sweden
P014
Sources of income for individuals with multiple sclerosis: a nationwide population-based study in Sweden
1Karolinska Institutet, Stockholm, Sweden
P015
Prevalence of complications in hospitalized multiple sclerosis patients among different age groups: national perspective
1Icahn School of Medicine at Mount Sinai, New York, NY, United States, 2Houston Methodist Hospital, Houston, TX, United States, 3Mount Sinai Hospital, New York, NY, United States, 4Mount Sinai St. Luke’s, New York, NY, United States, 5Saint Louis University, Saint Louis, MO, United States, 6Detroit Medical Center, Detroit, MI, United States, 7Michigan State University, East Lansing, MI, United States
P016
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
S Tauhid1, R Chu1, R Sasane2, BI Glanz1, M Neema1, JR Miller1, G Kim1, JE Sigornivich3, BC Healy1, T Chitnis1, HL Weiner1,
1Harvard/BWH, Boston, MA, United States, 2Novartis Pharmaceuticals, East Hanover, NJ, United States, 3Analysis Group, Boston, MA, United States
P017
Treatment patterns and cost in multiple sclerosis - a cross-sectional study from Slovakia
1F.D.Roosevelt Teaching Hospital, Neurology, Banska Bystrica, Slovakia, 2Pharm-In, Bratislava, Slovakia
P018
Multiple sclerosis and variation in health utilities: a systematic review of the literature
AO Ashaye1, S Cadarette1,
1Evidera, Lexington, MA, United States, 2Biogen Idec Inc., Cambridge, MA, United States
P019
Cost of MS - patients’ burden in Norway
1Haukeland University Hospital, Department of Neurology, Bergen, Norway, 2University of Bergen, Department of Clinical Medicine, Bergen, Norway
The average annual (2013) total, indirect plus direct, economic cost to patients was € 11,337. Indirect economic cost, loss of income, accounted for 63 %. Remodelling of houses, € 1,590, constituted the most important direct economic cost - patients’ payment for resources used due to the disease. Direct economic cost was close to identical for females and males. Indirect economic cost was close to 10 % higher for males, mainly due to higher salaries before diagnosis. Over a period of 30 years, the present value of the average annual total economic cost amounted to € 258,986 when a 2 % discount rate was used to adjust for differential timing of costs. In general, costs inceased with progressive disease severity, and patients with a rapid disability progression had a much higher cost than patients that progressed more slowly. For patients among the 10 % with the most rapid progression, the present value of the 30-year annual total economic costs from disease onset might easily exceed € 410,000 and be expected to come close to € 600.000 in extreme cases. For patients among the 10 % with the slowest progression expected present value ranged from € 29,000 to € 97,000.
P020
Updates from the Sonya Slifka longitudinal multiple sclerosis study and the comprehensive analysis of the direct and indirect costs of MS study
1Brigham and Women’s Hospital, Harvard Medical School, Psychiatry, Boston, MA, United States
A Comprehensive Analysis of the Direct and Indirect Costs of MS (MS Costs) was designed to produce detailed estimates of the types, amounts, and costs of health services used and health-related purchases made by individuals with MS.
P021
Improving clinical outcomes and healthcare resources utilization in multiple sclerosis: a Portuguese hospital perspective
1Novartis Farma - Produtos Farmacêuticos S.A., Porto Salvo, Portugal
P022
The economic cost of a multiple sclerosis relapse
1St Vincents University Hospital, Dublin, Ireland, 2National Centre for Pharmacoeconomics, St James’ Hospital, Dublin, Ireland
P023
MS disease severity does not affect patient or clinician satisfaction with clinic visits when using the FILMS quality of life assessment
1Jordan Research & Education Institute, Berkeley, CA, United States, 2Kaiser Permanente, Oakland, CA, United States, 3Alta Bates Summit Medical Center, Berkeley, CA, United States, 4Central Texas Neurology Consultants, Round Rock, TX, United States, 5UT Southwestern Medical Center at Dallas, Dallas, TX, United States
Patient perception: Overall patient satisfaction for the visits was not correlated with clinician rated disease severity. All 9 patients with severe disease responded that they were satisfied with both visits 1 and 2. 76 patients with mild disease had greater odds of being satisfied with visit 2 (FILMS) and not satisfied with visit 1 (no FILMS) however this correlation did not prove to be statistically significant (p=0.69)
Clinician Perception: Clinicians’ satisfaction with visits when FILMS was not used and when FILMS was used was not correlated with patient disease severity. Clinicians were more likely to be satisfied with the visit when FILMS was used whether the patient’s disease severity was rated mild (p=0.0002) or severe (p=0.01).
P024
People with multiple sclerosis unmet perceived needs point toward a personalised intervention
M Ponzio1, P Zaratin1, C Vaccaro2,
1Italian Foundation of Multiple Sclerosis, Scientific Reseach Area, Genoa, Italy, 2Fondazione CENSIS, Rome, Italy, 3University of Siena, Department of Physiopathology, Experimental Medicine and Public Health, Siena, Italy
P025
A health resource utilization in Thai patients with idiopathic inflammatory demyelinating central nervous system disorders
C Chanatittarat1,
1Social and Administrative Pharmacy Excellence Research (SAPER) Unit, Pharmacy, Mahidol University, Bangkok, Thailand, 2Division of Neurology,Siriraj Hospital, Bangkok, Thailand, 3Bumrungrad International Hospital, Neurology Dept., Bangkok, Thailand, 4Sriphat Medical Center, Chiang Mai University, Chiang Mai, Thailand
P026
The impact of persistence with therapy on hospitalization and emergency room visits in the US among patients with multiple sclerosis
A Farr1, S Curkendall2, E Yu3,
1Truven Health Analytics, Life Sciences, Cambridge, MA, United States, 2Independent Consultant, Bend, OR, United States, 3Genentech, San Francisco, CA, United States
P027
National estimates on the prevalence and characteristics of medicare patients using treatments for multiple sclerosis and related symptoms in the USA
1University of Pennsylvania, Department of Neurology, Philadelphia, PA, United States, 2University of Pennsylvania, Department of Medicine, Philadelphia, PA, United States
We linked individuals with their prescription drug claims through Medicare Parts B & D. Logistic regressions were used to identify factors associated with DMT use.
Cases most commonly received symptomatic treatment for pain (80%), followed by spasticity (57%), seizures (42%), tremor (27%), incontinence (25%), fatigue (14%), cognitive dysfunction (8%) and gait dysfunction (4%).
After adjustment for potential confounders including age and socioeconomic status, individuals≤ 65 years old were more likely to be treated (Odds Ratio (OR) 2.77 p< 0.001) compared to individuals 65-69 years-old. Individuals receiving treatment for gait dysfunction, fatigue or urinary incontinence were more likely to be on DMT (OR 3.06, 2.07, and 1.52, respectively; p< 0.001).
Within the treated subgroup, younger age and fatigue treatment were associated with use of Interferon beta-1a, Glatiramer acetate and Natalizumab (OR 1.9-3.66, p< 0.001 and OR 1.37 - 1.7, p≤0.01, respectively). Treatment for incontinence was associated with Interferon beta-1b and Natalizumab use (OR 1.41 -1.85, p≤0.03). Treatment for gait dysfunction was associated with Glatiramer acetate and Natalizumab use (OR 2.46 - 3.35, p< 0.001).
P028
MS with versus without relapse - the economic perspective in the PEARL study
1Novartis Pharma GmbH, Nuremberg, Germany, 2Universitätsklinikum Karl Gustav Carus, Dresden, Germany
In the first study year, 411 patients relapsed at least once (
MS-related sick leave was more frequent among ACTIVE patients even in the quarter before the study began, throughout the two years and up to the last quarter (A: 33%→18%, I: 18%→8%, [of patients/quarter]). Sick leave duration per sick leaving patient declined over the two years comparably in both groups (A: 21→14 d, I: 22→14 d).
More ACTIVE patients were hospitalized prior to the study, throughout and up to the end of the study (A: 7.1%→3.3%, I: 4.0%→1.2%, [of patients/quarter]). Duration of hospitalization due to MS declined less in ACTIVE patients (A: 7.2→6.4, I: 9.8→4.5, [days/hospitalization]).
Rehabilitation stays were more often in ACTIVE patients declining over the two years and assimilating among groups (A: 2.7%→1.4%, I: 1.8%→1.0%, [of patients/year]). Duration of rehabilitation was comparable among groups and over time (A: 30→24, I: 25→28, [days/stay]).
P029
Impact of improved adherence to disease-modifying therapies on healthcare resource utilization and medical costs for patients with multiple sclerosis
1Analysis Group Inc, Boston, MA, United States, 2Biogen Idec Inc., Weston, MA, United States, 3Biogen Idec Inc., Cambridge, MA, United States
P030
Application of the RAND/UCLA method to explore the appropriateness of current and emerging treatments for relapsing-remitting multiple sclerosis
1Ismar Healthcare, Centre for Decision Analysis and Support, Lier, Belgium, 2VU University Medical Center, Department of Radiology, Amsterdam, Netherlands, 3Innsbruck Medical University, Clinical Department of Neurology, Innsbruck, Austria, 4U.O.C. Neurologia, Department of Neuroscience, Rome, Italy, 5Salpêtrière Hospital, Department of Neurology, Paris, France, 6CHU de Reims, Department of Neurology, Reims, France, 7University Clinic Carl Gustav Carus, Department of Neurology, Dresden, Germany
P031
Presenteeism and quality of life between MS patients and healthy workers
A Ferreira1, AM Passos1,
1Instituto Universitário de Lisboa (ISCTE-IUL), Business Research Unit, Lisboa, Portugal, 2Hospital de São João, Porto, Portugal
To compare productivity in spite of both presenteeism and QoL of individuals with and without MS
To analyze the influence of psychological antecedents of depression and anxiety on productivity in spite of presenteeism and QoL of MS patients.
P032
Patterns of use of tests to monitor disease activity among patients with relapsing remitting multiple sclerosis in the United States and Europe
1Ipsos Healthcare, New York, NY, United States, 2Ipsos Healthcare, Columbia, MD, United States, 3Ipsos Healthcare, London, United Kingdom
Clinical outcome measures
P033
Video-based paired-comparison ranking: a validation tool for fine-grained measures of motor dysfunction in multiple sclerosis
1VU University Medical Center, Amsterdam, Netherlands, 2University Hospital Basel, Basel, Switzerland, 3Novartis Pharma AG, Basel, Switzerland, 4Microsoft Research, Cambridge, United Kingdom, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
P034
eEDSS - an electronic capturing of standardized neurological assessments with real time feedback as a tool to improve consistency. A validation study
1Universitiy Hospital Basel, Neurology, Basel, Switzerland, 2Definition12, Basel, Switzerland, 3University Hospital Basel, Clinical Trial Unit, Basel, Switzerland, 4Claudiabasel GmbH, Basel, Switzerland, 5Novartis Pharma AG, Basel, Switzerland
P035
Infrared depth sensor based automated classification of motor dysfunction in multiple sclerosis - a proof-of-concept study
1University Hospital Basel, Neurology, Basel, Switzerland, 2VU University Medical Center, Neurology, Amsterdam, Netherlands, 3Microsoft Research, Cambridge, United Kingdom, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
P036
The squares test as a measure of hand function in multiple sclerosis
1Free University of Brussels, NEUR, Brussel, Belgium, 2University of Antwerp, Institute Born-Bunge, Antwerp, Belgium, 3University Medical Center, Alzheimer Research Center Groningen, Groningen, Netherlands, 4ZNA Middelheim, Neurology, Antwerp, Belgium, 5Université de Mons, Service d’Orthopédagogie Clinique, Faculté de Psychologie et des Sciences de l’Education, Mons, Belgium, 6National MS Center, Melsbroek, Belgium
Statistical analyses were performed in R and MATLAB.
The 49 TRT controls were re-evaluated with the ST within four weeks of the first assessment. The correlation between these two measures was good (r=0.67, p< 0.0001). The average difference between the two measurements was 11.5 % ± 10.2 of the baseline value.
P037
Influence of method of analysis on responsiveness to change of an IRT score of global disability derived from NARCOMS performance scales
1University of Alabama at Birmingham, Epidemiology, Birmingham, AL, United States, 2University of Alabama at Birmingham, Biostatistics, Birmingham, AL, United States, 3New York University, Neurology, New York, NY, United States
P038
Assessment of upper extremity function using the manual dexterity component of the multiple sclerosis performance test: validation of novel metrics
1Cleveland Clinic, Mellen Center for MS Treatment and Research, Cleveland, OH, United States, 2Cleveland Clinic, Biomedical Engineering, Cleveland, OH, United States, 3Cleveland Clinic, Center for Brain Health, Cleveland, OH, United States, 4Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH, United States
Clinical trials
P039
Improvement in MRI outcomes across subgroups with alemtuzumab versus interferon beta-1a in treatment-naive relapsing-remitting multiple sclerosis
1Edifici Cemcat, Vall d’Hebron University Hospital and Research Institute, Barcelona, Spain, 2NeuroRx Research, Montréal, QC, Canada, 3Montréal Neurological Institute, McGill University, Department of Neurology and Neurosurgery, Montréal, QC, Canada, 4Cleveland Clinic, Department of Biomedical Engineering, Cleveland, OH, United States, 5Genzyme, a Sanofi Company, Cambridge, MA, United States
P040
MRI outcomes in patients with early multiple sclerosis treated with teriflunomide: subgroup analyses from the TOPIC phase 3 study
1University of Texas Health Science Center at Houston, Houston, TX, United States, 2Genzyme, a Sanofi Company, Chilly-Mazarin, France, 3Sanofi, Bridgewater, NJ, United States, 4Icahn School of Medicine at Mount Sinai, New York, NY, United States
P041
Effect of laquinimod on gray matter and white matter atrophy in relapsing-remitting multiple sclerosis: analysis of the BRAVO phase III trial
1McGill University, Montreal, QC, Canada, 2University of Colorado, Aurora, CO, United States, 3Teva Pharmaceutical Industries, Netanya, Israel, 4Teva Pharmaceutical Industries, Frazer, PA, United States, 5Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 6NeuroRx Research, Montreal, QC, Canada
There was a significant treatment effect of LAQ on GM atrophy (51% at year 1 and 28% at year 2, both p< 0.001) compared with PLC. The IFN group showed worsening of 31% (p=0.004) at year 1 and 12% at year 2 (p=0.075). The treatment effect of LAQ on WM atrophy was 39% (p=0.001) at year 1 and 15% (p=0.015) at year 2, compared with PLC. The IFN group was not statistically different from PLC in WM rates at year 1 (p=0.488) and year 2 (p=0.239). The rates of atrophy in the second year for GM and WM in LAQ and IFN were not different than PLC.
P042
Peginterferon beta-1a may improve recovery following relapses: data from the 2-year ADVANCE relapsing-remitting multiple sclerosis study
1Heinrich-Heine University, Department of Neurology, Düsseldorf, Germany, 2Alleghany General Hospital, Department of Neurology, Pittsburgh, PA, United States, 3Drexel University College of Medicine, Department of Neurology, Pittsburgh, PA, United States, 4Johns Hopkins School of Medicine, Department of Neurology, Baltimore, MD, United States, 5Biogen Idec Inc., Cambridge, MA, United States
P043
Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study
1Department of Neurology and Center for Neuropsychiatry, Heinrich-Heine University, Düsseldorf, Germany, 2Department of Neurology and Neurosurgery, Montréal Neurological Institute, McGill University, Montréal, QC, Canada, 3Mellen Center and Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, United States, 4University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, 5University of Texas Medical Branch, Round Rock, TX, United States, 6Department of Neurology, First School of Medicine, Charles University, Prague, Czech Republic, 7Medical University of Łódź, Department of Neurology, Łódź, Poland, 8Genzyme, a Sanofi Company, Cambridge, MA, United States, 9Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
P044
Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: 3-year follow-up of CARE-MS II
1Burgundy University, Dijon University Hospital, Dijon, France, 2Genzyme, a Sanofi Company, Cambridge, MA, United States, 3PROMETRIKA, LLC, Cambridge, MA, United States, 4MS Center for Innovations in Care, St. Louis, MO, United States
P045
Larger treatment effects in early multiple sclerosis: a meta analysis of randomized trials
1University of Genoa, Health Sciences, Section of Biostatistics, Genoa, Italy
P046
Evaluating the effect of teriflunomide in subgroups defined by prior treatment: pooled analyses of the phase 3 TEMSO and TOWER studies
1University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, 2Sanofi, Bridgewater, NJ, United States, 3Genzyme, a Sanofi Company, Chilly-Mazarin, France, 4University Hospital Basel, Basel, Switzerland
Teriflunomide 14 mg generally demonstrated efficacy vs placebo across the patient subgroups for ARR and risk of disability progression; there were no significant treatment-by-subgroup interactions. Relative risk reductions for ARR with teriflunomide 14 mg vs placebo were 46.7%, 27.7%, and 35.9% for >1 prior DMT, 1 prior DMT, and no prior DMT, respectively; corresponding hazard rate reductions for risk of disability progression were 78.6%, 46.6%, and 17.4%. A more robust effect was observed on disability progression with teriflunomide 14 mg versus teriflunomide 7 mg, whereas similar results were observed on ARR with both doses.
P047
The effects of age and gender on brain volume in FREEDOMS, FREEDOMS II and TRANSFORMS phase 3 studies
1University Hospital Basel, Medical Image Analysis Centre, Basel, Switzerland, 2University of Texas Health Science Center at Houston, Department of Neurology, Houston, TX, United States, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States, 5VU Medical Centre, Image Analysis Centre, Amsterdam, Netherlands
P048
Follow-up data from the Mirror study: a dose-ranging study of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis
1Copenhagen University Hospital, Rigshospitalet, Department of Neurology, Copenhagen, Denmark, 2GlaxoSmithKline, Clinical Statistics, Neurosciences, Research Triangle Park, NC, United States, 3GlaxoSmithKline, Clinical Pharmacology, Stockley Park West, United Kingdom, 4GlaxoSmithKline, Clinical Statistics, Neurosciences, Stockley Park West, United Kingdom, 5GlaxoSmithKline, Stiefel Global Clinical Dev US, Research Triangle Park, NC, United States, 6GlaxoSmithKline, RD Projects Clinical Platforms & Sciences, Research Triangle Park, NC, United States, 7GlaxoSmithKline, Neurosciences Therapy Area Unit, Research Triangle Park, NC, United States, 8McGill University and McGill University Health Center, Montreal Neurological Institute and Hospital, Montreal, QC, Canada
During the 24-week follow-up phase, the most common adverse events (AEs) were related to infections, observed in 25% of subjects across treatment groups. There was no evidence of a relationship between dose and the incidence or severity of AEs. Twelve serious adverse events (SAEs) were reported by 9 subjects with no SAE reported by more than one subject; no cases of progressive multifocal leukoencephalopathy or opportunistic infections were observed.
Assessment of efficacy data showed that the MRI lesion suppression seen during the 24-week treatment phase persisted through week 48 for the OFA treatment groups. As of the week 48 visit (equivalent to 36 weeks post-last dose for all groups except 60mg q4w, for which it was 28 weeks post-last dose), B-cell repletion (defined as ≥ baseline level or ≥ 0.11 GI/L) had been achieved by 46% of PBO/3mg-treated subjects, 35% of 3mg q12w-treated subjects, 40% of 30mg q12w-treated subjects, 33% of 60mg q12w-treated subjects, and 19% of 60mg q4w-treated subjects.
P049
Safety, tolerability and efficacy of Boswellic acids in relapsing-remitting multiple sclerosis - the SABA proof-of-concept trial
1University Medical Center Hamburg-Eppendorf, Institute for Neuroimmunology and Multiple Sclerosis Research (INIMS), Hamburg, Germany, 2Charité Universitätsmedizin Berlin, NeuroCure Clinical Research Center (NCRC), Berlin, Germany, 3University Hospital Zürich, Department of Neuroimmunology and MS Research, Zürich, Switzerland
P050
Modeling dose-PK-lymphocytes relationship under siponimod (BAF312) treatment to infer time to immune reconstitution
1Novartis Pharma AG, Basel, Switzerland
P051
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
1NeuroRx Research, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada, 3University Hospital, Basel, Switzerland, 4First School of Medicine, Charles University, Prague, Czech Republic, 5Medical University of Lodz, Lodz, Poland, 6Moscow Multiple Sclerosis Center, Moscow, Russian Federation, 7Carolinas Medical Center, Charlotte, NC, United States, 8University of Münster, Münster, Germany, 9University of Utah Medical School, Salt Lake City, UT, United States, 10Abbvie Biotherapeutics Inc, Redwood City, CA, United States, 11Biogen Idec, Cambridge, MA, United States
P052
Effect of bismuth subsalicylate on gastrointestinal events associated with delayed-release dimethyl fumarate: a double-blind, placebo-controlled study
1Department of Neurology, Georgetown University Hospital, Washington, DC, United States, 2Biogen Idec, Inc., Cambridge, MA, United States, 3PharmStats, Ltd., Escondido, CA, United States
P053
Comparable clinical and MRI efficacy of glatiramer acetate 40mg/mL TIW and 20mg/mL QD: results of a systematic review and meta-analysis
1University of Alabama at Birmingham, Birmingham, AL, United States, 2University of Texas, Health Science Center at Houston, Houston, TX, United States, 3San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy, 4Teva Pharmaceutical Industries, Petach Tiqva, Israel, 5Teva Pharmaceutical Industries, Frazer, PA, United States, 6Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 7Teva Pharmaceutical Industries, Netanya, Israel, 8Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI, United States, 9Sastry Foundation Advanced Imaging Laboratory, Wayne State University School of Medicine, Detroit, MI, United States
p< .0001). In GALA, the ARR was reduced by 34% with GA 40mg TIW vs. PBO (RR=0.66, 95% CI 0.54, 0.80; p< .0001). Confidence intervals (CIs) for RRs of GA 20mg QD vs. PBO and GA 40mg TIW vs. PBO on ARR substantially overlapped, indicating similarity of GA 40mg TIW effect to that of GA 20mg QD. GA 20mg QD reduced new T2 lesions by 43% vs. PBO (RR=0.57, 95% CI 0.39, 0.81; p=.002) while in GALA, the GA 40mg TIW reduction was 35% (RR=0.65, 95%CI 0.55, 0.78; p< .0001). The RR CI for GA 40mg TIW was wholly contained within that of GA 20mg QD, suggesting a similar treatment effect on new T2 lesions.
P054
Switching from interferon β-1a IM to laquinimod: safety and efficacy results from the BRAVO study extension
1University of Colorado, Aurora, CO, United States, 2Teva Pharmaceutical Industries, Netanya, Israel, 3Teva Pharmaceutical Industries, Petach Tiqva, Israel, 4Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
P055
Effects of a very low fat, plant-food-based diet on fatigue in multiple sclerosis: report of a pilot trial
1Oregon Health & Science University, Neurology, Portland, OR, United States, 2Portland Veterans’ Affairs Medical Center, Neurology, Portland, OR, United States, 3Novant Medical Group, Charlotte, OR, United States, 4McDougall Research and Education Foundation, Santa Rosa, CA, United States, 5Louisiana State University, Neurology, New Orleans, LA, United States, 6Lsu, Neurology, Neurology, LA, United States
Changes in blood lipids by nuclear magnetic resonance spectroscopy, blood insulin, C- reactive protein and 25 hydroxy vitamin D levels were assessed.
P056
Results from a randomized double-blind crossover study comparing oral L-carnitine versus placebo for the treatment of fatigue in multiple sclerosis
1Service de Neurologie, Hôpital Pellegrin CHU de Bordeaux, Bordeaux, France, 2Service de Neurologie, Université de Nantes, Nantes, France, 3CHU de Nancy, Service de Neurologie, Hôpital Central, Nancy, France, 4CHU de Nice, Service de Neurologie, Hôpital Pasteur, Nice, France, 5CHU de Fort-de-France, Service de Neurologie, Hôpital Pierre Zobda-Quitman, Fort-de-France, Martinique, 6CHU de Toulouse, Service de Neurologie, Hôpital Purpan, Toulouse, France, 7CHU de Bordeaux, Université de Bordeaux, Unité de Soutien à la Recherche Clinique et Épidémiologique du CHU de Bordeaux, Bordeaux, France, 8CHU de Bordeaux, Service de Neurologie, Hôpital Pellegrin, Bordeaux, France
Eligible MS patients were affected of fatigue for more than 3 months with global score on Modified Fatigue Impact Scale (MFIS)>45%.The primary outcome measure was the global score on the 21 item MFIS. Secondary outcome measures included the Fatigue Severity Scale (FSS), Fatigue Visual Analogic Scale (VAS), physical dimension scale of MFIS, and the SEP59 Quality Of Life scale (derived from the MSQOL-54, validated in French). Free carnitine and acyl-carnitine serum dosages were scheduled at baseline and at the end of study. A mixed linear regression model was used to assess the effect of the treatment and the treatment-period interaction.
P057
Delayed-release dimethyl fumarate and disability assessed by the multiple sclerosis functional composite: integrated analysis of DEFINE and CONFIRM
1Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom, 2St. Josef Hospital, Ruhr University, Bochum, Germany, 3University Hospital, Basel Neurology, Basel, Switzerland, 4McGill University, Montreal Neurological Institute, Montreal, QC, Canada, 5Biogen Idec Inc., Cambridge, MA, United States
P058
The efficacy of teriflunomide is evident before steady-state plasma concentrations are reached
1University of Texas Health Science Center at Houston, Houston, TX, United States, 2Sanofi, Bridgewater, NJ, United States, 3Genzyme, a Sanofi Company, Chilly-Mazarin, France, 4University Hospital Basel, Basel, Switzerland
P059
Five-year follow-up of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM, and ENDORSE
1NeuroRx Research, Montreal, AB, Canada, 2Montreal Neurological Institute, McGill University, Montreal, AB, Canada, 3Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, United States, 4St. Josef Hospital, Ruhr University, Bochum, Germany, 5Charles University, Department of Neurology, First Faculty of Medicine, Prague, Czech Republic, 6University Hospital, Basel Neurology, Basel, Switzerland, 7University College London Institute of Neurology, Queen Square Multiple Sclerosis Centre, NMR Research Unit, London, United Kingdom, 8Biogen Idec Inc., Cambridge, MA, United States
P060
Effect of teriflunomide on lymphocyte and neutrophil counts: pooled analyses from four placebo-controlled studies
1University Vita-Salute San Raffaele, Milan, Italy, 2University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3University Hospital Basel, Basel, Switzerland, 4Icahn School of Medicine at Mount Sinai, New York, NY, United States, 5Karolinska Institute, Stockholm, Sweden, 6University of Texas Health Science Center at Houston, Houston, TX, United States, 7Genzyme, a Sanofi Company, Chilly-Mazarin, France, 8Sanofi, Bridgewater, NJ, United States, 9University of Toronto, Toronto, ON, Canada
P061
Consistent effect of laquinimod on relapse-related and disability progression-related endpoints
1San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy, 2University of Colorado, Aurora, CO, United States, 3Clinical Research and Biomedicine, University Hospital Basel, Basel, Switzerland, 4Hospital Universitari de la Vall d’Hebron, Barcelona, Spain, 5Teva Pharmaceutical Industries, Netanya, Israel, 6Teva Pharmaceutical Industries, Frazer, PA, United States, 7Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany
P062
Clinical efficacy of laquinimod 0.6mg once-daily in worsening relapsing-remitting multiple sclerosis defined by baseline EDSS over 3
1University of Colorado, Aurora, CO, United States, 2San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy, 3Clinical Research and Biomedicine, University Hospital Basel, Basel, Switzerland, 4Hospital Universitari de la Vall d’Hebron, Barcelona, Spain, 5University of Alabama at Birmingham, Birmingham, AL, United States, 6Teva Pharmaceutical Industries, Frazer, PA, United States, 7Teva Pharmaceutical Industries, Netanya, Israel, 8Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany
P063
The POPARTMUS French-Italian multicentric trial of postpartum progestin and estradiol in multiple sclerosis: MRI findings
1Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Neurologie A et Fondation Eugène Devic EDMUS pour la Sclérose en Plaques, Bron Cedex - Lyon, France, 2CREATIS-LRMN, UMR 5220 CNRS & U 1044 INSERM & Université de Lyon, Villeurbanne, France, 3INSERM, Le Kremlin-Bicêtre, France, 4Bioclinica, Lyon, France, 5Service de Radiologie - CHU Lyon, Centre Hospitalier de Lyon Sud, Pierre Bénite, France, 6Université de Lyon, Lyon, France, 7Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Centre d’Investigations Cliniques, Bron Cedex - Lyon, France, 8Service de Biostatistique des Hospices Civils de Lyon, Lyon, France, 9University of Torino, Torino, Italy, 10Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, Equipe Neuro-Oncologie et Neuro-Inflammation, Lyon, France
P064
Long-term efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE
1St. Josef Hospital, Ruhr University, Bochum, Germany, 2Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom, 3Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX, United States, 4Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, United States, 5Biogen Idec Inc., Cambridge, MA, United States
P065
Efficacy of delayed-release dimethyl fumarate for RRMS in prior interferon users in the DEFINE and CONFIRM studies
1Hospital Regional Universitario, Málaga University, Department of Neurology, IBIMA (Instituto de Investigación Biomédica de Málaga), Málaga, Spain, 2Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom, 3Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, United States, 4St. Josef Hospital, Ruhr University, Bochum, Germany, 5Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX, United States, 6Biogen Idec Inc., Cambridge, MA, United States
P066
Long-term follow-up of the safety of delayed-release dimethyl fumarate in RRMS: interim results from the ENDORSE extension study
1Sapienza University of Rome, Rome, Italy, 2Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX, United States, 3Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, United States, 4Medical University of Lodz, Lodz, Poland, 5Biogen Idec Inc., Cambridge, MA, United States, 6St. Josef Hospital, Ruhr University, Bochum, Germany
P067
Effect of peginterferon beta-1a on MRI measures and freedom from measured disease activity: 2-year results from the phase 3 ADVANCE study
1Montreal Neurological Institute, McGill University, Montreal, QC, Canada, 2NeuroRx Research, Montreal, QC, Canada, 3Johns Hopkins University, Department of Neurology, Baltimore, MD, United States, 4Heinrich-Heine University, Department of Neurology, Düsseldorf, Germany, 5Biogen Idec Inc., Cambridge, MA, United States
P068
Ambulation benefit with laquinimod in patients with worsening MS (EDSS over 3) is consistent with reduction in confirmed disability progression
1University of Colorado, Aurora, CO, United States, 2San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy, 3University of Alabama at Birmingham, Birmingham, AL, United States, 4Hospital Universitari de la Vall d’Hebron, Barcelona, Spain, 5Teva Pharmaceutical Industries, Frazer, PA, United States, 6Teva Pharmaceutical Industries, Netanya, Israel, 7Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany
P069
Laquinimod effect on confirmed disability progression: minimal mediation by relapse or T2 lesions reduction
1University of Genoa, Genoa, Italy, 2University of Colorado, Aurora, CO, United States, 3San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy, 4Teva Pharmaceutical Industries, Netanya, Israel, 5Teva Pharmaceutical Industries, Frazer, PA, United States, 6Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany
P070
Laquinimod disability progression effects are maintained with increasingly rigorous confirmation time intervals
1San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy, 2University of Colorado, Aurora, CO, United States, 3Clinical Research and Biomedicine, University Hospital Basel, Basel, Switzerland, 4Hospital Universitari de la Vall d’Hebron, Barcelona, Spain, 5Teva Pharmaceutical Industries, Netanya, Israel, 6Teva Pharmaceutical Industries, Frazer, PA, United States, 7Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany
P071
Temporal pattern of laboratory changes with laquinimod treatment
1University of Colorado, Aurora, CO, United States, 2San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy, 3Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 4Teva Pharmaceutical Industries, Netanya, Israel, 5Teva Pharmaceutical Industries, Frazer, PA, United States, 6Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany
P072
Effect of high- dose erythropoietin on clinical disability and MRI in patients with progressive multiple sclerosis
1Rigshospitalet, Danish MS Research Center, Copenhagen, Denmark, 2University Hospital Hvidovre, Danish Centre for Magnetic Resonance, Copenhagen, Denmark, 3Rigshospitalet, Danish Multple Sclerosis Research Center, Copenhagen, Denmark, 4University Hospital Hvidovre, Danish Research Centre for Magnetic Resonance, Copenhagen, Denmark
P073
Quantifying the effect of natalizumab on the total disability burden of MS patients in AFFIRM using an exploratory area under the curve analysis
1Mellen Center, Cleveland Clinic Foundation, Cleveland, OH, United States, 2Biogen Idec, Cambridge, MA, United States
1Liu C and Blumhardt LD, JNNP 1999; 67:451-6
P074
Impact of peginterferon beta-1a treatment and disease factors on risk of physical deterioration in patients with multiple sclerosis: ADVANCE study
1Biogen Idec Inc., Cambridge, MA, United States, 2Evidera, Lexington, MA, United States, 3Evidera, Montreal, QC, Canada
P075
Alemtuzumab improves MRI outcomes regardless of subgroup versus interferon beta-1a in relapsing-remitting MS patients who relapsed on prior therapy
1VU University Medical Center, Amsterdam, Netherlands, 2Cleveland Clinic, Department of Biomedical Engineering, Cleveland, OH, United States, 3Genzyme, a Sanofi Company, Cambridge, MA, United States, 4NeuroRx Research, Montréal, QC, Canada, 5Department of Neurology and Neurosurgery, Montréal Neurological Institute, McGill University, Montreal, QC, Canada
P076
Double-blind, placebo- and active comparator-controlled study in healthy males to assess the safety, pharmacokinetics and -dynamics of 2B3-201
1to-BBB technologies BV, Leiden, Netherlands, 2Centre for Human Drug Research, Leiden, Netherlands
P077
Lymphocyte count reductions with delayed-release dimethyl fumarate: integrated analysis of the phase 2, phase 3, and extension studies
1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, United States, 2St. Josef Hospital, Ruhr University, Bochum, Germany, 3Multiple Sclerosis Program, Baylor Institute for Immunology Research, Dallas, TX, United States, 4Medical University of Lodz, Lodz, Poland, 5Biogen Idec, Inc., Cambridge, MA, United States
P078
Teri-PRO: study design and US patients’ baseline characteristics
1Stony Brook University Medical Center, Stony Brook, NY, United States, 2Multiple Sclerosis Center of Northeastern New York, Latham, NY, United States, 3Regional MS Center, Center for Neurological Disorders, Milwaukee, WI, United States, 4North Central Neurology Associates, Cullman, AL, United States, 5Lincoln, Boulogne-Billancourt, France, 6Genzyme, a Sanofi Company, Cambridge, MA, United States
P079
Long-term MRI outcomes from patients treated with teriflunomide: results from a phase 2 extension study
1University of British Columbia and MS/MRI Research Group, Vancouver, BC, Canada, 2Genzyme, a Sanofi Company, Chilly-Mazarin, France, 3Sanofi, Bridgewater, NJ, United States, 4University of Toronto, Toronto, ON, Canada
P080
Convenience of glatiramer acetate 40mg/mL three times weekly: evidence from the GLACIER study
1University of Texas, Health Science Center at Houston, Houston, TX, United States, 2Mecklenburg Neurological Associates, Charlotte, NC, United States, 3Advanced Neurological Specialists, Great Falls, MT, United States, 4Swedish Medical Center, Littleton, CO, United States, 5Teva Pharmaceutical Industries, Netanya, Israel, 6Teva Pharmaceutical Industries, Frazer, PA, United States, 7Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 8Teva Pharmaceutical Industries, Cleveland, OH, United States
P081
Time to brain atrophy is prolonged in continuously fingolimod-treated MS patients vs placebo or interferon beta 1-a in phase 3 studies of fingolimod
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
P082
A randomized, double-blind, placebo-controlled phase IIa study of alpha B-crystallin in multiple sclerosis
1Delta Crystallon, Leiden, Netherlands
P083
Safety and tolerability of fingolimod in relapsing-remitting multiple sclerosis: results from a large open-label clinical trial
1University of Genova, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Genova, Italy, 2University Federico II, Department of Neurological Sciences, Napoli, Italy, 3S. Giuseppe Hospital, Neurology Unit, Empoli, Italy, 4University La Sapienza, Department of Neurology, Roma, Italy, 5Vita-Salute San Raffaele University, Scientific Institute San Raffaele, Department of Neurology, INSPE, Milano, Italy, 6University ‘G. D’Annunzio’, Department of Neuroscience and Imaging, Chieti, Italy, 7Novartis Farma, Origgio, Italy
P084
Dose-response and safety of high dose vitamin D supplementation: subgroup analysis of an exploratory randomized double blind placebo controlled trial
1St Vincents University Hospital, Department of Neurology, Dublin, Ireland, 2Mater University Hospital, Department of Biochemistry, Dublin, Ireland, 3St Vincent’s University Hospital, Pharmacy Department, Dublin, Ireland, 4Trinity College Dublin, Department of Immunology, Dublin, Ireland, 5St Vincents University Hospital, Department of Radiology, Dublin, Ireland, 6Royal Victoria Eye and Ear Hospital, Dublin, Ireland, 7Mater University Hospital, Department of Neurology, Dublin, Ireland
EU Clinical Trials Register: EudraCT: 2012-000635-68. ClinicalTrials.gov identifier: NCT01728922
P085
Safety and tolerability of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the ADVANCE study
1Heinrich-Heine University, Department of Neurology, Düsseldorf, Germany, 2Johns Hopkins University, Department of Neurology, Baltimore, MD, United States, 3Biogen Idec Inc., Cambridge, MA, United States
1Calabresi PA, et al. Lancet Neurol, In Press.
P086
An interim analysis of the German START-study confirms the good cardiac safety profile of fingolimod
1Neurologische Klinik, Kliniken der Stadt Köln, Cologne, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany, 3Neurologische Praxis, NTD Study Group, Ulm, Germany, 4Neurologische Gemeinschaftspraxis, NTD Study Group, Bonn, Germany, 5Neurologische Klinik, Universität Dresden, Dresden, Germany
All ECG recordings are centrally evaluated by cardiologists.
The cardiac safety profile analyzed by the START study focuses in particular on cardiac events requiring extended monitoring according to the label: bradycardia, prolongation of QTcF (Fridericia)-interval as well as second- and third degree AV blocks.
The results of the most recent analysis conducted in August 2014 will be presented.
P087
Vitamin D levels in multiple sclerosis in correlation to age, sex, EDSS and dosage of substitution.
1Marianne Strauss Klinik, Berg, Germany
High dose substitution with 20.000 IE led to a higher increase of 25-OH vitamin D levels (mean 51,4 µg/l) than weekly doses below 10.000 IE (mean 27,5 µg/l).
P088
Alemtuzumab reduces disease activity in treatment-naive patients with highly active relapsing-remitting multiple sclerosis
1Mount Sinai Medical Center, New York, NY, United States, 2Hôpital de la Salpêtrière, Paris, France, 3Genzyme, a Sanofi Company, Cambridge, MA, United States
P089
Interferon beta-1b in treatment-naïve paediatric patients with relapsing-remitting MS: baseline data from the BETAPAEDIC study
1University Medical Center, Göttingen, Germany, 2Bayer Pharma AG, Berlin, Germany
P090
Efficacy and safety of alemtuzumab in treatment-naive patients with relapsing-remitting MS: four-year follow-up of the CARE-MS I study
1University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, 2Montréal Neurological Institute, McGill University, Department of Neurology and Neurosurgery, Montréal, QC, Canada, 3Mellen Center and Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, United States, 4University of Texas Medical Branch, Round Rock, TX, United States, 5Heinrich-Heine University, Department of Neurology and Center for Neuropsychiatry, Düsseldorf, Germany, 6First School of Medicine, Charles University, Department of Neurology, Prague, Czech Republic, 7Medical University of Łódź, Department of Neurology, Łódź, Poland, 8Genzyme, a Sanofi Company, Cambridge, MA, United States, 9University of Cambridge, Department of Clinical Neurosciences, Cambridge, United Kingdom
P091
Attitudes of people with multiple sclerosis towards clinical research
1St Vincent’s University Hospital, Neurology, Dublin, Ireland
P092
GNbAC1, a monoclonal antibody against the MSRV envelope protein, pharmacodynamic responses in patients with multiple sclerosis
1GeNeuro, Plan les Ouates, Switzerland
P093
First-in-human phase 1 study of invariant NKT cell ligand OCH
1National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Department of Immunology, Kodaira, Japan, 2National Center Hospital, NCNP, Multiple Sclerosis Center, Kodaira, Japan, 3National Center Hospital, NCNP, Department of Neurology, Kodaira, Japan, 4Juntendo University Graduate School of Medicine, Department of Immunology, Bunkyo-ku, Japan
P094
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
1Medical University of Lodz, Lodz, Poland, 2University Hospital, Basel, Switzerland, 3NeuroRx Research, Montreal, QC, Canada, 4McGill University, Montreal, QC, Canada, 5First School of Medicine, Charles University, Prague, Czech Republic, 6Moscow Multiple Sclerosis Center, Moscow, Russian Federation, 7Carolinas Medical Center, Charlotte, NC, United States, 8University of Münster, Münster, Germany, 9University of Utah Medical School, Salt Lake City, UT, United States, 10Abbvie Biotherapeutics Inc, Redwood City, CA, United States, 11Biogen Idec, Cambridge, MA, United States
P095
Efficacy of teriflunomide in patients with early stage MS: analysis of the TOPIC study using 2010 McDonald diagnostic criteria
1University of Texas Health Science Center at Houston, Houston, TX, United States, 2Genzyme, a Sanofi Company, Chilly-Mazarin, France, 3Sanofi, Bridgewater, NJ, United States, 4Icahn School of Medicine at Mount Sinai, New York, NY, United States
P096
Differential recovery from relapse between treatment groups in the CONFIRM study of delayed-release dimethyl fumarate
1St. Josef Hospital, Ruhr University, Bochum, Germany, 2Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX, United States, 3Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, United States, 4Biogen Idec Inc., Cambridge, MA, United States
P097
Pooled safety analyses from the teriflunomide clinical development program
1Comprehensive Multiple Sclerosis Center, Thomas Jefferson University Hospital, Philadelphia, PA, United States, 2University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3University Hospital Basel, Basel, Switzerland, 4Karolinska Institute, Stockholm, Sweden, 5Icahn School of Medicine at Mount Sinai, New York, NY, United States, 6University of Texas Health Science Center at Houston, Houston, TX, United States, 7University of Toronto, Toronto, ON, Canada, 8Genzyme, a Sanofi Company, Chilly-Mazarin, France, 9Sanofi, Bridgewater, NJ, United States, 10University Vita-Salute San Raffaele, Milan, Italy
P098
TRUST study design-a study to evaluate an integrated approach for optimized patient management in multiple sclerosis patients treated with natalizumab
H-P Hartung1, T Ziemssen2, A Bayas3, B Tackenberg4, J Würfel5,6, V Limmroth7, R Linker8, M Mäurer9, J Haas10, M Stangel11,
1University of Düsseldorf, Dept. of Neurology, Düsseldorf, Germany, 2University of Dresden, Center of Clinical Neuroscience, Dresden, Germany, 3Hospital of Augsburg, Dept. of Neurology, Augsburg, Germany, 4Philipps University, Dept. of Neurology, Marburg, Germany, 5University of Göttingen, Göttingen, Germany, 6Charite, Berlin, Germany, 7Cologne City Hospitals, University of Cologne, Dept. of Neurology, Cologne, Germany, 8Friedrich-Alexander-Universität, Dept. of Neurology, Erlangen, Germany, 9Caritas Hospital, Dept. of Neurology, Bad Mergentheim, Germany, 10Jewish Hospital Berlin, Centre for Multiple Sclerosis, Berlin, Germany, 11Hannover Medical School, Dept. of Neurology, Hannover, Germany, 12Biogen Idec, Ismaning, Germany, 13Universitätsmedizin Mannheim, University of Heidelberg, Dept. of Neurology, Mannheim, Germany
P099
Physician and participant treatment guesses in the double-blind CombiRx study
1University of Alabama at Birmingham, Birmingham, AL, United States, 2Icahn School of Medicine at Mount Sinai, New York, NY, United States, 3University of Texas Health Science Center at Houston, Houston, TX, United States
Of the 404 with both a participant and physician treatment guess, 84.9% agreed and 76.1% were correct, with 9.3% guessing IFN but taking IFN+GA, 3.8% guessing GA but IFN+GA, 5.5% guessing IFN+GA but IFN, 3.8% guessing IFN+GA but GA, with 1.5% guessing the wrong single agent arm (0.9% guess IFN but GA, 0.6% guess GA but IFN).
Considering only those that guessed a treatment allocation, of the participants taking IFN (IFN or IFN+GA): 88.9% physicians (93.1% participants) guessed IFN or IFN+GA. Of the participants taking GA (GA or IFN+GA): 83.1% physicians (83.8% participants) guessed GA or IFN+GA.
Considering all 1008 treatment allocations, of the 749 participants taking IFN (IFN or IFN+GA): 39.4% physicians (66.2% participants) guessed IFN or IFN+GA. Of the 758 participants taking GA (GA or IFN+GA): 37.1% physicians (59.2% participants) guessed GA or IFN+GA.
P100
Indirect comparison of glatiramer acetate 40mg/mL TIW and 20mg/mL QD dosing regimen effects on relapse rate: results of a predictive statistical model
1University of Alabama at Birmingham, Birmingham, AL, United States, 2University of Texas, Health Science Center at Houston, Houston, TX, United States, 3San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy, 4Teva Pharmaceutical Industries, Petach Tiqva, Israel, 5Teva Pharmaceutical Industries, Frazer, PA, United States, 6Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 7Teva Pharmaceutical Industries, Netanya, Israel, 8Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI, United States, 9Sastry Foundation Advanced Imaging Laboratory, Wayne State University School of Medicine, Detroit, MI, United States
P101
Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: post hoc analysis of the FREEDOMS study
1Medical Image Analysis Center (MIAC), University Hospital, Basel, Switzerland, 2University Hospital, Department of Neurology, Basel, Switzerland, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
P102
No evident disease activity at 24 weeks in patients with relapsing MS treated with interferon β-1a SC vs. interferon β-1a IM in the EVIDENCE study
1Stony Brook University, Department of Neurology, Stony Brook, NY, United States, 2EMD Serono, Inc., Rockland, MA, United States, 3University of Chicago, Chicago, MA, United States
Cleveland Clinic Center for Continuing Education. Multiple Sclerosis Virtual Grand Rounds Treating to Target in MS: Disease Free Status? http://www.clevelandclinicmeded.com/online/webcasts/ms-vgr/treating-to-target-in-MS/.
P103
Alemtuzumab improves MRI outcomes in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: three-year follow-up of CARE-MS II
1Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, United States, 2VU University Medical Centre, Amsterdam, Netherlands, 3Mellen Center and Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, United States, 4University of Texas Medical Branch, Round Rock, TX, United States, 5Medical University of Łódź, Department of Neurology, Łódź, Poland, 6Genzyme, a Sanofi Company, Cambridge, MA, United States, 7NeuroRx Research, Montréal, QC, Canada, 8Department of Neurology and Neurosurgery, Montréal Neurological, Montréal, QC, Canada
P104
No evident disease activity in relapsing MS patients treated with interferon β-1a SC vs. interferon β-1a IM: subgroup analyses of the EVIDENCE study
1Stony Brook University, Department of Neurology, Stony Brook, NY, United States, 2EMD Serono, Inc., Rockland, MA, United States, 3University of Chicago, Chicago, IL, United States
P105
A double-blind, randomized, versus-placebo study of palmitoylethanolamide in relapsing-remitting multiple sclerosis
1Federico II University, Department of Pharmacology, Naples, Italy, 2University of Verona, Neurology Unit, Department of Neurological and Movement Sciences, Verona, Italy, 3Federico II University-School of Medicine, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Naples, Italy
Despite, other studies are necessary to confirm the best responder profile and the full potential of PEA-um® in MS-related disease and inflammatory progression.
P106
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
1AbbVie, Clinical Pharmacology and Pharmacometrics, North Chicago, IL, United States, 2Biogen Idec, Clinical Pharmacology and Pharmacometrics, Cambridge, MA, United States, 3AbbVie Biotherapeutics, Redwood City, CA, United States, 4Current address: Genentech, Clinical Pharmacology, San Francisco, CA, United States
P107
24 month PANGAEA: a 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice
1Karl Gustav Carus University Hospital, Center of Clinical Neuroscience, Dresden, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany, 3Kantar Health, Munich, Germany
The annual relapse rate of all PANGAEA patients improved from 1.5 ± 0.13 (baseline) to 0.42 ± 0.08 in the first year of PANGAEA and to 0.49 ± 0.12 in the second year of PANGAEA. Of all PANGAEA patients 63.2% in the first and 64.1% in the 2nd year of PANGAEA were relapse free. The average EDSS of all PANGAEA patients was stable over 24 months at 3.0 (±0.06 Baseline; ±0.14 month 24). The proportion of patients with at least 6 months stable EDSS improved from 85.0% (month 3) to 94.0% (month 24). 12.7% of all patients discontinued the fingolimod therapy, 4.7% because of adverse events. After 24 months, more than 98.0% of patients and physicians rated fingolimod tolerability as good or very good.
6815 adverse events were documented in PANGAEA. 168 (3.9%) adverse events were rated as serious. 45.4% of the patients experienced no adverse events so far.
P108
Efficacy of delayed-release dimethyl fumarate in multiple sclerosis patients with moderate disability: an integrated analysis of the phase 3 studies
1St. Vincent’s University Hospital, Dublin, Ireland, 2Biogen Idec Inc., Cambridge, MA, United States, 3Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, United States, 4St. Josef Hospital, Ruhr University, Bochum, Germany
P109
Modeling concentration-efficacy relationship for MRI lesion counts under siponimod treatment and its dependence on the effect on lymphocyte reduction
1Novartis Pharma AG, Basel, Switzerland
P110
Five-year follow-up of delayed-release dimethyl fumarate in RRMS: integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies
1St. Josef Hospital, Ruhr University, Bochum, Germany, 2Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX, United States, 3McGill University, Montreal Neurological Institute, Montreal, QC, Canada, 4St. Vincent’s University Hospital, Dublin, Ireland, 5University Hospital, Basel Neurology, Basel, Switzerland, 6Biogen Idec Inc., Cambridge, MA, United States, 7Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, United States
P111
Innate immune modulator MIS416 enhances systemic levels of negative regulators of inflammation in phase 2a clinical trial plasma samples
1Innate Immunotherapeutics Ltd, Auckland, New Zealand
White M, Webster G, O’Sullivan D, Stone S, La Flamme AC. Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS One. 2014;9(1):e87712.
P112
Impact of fingolimod on achieving no evidence of disease activity in pre-treated patients with high disease activity in FREEDOMS and FREEDOMS II
1Novartis Pharma AG, Basel, Switzerland, 2University Hospital, Basel, Switzerland
Kappos L et al. N Engl J Med 2010;362:387-401.
Calabresi PA et al. Lancet Neurol 2014;S1474-4422(14)70049-3. doi: 10.1016/S1474-4422(14)70049-3.
P113
Natalizumab decreases progression of disability in RRMS patients as measured by the composite EDSS-Plus in AFFIRM
1Biogen Idec, Cambridge, MA, United States, 2Mellen Center, Cleveland Clinic Foundation, Cleveland, OH, United States
Cognitive function
P114
Independent component analysis of cognitive performance in primary-progressive multiple sclerosis
1Federico II University, Neuroscience, Naples, Italy, 2Mount Sinai School of Medicine, Neurology, New York, NY, United States, 3New York University, Neurology, New York, NY, United States, 4Columbia University, Neurology, New York, NY, United States, 5Mount Sinai School of Medicine, Neuroscience, New York, NY, United States, 6Mount Sinai School of Medicine, Radiology, New York, NY, United States
to explore resting state (RS) functional connectivity (FC) abnormalities in patients with PP-MS through an independent component analysis (ICA) approach;
to investigate whether such abnormalities correlate with cognitive performance.
T2 Dual turbo spin echo;
T1 weighted 3D turbo field echo;
echo planar imaging for RS fMRI.
On the same day, PP-MS patients underwent neurological examination and neuropsychological testing (MACFIMS battery). RS fMRI sequences were pre-processed using DPARSF pipeline from SPM8. 50 independent RS networks (RSN) were detected and extracted with MELODIC toolbox from FSL4; and the following networks involved in cognitive functions were identified: working memory network-WMN; salience network-SN; executive control network-ECN; default mode network-DMN; anterior hippocampal network-AHN; posterior hippocampal network-PHN. For each RSN, intrinsic FC of each cluster was computed and compared between CTRLs and patients. Between-group differences were assessed using SPM8. Correlation of clinical parameters with FC data was assessed with Spearman’s correlation coefficient.
WMN
SN
ECN
DMN
AHN
PHN
In PP-MS patients, decreased RS FC in WMN was significantly correlated with total coding (TC) scores (p< 0.01); decreased RS FC in DMN was correlated with TC (p< 0.05) and FAS scores (p< 0.01); decreased RS FC in SN was correlated with TC scores (p< 0.05). Correlation trends were detected between RS FC in DMN and DKEFS scores (p=0.07), and RS FC in ECN and DKEFS scores (p=0.08).
P115
Thalamic functional connectivity and cognitive impairment: comparison between relapsing remitting and secondary progressive multiple sclerosis
1University Sapienza, Neurology and Psychiatry, Rome, Italy, 2Santa Lucia Fundation, Rome, Italy
Thalamo-cortical FC was higher in RR than in HS in the right frontal and in the mesial occipital and cingulate cortices, bilaterally; SP showed increased FC also in the right temporo-occipital cortex, hippocampi and posterior thalami, in addition to the aforementioned brain areas. PASAT scores were significantly lower in patients than HS and in SP than in RR. In RR, PASAT scores significantly correlated with thalamo-cortical FC in the frontal cortex bilaterally, thalami and left anterior insula, indicating that worse the performance greater the FC. In SP widespread hyperconnectivity, including the cerebellum, thalami, posterior cingulate, anterior insula and multiple foci in the whole cerebral cortex, inversely correlated with PASAT scores.
P116
Emotional modifications in multiple sclerosis: a neuropsychological and fMRI study
1University of Strasbourg, CNRS, ICUBE-IPB, UMR 7357, Strasbourg, France, 2Hôpitaux Universitaires de Strasbourg, Neurologie, Strasbourg, France
During fMRI scanning period, participants had to visualize emotional scene stemming from the IAPS, differing in valence (positive, negative, neutral), and arousal (ranging from calm to excited). After MRI occurs a debriefing, participants estimated their experience by seeing again every image and scoring the valence and the arousal sensation.
In fMRI, all subjects show significant brain activation in amygdala, frontal and visual areas, with a strong modulation for arousal. A different pattern of activation exists between patient and control for positive stimulation with less amygdala activation (p< 0.001, unc.).
P117
Brain intrinsic resting-state functional connectivity modulation induced by mental effort in multiple sclerosis patients with fatigue
1Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Neurology, Lugano, Switzerland, 2Neuroradiology Department, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland, 3Neuroimaging Research Unit, Institute of Experimental Neurology, Vita-Salute San Raffaele University, Milan, Italy
P118
Brief computerized cognitive testing in pediatric-onset multiple sclerosis (MS)
1Stony Brook University, Department of Neurology, Stony Brook, NY, United States, 2Lourie Center for Pediatric MS, Stony Brook, NY, United States, 3CogState Inc., & Child Study Center, Yale University School of Medicine, New Haven, CT, United States
P119
A new computerized tool detects subtle differences in information processing speed in children with MS
1The Hospital for Sick Children, Division of Neurology, Toronto, ON, Canada, 2University of Manitoba, Departments of Internal Medicine and Community Health Sciences, Winnipeg, MB, Canada, 3York University, Department of Psychology, Toronto, ON, Canada, 4University of Toronto, Department of Psychiatry, Toronto, ON, Canada, 5The Children’s Hospital of Philadelphia, Division of Neurology, Philadelphia, PA, United States
P120
How does neurological reserve compare between MS patients and healthy controls?
1DeltaQuest Foundation, Concord, MA, United States, 2Tufts University Medical School, Medicine and Orthopaedic Surgery, Boston, MA, United States, 3Oslo and Akershus University College of Applied Sciences, Nursing, Oslo, Norway, 4University of Buffalo, Department of Neurology, Buffalo, MA, United States, 5University of Buffalo, Pharmaceutical Sciences, Buffalo, NY, United States
P121
Cortical lesions and cognitive impairment in multiple sclerosis: cortex or juxta-cortex?
1AA Martinos Center For Biomedical Imaging, Charlestown, MA, United States, 2Harvard University, Boston, MA, United States, 3Beth Israel Deaconess Medical Center, Boston, MA, United States, 4Virginia Mason Medical Center, Seattle, WA, United States, 5Ecole Polytechnique de Montréal, Montreal, QC, Canada
P122
A longitudinal evaluation of cognitive fatigue in MS using the PASAT
1Ottawa Hospital Research Institute, Psychology, Ottawa, ON, Canada, 2The Ottawa Hospital, Psychology, Ottawa, ON, Canada, 3The Ottawa Hospital, Medicine, Ottawa, ON, Canada
P123
Application of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) to pediatric-onset MS
1Stony Brook University, Department of Neurology, Stony Brook, NY, United States, 2Lourie Center for Pediatric MS, Stony Brook, NY, United States
P124
Rasch analysis of performance based cognitive measures in two distinct medical diseases, MS and HIV
1McGill University, MS Clinic, Montreal, QC, Canada, 2Montreal Neurological Institute, MS Clinic, Montreal, QC, Canada, 3McGill University Health Centre Research Institute, Montreal, QC, Canada, 4McGill University, Montreal, QC, Canada, 5McGill University, Neurology and Neurosurgery, Montreal, QC, Canada
P125
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): an Irish validation study
1St Vincents University Hospital, Dublin, Ireland, 2Royal Holloway, University of London, Department of Clinical Psychology, Surrey, United Kingdom
Using regression based norms derived from the control sample only 28 (42%) of patients compared to 48 (79%) of control’s results were within the normal range on all 3 tests.
Eleven (16%) and 13 (19%) of patients fulfilled criteria for depression and anxiety respectively based on their HADS score but no statistically significant association with individual test scores or cognitive outcome was seen.
P126
Spatial memory test (SMT): a self-administered iPad®-based tool for assessing nonverbal episodic memory dysfunction in MS
1Cleveland Clinic, Cleveland, OH, United States
effects of age, education and gender on SMT performance,
SMT test-retest reliability and practice effects, and
convergent validity of the SMT and 10/36.
P127
A comparison of the Brief International Cognitive Assessment for Multiple Sclerosis and the brief repeatable battery in multiple sclerosis patients
1University of Florence, Department of Neurofarba, Florence, Italy, 2IRCCS San Raffaele, Milan, Italy, 3Santa Lucia Foundation, Rome, Italy, 4University of Cagliari, Cagliari, Italy, 5Ospedale dei Colli Monaldi Cotugno CTO, Napoli, Italy, 6Hospital of Lanciano, Lanciano, Italy, 7University of Bari, Bari, Italy, 8Hospital of Barletta, Barletta, Italy, 9University of Chieti, Chieti, Italy, 10Hospital of Gallarate, Gallarate, Italy, 11Villa Mazzacorati, Bologna, Italy
P128
Demonstration of altered neural substrates of information processing speed in pediatric-onset MS using an fMRI version of the SDMT
1The Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Institute of Medical Science, Toronto, ON, Canada, 3York University, Psychology, Toronto, ON, Canada, 4Rotman Research Institute, Baycrest, Toronto, ON, Canada, 5Children’s Hospital of Philadelphia, Philadelphia, PA, United States
P129
Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome
1Charles University in Prague, First Faculty of Medicine and General University Hospital, Department of Neurology and Center of Clinical Neuroscience, Prague, Czech Republic, 2School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo Neuroimaging Analysis Center, Department of Neurology, Buffalo, NY, United States, 3IRCCS “S.Maria Nascente”, Don Gnocchi Foundation, Milan, Italy, 4Melbourne Brain Centre, University of Melbourne, Department of Medicine, Melbourne, Australia, 5Royal Melbourne Hospital, Department of Neurology, Melbourne, Australia, 6Charles University in Prague, First Faculty of Medicine and General University Hospital, Department of Radiology, Prague, Czech Republic, 7School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, MR Imaging Clinical Translational Research Center, Buffalo, NY, United States
P130
Perservation of GM volume is related to increased learning effect on PASAT in patients with CIS
1Charles University in Prague, First Faculty of Medicine and General University Hospital, Department of Neurology and Center of Clinical Neuroscience, Prague, Czech Republic, 2School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo Neuroimaging Analysis Center, Department of Neurology, Buffalo, NY, United States, 3IRCCS “S.Maria Nascente”, Don Gnocchi Foundation, Milan, Italy, 4Charles University in Prague, First Faculty of Medicine and General University Hospital, Department of Radiology, Prague, Czech Republic, 5School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, MR Imaging Clinical Translational Research Center, Buffalo, NY, United States
P131
Effectively assessing executive function impairment in MS: comparisons of the Delis-Kaplan executive function system and Wisconsin card sorting tests
1Yeshiva University, Ferkauf Graduate School of Psychology, Bronx, NY, United States, 2Holy Name Medical Center Multiple Sclerosis Center, Teaneck, NJ, United States
P132
Brief International Cognitive Assessment for MS (BICAMS): preliminary findings from the Canadian validation study
1The Ottawa Hospital, Psychology, Ottawa, ON, Canada, 2Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3University of Ottawa, Psychology, Ottawa, ON, Canada, 4The Ottawa Hospital, Neurology, Ottawa, ON, Canada
P133
Physical disability and cognitive impairment evolution in benign multiple sclerosis: a five years prospective study
1University of Verona, Dpt of Neurological and Movement Sciences, Verona, Italy, 2Casa di Cura Pederzoli, Neurology Unit, Peschiera del Garda, Italy, 3Azienda Ospedaliera Universitaria Integrata, Neurology Unit, Verona, Italy
P134
SDMT performance predicts real-world functioning in adults with multiple sclerosis (MS)
1Stony Brook University, Department of Neurology, Stony Brook, NY, United States, 2Lourie Center for Pediatric MS, Stony Brook, NY, United States
P135
Predictive validity of the BRB-N in the assessment of cognitive impairment in RRMS according to EDSS disability degree
1Hospital Santa Creu i Sant Pau, Neurology Department, Barcelona, Spain, 2Hospital Universitario Virgen Macarena, Neurology Department, Sevilla, Spain
P136
Cognitive disturbances and psychoaffective deficits in children and juveniles with multiple sclerosis: the MUSICADO - multicentric validation study
1University of Basel, Dept. of Cognitive Neuroscience, Basel, Switzerland, 2University of Munich, Dept. of Neuropediatrics, Munich, Germany, 3University of Vechta, Dept. of Psychology, Vechta, Germany, 4University of Cologne, Psychology, Cologne, Germany, 5Merck-Serono, Darmstadt, Germany
P137
Does the presence of brain lesions predict cognitive functioning after acute demyelination in children?
1Hospital for Sick Children, Neurosciences and Mental Health, Toronto, ON, Canada, 2Alberta Children’s Hospital, Neurology, Calgary, AB, Canada, 3Alberta Children’s Hospital, Neurosciences Program, Calgary, AB, Canada, 4University of Calgary, Pediatrics and Clinical Neurosciences, Calgary, AB, Canada, 5Alberta Children’s Hospital, Research Institute, Calgary, AB, Canada, 6Hospital for Sick Children, Neurology, Toronto, ON, Canada, 7Children’s Hospital of Philadelphia, Neurology, Philadelphia, PA, United States, 8York University, Psychology, Toronto, ON, Canada
P138
Attention network efficiency and performance variability is associated with white matter microstructure in persons with multiple sclerosis
1Dalhousie University, Psychology and Neuroscience, Halifax, NS, Canada, 2University of Calgary, Department of Radiology, Calgary, AB, Canada, 3Dalhousie University, Psychology and Neuroscience, Psychiatry, Halifax, NS, Canada
P139
The role of the cerebellum in cognitive test performance in children and adolescents with multiple sclerosis
1McGill University, Montreal Neurological Institute, Montreal, QC, Canada, 2York University, Department of Psychology, Toronto, ON, Canada, 3The Hospital for Sick Children, Neurosciences and Mental Health Program, Toronto, ON, Canada, 4University of Toronto, Department of Pediatrics (Neurology), Toronto, ON, Canada, 5University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
P140
Subjective and objective measures of cognition in MS: a preliminary analysis of correlations and test-retest reliability
1Ottawa Hospital Research Institute, Ottawa, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada, 3The Ottawa Hospital, Ottawa, ON, Canada
P141
Self-reported cognitive fatigue is a function of time on task in multiple sclerosis
1Kessler Foundation, West Orange, NJ, United States, 2Rutgers New Jersey Medical School, Physical Medicine and Rehabilitation, Newark, NJ, United States, 3Rutgers New Jersey Medical School, Neurology & Neurosciences, Newark, NJ, United States, 4War Related Illness & Injury Study Center, Department of Veterans Affairs, East Orange, NJ, United States
P142
Response inhibition on a Go/No-go task in pediatric-onset multiple sclerosis patients: an fMRI study
1York University, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Children’s Hospital of Philadelphia, Philadelphia, PA, United States
P143
Age of onset and cognitive reserve as moderators of cognitive decline in pediatric-onset multiple sclerosis patients
1York University, Psychology, Toronto, ON, Canada, 2The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, 3Children’s Hospital of Philadelphia, Dept. of Neurology, Philadelphia, PA, United States
P144
Transfer of information across the corpus callosum is slowed in patients with multiple sclerosis compared to healthy controls
1Yeshiva University, Pscyhology, New York, NY, United States, 2New York University School of Medicine, Neurology, New York, NY, United States
P145
Correlates of cognitive performances with fractional anisotropy decrease in clinically isolated syndromes
1Université de Bordeaux, U INSERM 862, Bordeaux, France, 2CHU de Bordeaux, Neurology, Bordeaux, France, 3Université de Bordeaux, TRAIL, Bordeaux, France, 4Brigham & Women’s Hospital, Neurological Imaging, Boston, MA, United States, 5Université de Bordeaux & CHU de Bordeaux, Bordeaux, France
P146
CTIP performance in early relapsing-remitting MS: group differences and potential confounds
1The Ottawa Hospital, Psychology, Ottawa, ON, Canada, 2University of Ottawa, Psychology, Ottawa, ON, Canada, 3Dalhousie University, Psychology, Halifax, NS, Canada, 4The Ottawa Hospital, MS Clinic, Ottawa, ON, Canada, 5University of Ottawa, Neurology, Ottawa, ON, Canada
P147
Does cognitive impairment, fatigue, depression or physical disability influence computer assisted tests for driving performance in MS patients?
1Neurologische Gemeinschaftspraxis Dillingen, Dillingen an der Donau, Germany
P148
Inhibitory control in early multiple sclerosis
1Institute for Neurological Research Dr. Raúl Carrea (FLENI), Buenos Aires, Argentina
P149
Accuracy of clinical screening for cognitive impairment in multiple sclerosis: an empirical study
G Hoffnung1, L Glukhovsky1, S Flood1, J Botvinick1, J Sloan1,
1Yeshiva University, Bronx, NY, United States, 2Holy Name Medical Center, Teaneck, NJ, United States
P150
Cognitive impairment as measured by Audio Recorded Cognitive Screen in an MS clinic population with up to 6 years follow up
1Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia, 2University of Newcastle, Newcastle, Australia, 3John Hunter Hospital, Neurology, Newcastle, Australia
P151
Self-reported episodic memory and future thinking and their relation to cerebral structure in early multiple sclerosis patients
1Oslo University Hospital, Department of Neurlogy, Oslo, Norway, 2University of Oslo, Faculty of Medicine, Oslo, Norway, 3University of Oslo, Institute of Psychology, Oslo, Norway
P152
Including ecological assessment in cognitive screening: a new approach to detect cognitive impairment in MS patients
1Université de Bordeaux, INSERM U 862, Bordeaux, France, 2CHU de Bordeaux, Neurology, Bordeaux, France
The large battery (A) included 13 paper-pencil NP tests of IPS, EM, WM, EF and attention and several computerized tasks from the Test of Attentional Performance (TAP). The short battery (B) included the SDMT, the immediate recall score of the California Verbal Learning Test and an in-house developed task assessing divided attention in a VE: the Urban Daily Cog©. The percentages of cognitively impaired patients at the B battery (at least 1 test < 1.5 standard deviation (SD) of HC) and at the A battery (at least 3 tests < 1.5 SD of HC) were calculated. Predictives values of the short B battery were calculated to predict cognitive status assessed by the large battery.
P153
Incipient cognitive dysfunction revealed by dual-task posturography in patients with multiple sclerosis
1Sapienza University, Neurology and Psychiatry, Rome, Italy, 2S. Andrea Hospital, Physical Therapy Unit, Rome, Italy
There was a significant effect of CD on DTC after controlling for gender, age, education, MS duration, EDSS score, single-task postural sway, fatigue and walking speed (F=6.856, p=0.002). Contrast analysis revealed that either overt and incipient CD were associated with greater DTC (p=0.024 and p< 0.001, respectively), while there was no difference between overt and incipient CD.
P154
Incidental recall performance on a processing speed test is associated with verbal memory abilities in multiple sclerosis
1University of Missouri-Kansas City, Psychology, Kansas City, MO, United States, 2Avila University, Psychology, Independence, MO, United States, 3University of Kansas Medical Center, Kansas City, KS, United States
P155
Changes in subjective cognitive difficulties, mental health and information processing speed at one year follow up in MS patients
1Dalhousie University, Halifax, NS, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3University of Calgary, Calgary, AB, Canada, 4University of British Columbia, Vancouver, BC, Canada, 5Capital District Health Authority, Halifax, NS, Canada
P156
Cognitive impairment, oxidative stress and neurodegeneration in multiple sclerosis
1University of Kansas, Psychology, Lawrence, KS, United States, 2University of Kansas Medical Center, Neurology, Kansas City, KS, United States, 3University of Kansas Medical Center, Molecular and Integrative Physiology, Kansas City, KS, United States, 4University of Kansas Medical Center, Hoglund Brain Imaging Center, Kansas City, KS, United States
P157
The efficacy of Wechsler Memory Scale-fourth edition (WMS-IV) in memory evaluation in multiple sclerosis patients
1Ribeirão Preto Medical School, Neuroscience and Behavior Sciences, Ribeirão Preto, Brazil, 2Brazilian Institute of Neuroscience (IBNeuro), Brasília, Brazil
P158
Cognitive impairment and corpus callosum atrophy in multiple sclerosis
1Hospital Universitario de Canarias, Service of Neurology, La Laguna, Spain, 2Hospital Universitario de Canarias, Research Unit, La Laguna, Spain
P159
Do disease modifying treatments affect cognitive performance in early multiple sclerosis?
1Hunter Medical Research Institute, Molecular Genetics, New Lambton, Australia, 2John Hunter Hospital, Neurology, Newcastle, Australia, 3Hunter Medical Research Institute, New Lambton, Australia, 4University of Sydney, Director of Neurophysiology, Westmead Hospital, Sydney, Australia, 5Barwon Health, Neuroscience, Geelong, Australia, 6Griffith University, School of Medicine, Gold Coast, Australia, 7University of Newcastle, Newcastle, Australia
P160
Prevalence of cognitive impairment in newly diagnosed MS patients
1University of Western Ontario, Clinical Neurological Sciences, London, ON, Canada, 2London Health Sciences Centre, London, ON, Canada, 3St. Joseph’s Health Care, London, ON, Canada
P161
Executive functions evaluation in MS Patients without cognitive impairment: a task switching experimental paradigm
S Migliore1, G Curcio2, A Couyoumdjian3, A Ghazaryan4,
1Università ‘Campus Bio-Medico’, Rome, Italy, 2Università di L’Aquila, L’Aquila, Italy, 3Università ‘La Sapienza’, Rome, Italy, 4Ospedale Fatebenefratelli, Isola Tiberina, Rome, Italy, 5Università ‘Tor Vergata’, Rome, Italy
P162
Cognitive impairment in patients with neuromyelitis optica spectrum disorder: a preliminary report
S-H Kim1, J-W Hyun1, I-H Jeong1, A Joung1, H-J Jo1, E-S Yu2, W Kim3,
1Research Institute and Hospital of National Cancer Center, Neurology, Go-Yang, Korea, Republic of, 2Research Institute and Hospital of National Cancer Center, Mental Health Clinic, Go-Yang, Korea, Republic of, 3The Catholic University of Korea, Neurology, Seoul, Korea, Republic of
P163
Utilization of the Brief International Cognitive Assessment for Multiple Sclerosis during treatment of relapses in patients with multiple sclerosis
O Oztürk1, B Piri Cinar2,
1Dokuz Eylul University, Izmir, Turkey, 2Giresun State Hospital, Giresun, Turkey, 3Dokuz Eylul University, Dept. of Neurology, Izmir, Turkey
P164
Are both storage and executive control components of working memory equally affected in pediatric-onset multiple sclerosis patients?
1York University, Psychology, Toronto, ON, Canada, 2The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, 3University of Toronto, Institute of Medical Science, Toronto, ON, Canada, 4Children’s Hospital of Philadelphia, Dept. of Neurology, Philadelphia, PA, United States
P165
Sustained attention, reaction time and traffic perception tests characterize different aspects of cognition and fatigue in MS patients
1Neurologische Gemeinschaftspraxis Dillingen, Dillingen an der Donau, Germany
P166
Regression-based norms for the Symbol Digit Modalities Test: demographic effects on identification of impairment in Dutch multiple sclerosis patients
1VU University Medical Center, Neurology, Amsterdam, Netherlands, 2VU University Medical Center, Epidemiology and Biostatistics, Amsterdam, Netherlands
P167
Relative corpus callosum volume is related to decreased information processing speed in relapse-remitting multiple sclerosis patients
1Charles University in Prague, First Faculty of Medicine and General University Hospital, Department of Neurology and Center of Clinical Neuroscience, Prague, Czech Republic, 2Charles University in Prague, First Faculty of Medicine and General University Hospital, Department of Radiology, Prague, Czech Republic
P168
Are there differences on the measures in the minimal assessment of cognitive function in MS by race/ethnicity?
1Yeshiva University, Ferkauf Graduate School of Psychology, Bronx, NY, United States, 2NYU School of Medicine, Department of Psychiatry, New York, NY, United States, 3Holy Name Medical Center, Teaneck, NJ, United States, 4NYU School of Medicine, Department of Rehabilitation Medicine, New York, NY, United States
P169
MS-Cortex study: the contribution of cortical lesions to cognitive impairment in patients with multiple sclerosis
1University Hospital Zurich, Department of Neurology, Zurich, Switzerland, 2Luzerner Kantonsspital, Department of Internal Medicine, Centre of Neurology and Neurorehabilitation, Luzern, Switzerland, 3University of Zurich, Institute of Psychology, Division of Neuropsychology, Zurich, Switzerland, 4Medizinisch Radiologisches Institut, Zurich, Switzerland
P170
Cognitive performance at early stages of MS in a Portuguese sample: influence of depressive symptoms, cognitive fatigue and disease characteristics
1Instituto Universitário de Lisboa (ISCTE-IUL), Lisboa, Portugal, 2Hospital S. João, Neurology Department, Porto, Portugal
The CI profile in MS usually involves memory, complex attention, information processing speed and executive functions. Depression and fatigue are common symptoms in MS and primary determinants to impaired quality of life of these patients. No association has been found between reports of fatigue and CI but depressive symptoms are thought to interfere largely with cognitive activities.
A multiple regression analysis was performed to analyze whether clinical factors can predict CP. The resulting predictors included depressive symptomatology (β= −2,77; p=0,009), age of diagnosis (β= −0,18; p=0,006) and EDSS score (β= −0,83; p=0,063). This final model revealed that 22,2% of CP is explained by those variables (F(3,57)= 6,42; p= 0,001).
A link between depressive symptoms and cognitive functioning was found, especially in aspects of cognitive functioning including processing speed and executive functioning. No association was found between cognitive fatigue and the performance on cognitive tests.
P171
Reaction time distributions in early-phase relapsing-remitting multiple sclerosis differ from controls
GT Howell1, J-A LeFevre1,2, LM Rees1,3,4, LI Berrigan5,
1Carleton University, Department of Psychology, Ottawa, ON, Canada, 2Carleton University, Institute of Cognitive Science, Ottawa, ON, Canada, 3University of Ottawa, School of Psychology, Ottawa, ON, Canada, 4Ottawa Hospital Research Institute, Ottawa, ON, Canada, 5Dalhousie University, Department of Psychiatry, Halifax, NS, Canada, 6University of Ottawa, Division of Neurology, Faculty of Medicine, Ottawa, ON, Canada
P172
Predictivity of executive functions deficit on episodic memory disorder in multiple sclerosis
R Barthelemy1,2,
1Hôpital Saint Vincent de Paul, Neurology, Lille, France, 2Centre d’Études et de Recherche sur la SEP, Lille, France, 3Universite Catholique de Lille, Faculté de Lettres et de Sciences Humaines, Lille, France, 4Universite Catholique de Lille, Faculté de Medecine, Lille, France
P173
The relationship between SDMT and everyday life performance: actual reality
1New York University, New York, NY, United States, 2Kessler Foundation, West Orange, NJ, United States
Comorbidities and risk behaviors
P174
Does smoking influence MRI disease activity in multiple sclerosis?
SAS Kvistad1, K-M Myhr1, T Holmøy2, S Bakke3, A Beiske4, K Bjerve5, H Hovdal6, KI Løken-Amsrud7, F Lilleås8, R Midgard9, T Pedersen10, J Šaltytė Benth11, S Wergeland12,
1Haukeland University Hospital, Neurology, Bergen, Norway, 2Akershus University Hospital, Neurology, Oslo, Norway, 3Oslo University Hospital, Department of Neuroradiology, Oslo, Norway, 4Multiple Sclerosis Centre, Hakadal, Norway, 5St. Olavs Hospital, Department of Medical Biochemistry, Trondheim, Norway, 6St.Olav University Hospital, Neurology, Trondheim, Norway, 7Innlandet Hospital Trust, Department of Neurology, Lillehammer, Norway, 8Curato, Oslo, Norway, 9Department of Neurology, Molde, Norway, 10Unilabs, Drammen, Norway, 11University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 12Haukeland University Hospital, Department of Neurology, Bergen, Norway
P175
Smoking and HLA genes impact on disease activity and severity before and during treatment with interferon-beta
1Copenhagen University Hospital, Rigshospitalet, Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen, Denmark, 2University of Aarhus, Department of Neuroepidemiology, Aarhus, Denmark, 3Copenhagen University Hospital, Rigshospitalet, The Danish Multiple Sclerosis Registry, The Danish MS Research Center, Copenhagen, Denmark
Multivariate analysis showed that the ARR in the two year period before treatment start was higher in women (p=0.008) and in younger patients (p< 0.001). At treatment start the MSSS was higher in patients with later age at disease onset (p< 0.001), in patients who started treatment at an early age (p< 0.001) and in patients who smoked in the two year period before treatment start; the more package years the higher MSSS (p=0.005). During IFN-beta treatment ARR was higher in patients who started treatment in an early age (p< 0.001) and there was interaction between HLA-DRB1*15:01 and smoking for higher ARR on treatment (p=0.005). The annualized MSSS increase during treatment was highest among patients with a late age at onset (p=0.045) and there was an interaction between HLA-DRB1*15:01 and smoking for higher annualized MSSS increase on treatment (p=0.003).
P176
Obesity interacts with infectious mononucleosis in risk of multiple sclerosis
1Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden, 2Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
P177
Central nervous system demyelinating disease in patients with inflammatory bowel disease
1Mayo Clinic, Neurology, Rochester, MN, United States, 2International Clinical Research Center, St. Anne’s University Hospital Brno, Brno, Czech Republic, 3Mayo Clinic, Gastroenterology and Hepatology, Rochester, MN, United States, 4Mayo Clinic, Division of Biomedical Statistics and Informatics, Rochester, MN, United States
P178
Prescription drug use among patients with multiple sclerosis
1University of Alberta, School of Public Health, Edmonton, AB, Canada, 2Alberta Ministry of Health, Surveillance and Assessment, Edmonton, AB, Canada, 3University of Calgary, Community Health Sciences, Calgary, AB, Canada, 4University of Alberta, Faculty of Nursing, Edmonton, AB, Canada, 5University of Alberta, Faculty of Rehabiliation Medicine, Edmonton, AB, Canada
P179
Comorbidities in patients with multiple sclerosis compared with the general population: retrospective analysis of the US MarketScan Database
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharma Co. Ltd, Shanghai, China
P180
Low prevalence of sleep disorders in demyelinating disease
1Hospital Universitario de Canarias, Servicio de Neurología, La Laguna, Spain, 2Universidad de La Laguna, Facultad de Física, La Laguna, Spain, 3Universidad de La Laguna, Facultad de Psicología, La Laguna, Spain, 4Hospital Universitario de Canarias, Servicio de Neurofisiología, La Laguna, Spain
P181
Higher weight in adolescence and young adulthood is associated with an earlier age at MS onset
1Jacobs Comprehensive MS Treatment and Research Center, Buffalo, NY, United States, 2New York State MS Consortium, Buffalo, NY, United States, 3State University of New York at Buffalo, Department of Neurology, Buffalo, NY, United States, 4Buffalo Neuroimaging Analysis Center, Department of Neurology, Buffalo, NY, United States
P182
Alcohol-use disorders and multiple sclerosis risk: a national record-linkage study
1University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom, 2University of Oxford, Unit of Health-Care Epidemiology, Nuffield Department of Population Health, Oxford, United Kingdom, 3Queen Mary University of London, Barts and the London School of Medicine and Dentistry, Blizard Institute, London, United Kingdom
P183
The metabolic syndrome in disabled multiple sclerosis patients: prevalence and characteristics
1Sheba Medical Center, Multiple Sclerosis Center, Ramat Gan, Israel, 2Sackler School of Medicine, Tel-Aviv, Israel, 3Sheba Medical Center, Pediatric Endocrinology, Ramat Gan, Israel, 4Medistat, Tel-Aviv, Israel
P184
Burden of comorbidities in patients with incident multiple sclerosis prior to and following diagnosis: a nationwide population study
1Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 2Division of Child Health, Obstetrics and Gynaecology, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 3Division of Paediatric Neurology and Paediatric General Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China, 4Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 5Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China
P185
Smoking, systemic inflammation and T-cell reactivity in patients with multiple sclerosis and healthy controls
1Copenhagen University Hospital, Rigshospitalet, Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen, Denmark
P186
Tobacco influence in the clinical progression of multiple sclerosis
1Centro Hospitalar e Universitário de Coimbra, Neurology, Coimbra, Portugal, 2Faculty of Medicine, University of Coimbra, Portugal, Neurology, Coimbra, Portugal
P187
Prevalence and predictors of substance abuse in multiple sclerosis
1Ohio State University College of Medicine, Columbus, OH, United States, 2Ohio State University, Department of Neurology, Columbus, OH, United States, 3Ohio State University Multiple Sclerosis Center, Columbus, OH, United States, 4Ohio State University, Department of Biostatistics, Columbus, OH, United States
P188
Elevated adiponectin levels induce pro-inflammatory responses in both myeloid cells and T-cells: linking adiposity and predisposition to pediatric MS
1Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada, 2Neurosciences and Mental Health, Hospital for Sick Children Research Institute, Toronto, ON, Canada, 3Experimental Therapeutics Program, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada, 4Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 5University Health Network, Toronto, ON, Canada, 6Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA, United States
P189
Investigating healthy lifestyle behaviors in multiple sclerosis: the role of neurological reserve and implicit processes of understanding
1DeltaQuest Foundation, Concord, MA, United States, 2Tufts University Medical School, Medicine and Orthopaedic Surgery, Boston, MA, United States, 3University of Buffalo, Department of Neurology, Buffalo, MA, United States, 4University of Rochester Medical Center, Psychiatry, Rochester, NY, United States, 5University of Rochester Medical Center, Rochester Health Care Decision Making Group, Rochester, NY, United States
P190
Concomitant diseases and MRI outcomes in multiple sclerosis
1State University of New York, Buffalo Neuroimaging Analysis Center, Buffalo, NY, United States, 2State University of New York at Buffalo, Neurology, Buffalo, NY, United States
P191
Multiple sclerosis in patients with common variable immunodeficiency disease: co-incidence or consequence?
1Barnabas Multiple Sclerosis Comprehensive Care Center, Livingston, NJ, United States, 2NYU Medical Center, New York, NY, United States
P192
Body mass index in patients with multiple sclerosis: does disability matter?
1Sheba Medical Center, Pediatric Endocrinology, Ramat Gan, Israel, 2Sackler School of Medicine, Tel-Aviv, Israel, 3Sheba Medical Center, Multiple Sclerosis Center, Ramat Gan, Israel, 4Medistat, Tel-Aviv, Israel
P193
The burden of comorbid psychiatric disorders in worsening the quality of life in multiple sclerosis patients
1University of Cagliari, Multiple Sclerosis Center, Department of Public Health, Clinical and Molecular Medicine, Cagliari, Italy, 2University of Cagliari, Consultation Liaison Psychiatric Unit, Department of Public Health, Clinical and Molecular Medicine, Cagliari, Italy, 3Italian National Institute of Health, Mental Health Unit, Centre of Epidemiology, Surveillance and Health Promotion, Roma, Italy, 4CRS4, Technology Park, Distributed Computing Group, Pula, Italy
P194
Subclinical coronary artery disease in multiple sclerosis patients
1Athens National and Kapodistrian University, Department of Neurology, ‘Aeginition’ Hospital, Athens, Greece
CSF studies
P195
Genetic risk factors are associated with cerebrospinal fluid measures in multiple sclerosis
1KU Leuven, Department of Neurosciences, Leuven, Belgium, 2Oslo University Hospital, Department of Neurology, Oslo, Norway, 3University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 4University Hospitals Leuven, Department of Neurology, Leuven, Belgium, 5Haukeland University Hospital, Department of Neurology, Bergen, Norway, 6University of Bergen, Department of Clinical Medicine, Bergen, Norway, 7University of Eastern Piedmont, Department of Health Sciences, Novara, Italy, 8University of Eastern Piedmont, Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), Novara, Italy, 9AOU “Maggiore della Carità”, Novara, Italy, 10San Raffaele Scientific Institute, Department of Neuro-rehabilitation, Milan, Italy, 11San Raffaele Scientific Institute, Division of Neuroscience, Milan, Italy, 12Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden, 13Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden, 14Technische Universität München, Department of Neurology, Munich, Germany, 15Université Catholique de Louvain-la-Neuve, Neurochemistry Unit, Louvain-la-Neuve, Belgium, 16Copenhagen University Hospital, Department of Neurology, Copenhagen, Denmark, 17Hospital Universitari Vall d’Hebron, Institut de Receca Vall d’Hebron, Barcelona, Spain, 18University of Newcastle, Hunter Medical Research Institute, Newcastle, Australia, 19Griffith University, School of Medicine, Queensland, Australia, 20Flinders University of South Australia, School of Medicine, Adelaide, Australia, 21University of Tasmania, Hobart, Australia, 22University of Western Australia, Centre for Neuromuscular and Neurological Disorders, Crawley, Australia, 23University of California San Francisco, School of Medicine, San Francisco, CA, United States, 24University of Cambridge, Department of Clinical Neurosciences, Cambridge, United Kingdom, 25University of Oslo, Department of Molecular Biology, Oslo, Norway
P196
CSF isoelectric focusing differentiates multiple sclerosis from other CNS autoimmune disorders
1Wayne State University, Detroit, MI, United States
P197
Importance of CSF analysis in the era of McDonald 2010 criteria: a retrospective multicenter study in patients with a clinically isolated syndrome
1University Hospital Ulm, Neurology, Ulm, Germany, 2Hannover Medical School, Hannover, Germany, 3University of Göttingen, Göttingen, Germany, 4Charité - Universitätsmedizin Berlin, Berlin, Germany, 5Paracelsus Medizinische Privatuniversität, Salzburg, Austria, 6University of Würzburg, Würzburg, Germany, 7University of Heidelberg, Heidelberg, Germany, 8University of Freiburg, Freiburg, Germany, 9University of Ulm, Ulm, Germany, 10University of Rostock, Rostock, Germany, 11University of Leipzig, Leipzig, Germany
discharge diagnosis of CIS,
availability of baseline CSF data, and
availability of baseline and follow-up MRI data sufficient to be classified according to the Swanton and Montalban criteria.
At disease onset 44/410 (11%) CIS patients fulfilled the McDonald 2010 criteria for MS, 138/410 (33%) the Swanton MRI criteria (dissemination in space), 84/410 (21%) the Montalban MRI criteria (dissemination in time), and 44/410 (11%) had no brain MRI lesions. Intrathecal IgG OCBs were detected in 351/406 (86 %).
290/410 (71%) converted to MS either clinically or on MRI according to the McDonald 2010 criteria during the follow-up period of up to 154 months (median 32 months).
While the conversion rate in CIS patients not fulfilling the McDonald 2010 criteria at onset (366/410) but showing intrathecal OCBs (310/366) was 74% (229/310), it was 44% (23/52) in those CIS patients with negative OCBs.
The median conversion time for CIS patients with positive OCBs was 25 months (95%CI=21-34) compared to 47 months (95%CI=36-85) in those patients without OCBs. CIS patients with intrathecal OCBs were twice as likely to convert to CDMS compared to OCB-negative individuals (hazard ratio=2.1, p=0.0014).
P198
Comprehensive Immunophenotyping of CSF cells in relapsing-remitting multiple sclerosis patients with daclizumb therapy
1National Institutes of Health, National Institute of Neurological Disorders and Stroke, Bethesda, MD, United States
P199
Intrathecal B-cell response in multiple sclerosis brain recognizes auto-antigens
DL Walker1, CE Estrem1, SW Anderson1, B Miller1,
1University of Colorado School of Medicine, Neurology, Aurora, CO, United States
P200
Increased intrathecal inflammation in progressive multiple sclerosis
1NIH, NINDS, Bethesda, MD, United States
P201
Diagnostic and prognostic significance of intrathecal synthesis of immunoglobulin free light chains in MS
1First Pavlov State Medical University, Saint-Petersburg, Russian Federation, 2Saint-Petersburg City Clinical Hospital #31, Saint-Petersburg Center MS and Autoimmune Diseases, Saint-Petersburg, Russian Federation
P202
Intrathecal IgG from patients with multiple sclerosis target patient-specific phage peptides
T Pointon1, S Manton1, M Davis1, G Braiotta1, L Schambers1, T Edwards1, B Polonsky1, M Graner2, M Burgoon1,
1University of Colorado Anschutz Medical Campus, Neurology, Aurora, CO, United States, 2University of Colorado Anschutz Medical Campus, Neurosurgery, Aurora, CO, United States
P203
Lipid-specific IgM oligoclonal bands in clinically isolated syndrome: 5-years follow-up
1Hospital Universitari i Politècnic La Fe, MS Unit - Neurology Department, Valencia, Spain, 2Hospital Universitari i Politècnic La Fe, Laboratory of Immunology, Valencia, Spain, 3Hospital Clínico Universitario, Unit of Neuroimmunology - Neurology Department, Valencia, Spain
P204
Subclinical intrathecal inflammation is risk for disease reactivation in early multiple sclerosis
1Tor Vergata University, Clinica Neurologica, Dipartimento di Medicina dei Sistemi, Rome, Italy, 2Fondazione Santa Lucia/Centro Europeo per la Ricerca sul Cervello (CERC), Rome, Italy
P205
What does an isolated cerebrospinal fluid monoclonal band mean: a tertiary centre experience
T Poyraz1,
1Medifema Private Hospital, Izmir, Turkey, 2Dokuz Eylul University, Neurology, Izmir, Turkey, 3Dokuz Eylul University, Biology, Izmir, Turkey, 4Dokuz Eylul University, Radiology, Izmir, Turkey
P206
Lipid-specific oligoclonal IgM bands: is there any influence on the response to treatment with fingolimod?
1Hospital Universitari Doctor Peset, Neurology Department, Valencia, Spain, 2Hospital Universitari i Politècnic La Fe, MS Unit - Neurology Department, Valencia, Spain, 3Hospital Clínico Universitario, Unit of Neuroimmunology - Neurology Department, Valencia, Spain, 4Hospital Universitari i Politècnic La Fe, Laboratory of Immunology, Valencia, Spain
P207
miR-142-3p expression in multiple sclerosis cerebrospinal fluid is related to better cognitive performance
1Neuroimmunology and Multiple Sclerosis Unit, Dr. Josep Trueta University Hospital, Department of Neurology, Girona, Spain, 2Girona Biomedical Research Institute (IDIBGI), Neurodegeneration and Neuroinflamation Group, Girona, Spain, 3Endocrinology and Nutrition (UDEN), Girona Biomedical Research Institute (IDIBGI), and CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03), Department of Diabetes, Girona, Spain
P208
Cytokines profile in the cerebrospinal fluid in chronic relapsing inflammatory demyelinating diseases of the central nervous system
1Hospital Universitari i Politècnic La Fe, Laboratory of Immunology, Valencia, Spain, 2Hospital Universitari i Politècnic La Fe, MS Unit - Neurology Department, Valencia, Spain, 3Hospital Clínico Universitario, Unit of Neuroimmunology - Neurology Department, Valencia, Spain, 4Hospital Clínic de Barcelona, MS Unit - Neurology Department, Barcelona, Spain
P209
Post-dural puncture headache is markedly reduced when 25 Sprotte needles are used
1AOU San Luigi Gonzaga, Neurologia 2 - Centro Riferimento Regionale Sclerosi Multipla (CRESM), Orbassano, Italy
P210
Oligoclonal bands predict multiple sclerosis in children with isolated optic neuritis: a retrospective multicenter cohort study
1Children’s Hospital Aschaffenburg, Aschaffenburg, Germany, 2University of Erlangen, Department of Neuropediatrics, Erlangen, Germany, 3University of Manchester, Institute of Population Health, Manchester, United Kingdom, 4University of Witten/Herdecke, Centre of Paediatrics and Youth Medicine, Witten/Herdecke, Germany, 5University of Frankfurt, Department of Neuropediatrics, Frankfurt, Germany, 6University of Vienna, Vienna, Austria, 7University of Essen, Department of Neuropediatrics, Essen, Germany, 8University of Würzburg, Department of Neurology, Würzburg, Germany, 9Carl Gustav Carus University Dresden, Dresden, Germany, 10Julius-Maximilian-University Munich, Dr. von Haunersches Kinderspital, Munich, Germany, 11University of Innsbruck, Department of Neuropediatrics, Innsbruck, Austria, 12University of Heidelberg, Department of Neuropediatrics, Heidelberg, Germany, 13University of Würzburg, Department of Neuropediatrics, Würzburg, Germany
P211
Intrathecal IgM index correlates with severe disease course in multiple sclerosis: clinical and MRI results
1Dokuz Eylul University, Dept. of Neurology, Izmir, Turkey, 2Giresun State Hospital, Giresun, Turkey, 3Dokuz Eylul University, Izmir, Turkey, 4Usak State Hospital, Usak, Turkey
P212
Lipid-specific oligoclonal IgM bands and cognition in early stages of multiple sclerosis
1Neuroimmunology and Multiple Sclerosis Unit, Dr. Josep Trueta University Hospital, Department of Neurology, Girona, Spain, 2Girona Biomedical Research Institute (IDIBGI), Neurodegeneration and Neuroinflamation Group, Girona, Spain, 3Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal para la Investigación Sanitaria (IRYCIS), Departments of Immunology, Madrid, Spain
P213
A retrospective study of the association between leucocytes, IgG-index, oligoclonale bands and age in demyelinating disease
1Glostrup Hospital, University of Copenhagen, Neurology, Glostrup, Denmark
ON-CIS group: Mann-Whitney U test for WBC count showed Z = −5.02, p = .000. Median for ON = 2.0, CIS = 4.0. CIS group has a significantly higher WBC count in the CSF than ON group. For IgG-index Z = −4.00, p = .000. Median ON = .56, CIS = .62. CIS group has a significantly higher IgG index than the ON group. Chi-square test for independence of OB showed Continuity Correction = 28.5 and Asympt.sig (2-sided) = .000. Since p < 0.05, there is a significant difference of OB in the CIS and the ON group.
RRMS group: Mann-Whitney U test for WBC Z = −.16, p = .87. For IgG-index Z = −.82, p = .41. Since p > 0,05, there is no statistical difference between the WBC counts and IgG index. Chi-square test for independence of OB showed Continuity Correction = .006 and Asympt.Sig (2-sided) = .94 (p > 0,05).
P214
Reduced level of sialylated IgG antibody in the CSF of patients with multiple sclerosis
T Curley1, T Pointon1, H Collins1, K Dennison1, G Im1, M Graner2, D Wagner3,
1University of Colorado School of Medicine, Neurology, Aurora, CO, United States, 2University of Colorado School of Medicine, Neurosurgery, Aurora, CO, United States, 3University of Colorado School of Medicine, Webb-Waring Center, Aurora, CO, United States
P215
Cerebrospinal fluid markers of the course of multiple sclerosis
1Altai State Medical University, Barnaul, Russian Federation
Databases
P216
A visualization and analysis platform in the Swedish national MS registry for real-time data feedback
1Karolinska Institutet, Clinical Neuroscience (CNS), Stockholm, Sweden, 2Karolinska Institutet, Learning, Informatics, Management and Ethics (LIME), Stockholm, Sweden, 3Carmona AB, Halmstad, Sweden
P217
Leveraging electronic health records for a phenome-wide examination of the comorbidity burden associated with multiple sclerosis disease outcome
1Harvard University, Department of Statistics, Cambridge, MA, United States, 2Brigham and Women’s Hospital, Department of Neurology, Boston, MA, United States, 3Harvard School of Public Health, Department of Biostatistics, Boston, MA, United States, 4Brigham and Women’s Hospital, Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Boston, MA, United States, 5Harvard Medical School, Boston, MA, United States
P218
Establishment of a global registry for multiple sclerosis patients on extended dose natalizumab schedules
1NYU Langone Medical Center, Neurology - Multiple Sclerosis Comprehensive Care Center, New York, NY, United States, 2Georgetown University Hospital, Neurology, Washington, DC, United States, 3Rocky Mountain MS Clinic, Salt Lake City, UT, United States, 4University of Buffalo, Neurology, Buffalo, NY, United States, 5Barnabas Health MS Center, Neurology, Livingston, NJ, United States, 6University of Texas Southwestern Medical Center, Neurology, Dallas, TX, United States, 7National Institue of Neurological Disease and Stroke, Bethesda, MD, United States, 8National Institue of Allergy and Immunology, Bethesda, MD, United States, 9University of Alabama at Birmingham, Birmingham, AL, United States
short- and long-term efficacy of ED approach;
short- and long-term safety;
tolerability;
to obtain sufficient statistical power to test the hypothesis whether PML risk is decreased with ED, and to plan:
prospective study of different NTZ ED schedules;
pharmacokinetic study of various ED NTZ schedules; and
evidence-based guidelines for optimization and individualization of NTZ dosage and frequency.
P219
NMOBase is a Web-based, global observational registry for an ‘orphan’ disorder: neuromyelitis optica
1New York University School of Medicine, Neurology, New York, NY, United States, 2Amiri Hospital, Kuwait, Kuwait, 3Karadeniz Technical University Farabi Hospital, Trabzon, Turkey, 4Hospital Italiano, Buenos Aires, Argentina, 5Ospedali Riuniti di Salerno, Salerno, Italy, 6Royal Melbourne Hospital, Melbourne, Australia, 7Hospital Donostia, Donostia-San Sebastian, Spain, 8Generale Provinciale Macerata, Macerata, Italy, 9Royal Hobart Hospital, Hobart, Australia, 10Mayis University, Samsun, Turkey, 11Westmead Hospital, Sydney, Australia
P220
Argentinean registry of patients with relapsing remitting multiple sclerosis treated with fingolimod (REAL): design and results of interim analysis
G
1Novartis Argentina SA, Medical, Buenos Aires, Argentina, 2Office, Buenos Aires, Argentina, 3INEBA, Buenos Aires, Argentina, 4Office, Salta, Argentina, 5IADIN, Buenos Aires, Argentina, 6Office, Santa Fe, Argentina, 7Office, Santa Cruz, Argentina, 8Office, Mendoza, Argentina, 9Fundacion Favaloro, Buenos Aires, Argentina, 10Office, Mar del Plata, Argentina, 11Office, Ushuaia, Argentina, 12DIABAID, Buenos Aires, Argentina, 13Office, Bahia Blanca, Argentina, 14Office, La Plata, Argentina, 15Office, Santiago del Estero, Argentina
P221
A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of natalizumab
1Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden, 2Lund University, Department of Neurology, Lund, Sweden, 3Linköping University, Department of Clinical and Experimental Medicine, Linköping, Sweden, 4Medical Products Agency, Uppsala, Sweden, 5Umeå University, Department of Pharmacology and Clinical Neuroscience, Umeå, Sweden, 6University of Gothenburg, Department of Clinical Neuroscience, Gothenburg, Sweden, 7Uppsala University, Department of Neuroscience, Uppsala, Sweden, 8Örebro University Hospital, Örebro, Sweden, 9Danderyd Hospital, Department of Clinical Science, Stockholm, Sweden
The Wilcoxon Signed-Rank Test was used to assess changes in in efficacy scores.
1,140 patients (48%) terminated treatment at some point, of which 237 later restarted. 1,356 patients are currently being treated with NTZ. The two main reasons for ending treatment are; anti-JC virus antibody positivity (JCV+) (39%) and pregnancy/planned pregnancy (17%). 23% of patients with ongoing treatment are JCV+.
In patients treated with NTZ continuously for ≥5 years (n=412), long lasting, significant, stabilization of disease activity are evident. EDSS scores improved with 10%, MSSS scores with 37%, MSIS-29 physical/psychological scores with 12% and 15%, respectively, and SDMT scores with 23% (mean values at 5 years of treatment compared to baseline values).
Serious AEs were rare (2.3%, 54 events), but included 7 non-fatal cases and 1 fatal case of progressive multifocal leukoencephalopathy (PML, 0.3%), with the latest case reported 2012-10-31. The proportion of JCV+ patients has been reduced over the last years as a result of JCV testing. This has reduced the rate of PML cases per patient years. A total of 11 patients (0.5%) have died for any reason.
Diagnosis and differential diagnosis
P222
Transverse myelitis in neuro-Behcet’s disease
1Yonsei University College of Medicine, Neurology, Seoul, Korea, Republic of, 2Kangbuk Samsung Hospital, Neurology, Seoul, Korea, Republic of, 3Catholic University of Korea, Neurology, Seoul, Korea, Republic of
P223
Methionyl-tRNA formyltransferase (MTFMT) deficiency mimicking neuromyelitis optica
1Baylor College of Medicine, Pediatric Neurology, Houston, TX, United States, 2Texas Children Hospital, Pediatric Neurology, Houston, TX, United States, 3Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, TX, United States
P224
Characteristic retinal pathology in Susac syndrome detected by spectral domain optical coherence tomography differentiates from multiple sclerosis
1Heinrich-Heine University, Medical Faculty, Neurology, Düsseldorf, Germany, 2University Hospital Münster, Neurology, Münster, Germany, 3Heinrich-Heine University, Medical Faculty, Ophthalmology, Düsseldorf, Germany, 4Charité - Universitätsmedizin Berlin, Ophthalmology, Berlin, Germany, 5Alfried Krupp Hospital, Neurology, Essen, Germany, 6Charité - Universitätsmedizin Berlin, NeuroCure Clinical Research Center, Berlin, Germany, 7University Hospital Heidelberg, Neurology, Devision of Molecular Neuroimmunology, Heidelberg, Germany
P225
Brain lesion location at onset helps differentiate neuromyelitis optica and multiple sclerosis
1Dongguk University Ilsan Hospital, Neurology, Goyang-si, Korea, Republic of, 2Sungkyunkwan University Samsung Seoul Hospital, Neurology, Seoul, Korea, Republic of, 3National Cancer Center, Neurology, Goyang-si, Korea, Republic of
P226
Application of the 2010 McDonald criteria to a cohort of patients with clinically isolated spinal cord syndrome
1CHU Rouen, Neurologie, Rouen, France, 2CHRU Lille, Lille, France, 3CHU Rouen, Rouen, France, 4CHU Caen, Caen, France, 5CHU Strasbourg, Strasbourg, France
Baseline cerebro-spinal MRI was peformed within the first 3 months after onset and patients were followed at month 3 and each 6 months. MS was diagnosed according to the 2005 McDonald criteria.
We applied the 2010 McDonald MRI criteria for dissemination in space (DIS 2010) and dissemination in time (DIT 2010).
A CSF analysis was performed searching intrathecal synthesis.
The sensitivity of DIT 2010 criteria is lower than expected and the sensitivity of DIT 2010 is surprisingly low, while the specificity remains high. If changing the DIT criteria, including the symptomatic gadolinium-enhancing lesions, the sensitivity increased to 55.9% while maintaining a specificity of 81.4%. This definifion of DIT could consider the particular feature of SC-CIS. CSF analysis is important in patients fulfilling neither 2005 nor 2010 McDonald criteria to identify those at risk of conversion to MS.
P227
Aggressive multiple sclerosis
1Western University, Clinical Neurological Sciences, London, ON, Canada, 2London Health Sciences Centre, London, ON, Canada, 3Lawson Health Research Institute, London, ON, Canada
P228
Perivascular inflammation in Baló’s concentric sclerosis - preliminary results from a 7T MRI study
1NeuroCure Clinical Research Center, Charite - Universitätsmedizin Berlin, Berlin, Germany, 2Asklepios Fachklinikum Teupitz, Department of Neurology, Teupitz, Germany, 3Charité - Universitaetsmedizin Berlin, Department of Neurology, Berlin, Germany, 4Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitaetsmedizin Berlin, Berlin, Germany, 5Berlin Ultrahigh Field Facility (B.U.F.F), Max Delbrueck Center for Molecular Medicine, Berlin, Germany, 6Experimental and Clinical Research Center, Charité - Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany, 7Institute of Neuroradiology, University Medicine Goettingen, Goettingen, Germany
MS brain lesions and their correlation to the cerebral vasculature can be visualized with very high anatomical details at 7 Tesla MRI (7T).
P229
Aquaporin-4 antibody-seropositive myelitis initially biopsied due to suspected spinal cord tumors: diagnostic considerations
1Tohoku University, Multiple Sclerosis Therapeutics, Sendai, Japan, 2Tohoku University School of Medicine, Neurology, Sendai, Japan, 3Federal University of Minas Gerais, Belo Horizonte, Brazil, 4University of São Paulo, São Paulo, Brazil, 5Tohoku University School of Medicine, Sendai, Japan, 6Tohoku University School of Medicine, Multiple Sclerosis Therapeutics, Sendai, Japan, 7Federal University of Minas Gerais, Neurology, Belo Horizonte, Brazil
NMOSD can be suspected in the biopsied material if some features such as cystic changes with vascular wall thickening and signs of astrocyte rarefaction are present.
P230
Artificial intelligence techniques in the diagnosis of clinically definite multiple sclerosis
1San Raffaele Hospital, Neurological Department, Milan, Italy, 2San Raffaele Hospital, Neurophysiology Unit, Milan, Italy, 3San Raffaele Hospital, Neuroimmunology Research Unit, Milan, Italy, 4San Raffaele Hospital, Neuroimaging Research Unit, Milan, Italy
The integration of all risk factors observed at clinical presentation into an estimate of absolute risk should be therefore the starting point for an accurate and personalized risk management at the onset of the disease.
P231
MRI study of Leber’s hereditary optic neuropathy and MS suggests common lesion pathology and an 83% risk of MS-like lesions in females with LHON
1University of Oxford, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom, 2Oxford University Hospitals NHS Trust, Department of Neurology, Oxford, United Kingdom, 3Medical University of Graz, Department of Neurology, Graz, Austria, 4Medical University of Graz, Department of Radiology, Graz, Austria, 5Hospital Vall D’Hebron, Department of Radiology, Barcelona, Spain, 6UCL Institute of Neurology, London, United Kingdom, 7University of Siena, Department of Neurological and Behavioural Sciences, Siena, Italy, 8Vita-Salute San Raffaele University, Neuroimaging Research Unit and Dept of Neurology, Milan, Italy, 9University of Copenhagen, Glostrup Hospital, Copenhagen, Denmark, 10St Josef Hospital Ruhr-University, Department of Radiology, Bochum, Germany
Of the 12 females in total with LHON, eight had LHON-MS and three had asymptomatic T2 hyperintense white matter lesions. Ten of 12 females with LHON were rated as having brain lesions consistent with MS, compared to three of 30 males, equating to a relative risk of 8.3 (95% CI 2.8 to 25.1, p< 0.01).
Mahad, D., et al., Brain, 2008. 131(Pt 7): p. 1722-35.
Dutta, R., et al., Ann Neurol, 2006. 59(3): p. 478-89.
Riordan-Eva, P., et al., Brain, 1995. 118 ( Pt 2): p. 319-37.
Vanopdenbosch, L., et al., J Neurol, 2000. 247(7): p. 535-43.
P232
Diagnosing multiple sclerosis with a gait measuring system, an analysis of the motor fatigue, and machine learning
1University of Liège, INTELSIG, Liège, Belgium, 2University of Liège, Liège, Belgium, 3University Hospital of Liège, Neurology, Liège, Belgium
P233
The diagnosis of multiple sclerosis: pinpointing the concept of “no better explanation”
1University Hospital of Verona, Dept. of Neurological and Movement Sciences, Verona, Italy, 2San Camillo Hospital, Rome, Italy, 3University of Bari, Bari, Italy, 4Neurologia 2-CRESM, AOU San Luigi Gonzaga, Orbassano, Italy, 5University of Palermo, Dept. of Experimental Medicine and Clinical Neurosciences, Palermo, Italy, 6Ospedale SS Annunziata, Chieti, Italy, 7Istituto Neurologico Mediterraneo, Pozzilli, Italy, 8A.O.U. Policlinico-Vittorio Emanuele, Catania, Italy, 9Tor Vergata, Dept. Neuroscienze Policlinico, Roma, Italy, 10Univeristy of Bari, Dept of Basic Medical Sciences, Neurosciences and Sense Organs, Bari, Italy, 11Ospedale Civile, Centro Sclerosi Multipla, Fidenza, Italy, 12Ospedale S. Antonio Abate, Gallarate, Italy, 13Azienda Ospedaliera Spedali Civili, Brescia, Italy, 14University of Naples Federico II, Napoli, Italy, 15University of Siena, Siena, Italy, 16Second University of Naples, Napoli, Italy, 17University of Cagliari., Public Health Clinical and Molecular Medicine, Cagliari, Italy, 18Cardiff University, Cardiff, United Kingdom, 19Policlinico Gemelli, Rome, Italy, 20Azienda Ospedaliera S. Andrea, Rome, Italy, 21Ospedale San Raffaele, Milano, Italy, 22Ospedale PA Micone, Genova, Italy
Among the 55 patients in which a MS diagnosis was excluded and other diagnoses were already possible, the most frequent diagnoses were migraine (in 15 cases), vascular encephalopathy including PTO (in 13 cases), recurrent optic neuritis (in 2 cases), systemic erythematous lupus (in 2 cases), dizziness (in 2 cases), neuroBechet’s disease (in 2 cases), neuromyelitis optica (in 2 cases).
P234
The thalamus and basal ganglia lesions in multiple sclerosis and primary angiitis of the central nervous system in southern Chinese people
1The First Affilated Hospital of Wenzhou Medical University, Neurolgical Department, Wenzhou, China, 2The Third Affiliated Hospital of Sun Yat-sen University, Neurological Department, Guangzhou, China, 3The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China, 4The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
P235
Patients with multiple sclerosis criteria subsequently displayed Behçet disease signs
1Mustapha Bacha University Hospital, Neurology, Algiers, Algeria, 2Institut Pasteur of Algeria, Immunology, Algiers, Algeria
P236
Non MS tumefactive inflammatory lesions: diagnosis and long term evolution of 10 patients in a multicentric study
1Universitary Hospital, Nancy, France, 2Universitary Hospital, Montpellier, France, 3Hospital, Toulouse, France, 4Hospital, Perpignan, France, 5Universitary Hospital, Bordeaux, France, 6Universitary Hospital, Caen, France, 7Universitary Hospital, Strasbourg, France
P237
Magnetic resonance spectroscopy in cases of clinical conflict between multiple sclerosis, vasculitis and multiple lacunar infarcts of the brain
1Alexandria, Neurology, Alexandria, Egypt, 2Alexandria, Alexandria, Egypt, 3Alexandria, Radiology, Alexandria, Egypt, 4Aexandria, Neurology, Alexandria, Egypt
P238
HTLV-1-associated myelopathy/tropical spastic paraparesis: a differential diagnosis in primary progressive multiple sclerosis
1Raigmore Hospital, Neurology, Inverness, United Kingdom, 2Matsumoto Medical Center, Neurology, Brasilia, Brazil
through sexual contact;
vertically by prolonged breast-feeding; and
via infected blood products.
P239
Microscopic polyangiitis presenting with long extended tranverse myelitis (LETMS)
HÖ Köse1, V Akdemir2,
1Kafkas University Medical Faculty, Neurology, Kars, Turkey, 2Trakya University, Edirne, Turkey
P240
Borrelia burgdorferi - infection agent - risk assessment in MS
1Outpatient Neurology Clinic MS Care Center Clinical Trials Site Hanka Hertmanowska, Plewiska, Poland
In all 4 patients - 3 exacerbations a year - antibodies present in WB: in IgG: OspC p25, p30, positive LTT, normal CD57 lymphocyte count and negative LUAT.
P241
Clinical course, radiologic features and treatment response in patients with tumefactive demyelinating lesions in Toronto
1University of Toronto, Division of Neurology, Toronto, ON, Canada, 2Sunnybrook Health Sciences Centre, Division of Neurology, Toronto, ON, Canada, 3St. Michael’s Hospital, Division of Neurology, Toronto, ON, Canada
Disease biomarkers
P242
Glial and neuronal markers in CSF predict progression in multiple sclerosis
1Department of Neurlogy, Joan XXIII University Hospital, Universitat Rovira i Virgili, Tarragona, Spain, 2Multiple Sclerosis Unit, Department of Neurology, Bellvitge University Hospital, Universitat de Barcelona, L’Hospitalet de Llobregat, Spain, 3Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Department of Psychiatry and Neurochemistry, Mölndal, Sweden, 4Institute of Neurology, University College London, London, United Kingdom
P243
Dicer and miRNA are differentially expressed and regulated in RRMS and SPMS
B Weinstock-Guttman1,
1SUNY University at Buffalo, Buffalo, NY, United States, 2Roswell Park Institute, Buffalo, NY, United States, 3SUNY University at Buffalo, Pharmaceutical Sciences, Buffalo, NY, United States, 4SUNY University at Buffalo, Neurology, Buffalo, NY, United States
Of ~600 miRNA identified in each group, several miRs appear to discriminate between RRMS and SPMS. miR-484 & miR-99a-5p show significantly decreased expression in SPMS NT patients and miR-107 with enhanced expression. Neither miR-342-3p nor miR-146b-5p was differentially expressed between healthy controls and RRMS patients; however, both were significantly decreased in SPMS.
P244
Interferon inducible transcriptional profile in secondary progressive multiple sclerosis patients
1Sheba Medical Center, Multiple Sclerosis Center, Ramat Gan, Israel
P245
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
G Disanto1, R Adiutori1, R Dobson1, V Martinelli2, G Dalla Costa2, T Runia3, E Evdoshenko4, E Thouvenot5, M Trojano6, N Norgren7, J Lorscheider8, C Teunissen9, L Kappos8, G Giovannoni1,
1Queen Mary University, London, United Kingdom, 2Vita-Salute San Raffaele University, Milan, Italy, 3Erasmus MC University Medical Center, Rotterdam, Netherlands, 4City Clinical Hospital # 31, St Petersburg, Russian Federation, 5Université Montpellier 1, Montpellier, France, 6University of Bari, Bari, Italy, 7Uman Diagnostics, Umea, Sweden, 8University Hospital, Basel, Switzerland, 9VU University Medical Centre, Amsterdam, Netherlands
P246
Gray matter related proteins in cerebrospinal fluid differentiate between multiple sclerosis and other acquired demyelinating syndromes in childhood
V Singh1,
1Erasmus MC, Rotterdam, Netherlands
P247
Global metabolomics identifies a metabolic profile of multiple sclerosis
1Johns Hopkins University School of Medicine, Neurology, Baltimore, MD, United States, 2Johns Hopkins University School of Medicine, Pathology, Baltimore, MD, United States
P248
CSF biomarkers of inflammation and neuronal damage in acute optic neuritis predict later development of MS and long-term disability
1Glostrup University Hospital, University of Copenhagen, Dept of Neurology, Glostrup, Denmark, 2Danish MS Center, Rigshospitalet, University of Copenhagen, Dept of Neurology, Copenhagen, Denmark
P249
Cerebrospinal fluid osteopontin and neurofilament levels mark different brain atrophy patterns in clinically isolated syndrome
1University of Bari, Bari, Italy
P250
The proteome profile of the urine is different in patients with neuromyelitis optica compared to multiple sclerosis and healthy subjects
1Odense University Hospital, Department of Neurology, Odense C, Denmark, 2Odense University Hospital, Center for Clinical Proteomics, Odense C, Denmark, 3University of Nebraska-Lincoln, School of Veterinary Medicine and Biomedical Sciences, Lincoln, NE, United States
P251
Diagnostic contribution of soluble CD163 to a panel of biomarkers in newly diagnosed patients with multiple sclerosis
1Aarhus University Hospital, Department of Neurology, Aarhus C, Denmark, 2Aarhus University, Department of Biomedicine, Aarhus C, Denmark, 3Aarhus University Hospital, Department of Clinical Biochemestry, Aarhus C, Denmark
P252
A diagnostic test for MS leading to novel insights into pathogenesis: unique B-cell mutational patterns that create antibodies with unique CNS binding
1University of Texas Southwestern, Dallas, TX, United States, 2DioGenix, Gaithersburg, MD, United States
P253
Peripheral blood cells from patients with benign multiple sclerosis are characterized by a TNF gene expression signature
1Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain
P254
Cerebrospinal fluid proteome analysis reveals differentially abundant proteins in multiple sclerosis
1University of Szeged, Department of Neurology, Szeged, Hungary, 2Uppsala University, Analytical Chemistry, Department of Chemistry-Biomedical Center, Uppsala, Sweden, 3Chalmers University of Technology, Analytical Chemistry, Department of Chemical and Biological Engineering, Göteborg, Sweden, 4Uppsala University, Department of Physics and Astronomy, Uppsala, Sweden, 5MTA-SZTE Neuroscience Research Group, Szeged, Hungary, 6Uppsala University, Science for Life Laboratory (SciLife Lab), Uppsala, Sweden
Fifty proteins were identified with at least 20 % coverage of all possible hits in the SwissProt database. After further quality restrictions 15 proteins were considered to be well identified. Based on the group median intensities all of these proteins were up-regulated in MS patients. Although the variation is high between individuals, there is a significant difference between the group means (p=0.002). Alpha-1-antichymotrypsin showed the highest increase in MS compared to the control group (MS/C ratio: 9.8).
P255
Levels and age dependency of neurofilament light in healthy individuals and its relation to the brain parenchymal fraction
1Umeå University, Dept. of Pharmacology and Clinical Neuroscience, Umeå, Sweden, 2Uman Diagnostics AB, Umeå, Sweden
P256
UP-regulation of Nod-like receptor signaling in multiple sclerosis
1Fondazione Don C. Gnocchi ONLUS IRCCS, Laboratorio di Medicina Molecolare e Biotecnologie, Milano, Italy, 2University of Milano, Milano, Italy
P257
Discovery of biomarkers reflecting progression pathophysiology for relapse remitting and primary progressive MS subtypes by multiplex aptamer approach
1VU University Medical Center, Clinical Chemistry, Amsterdam, Netherlands, 2VU University Medical Center, Neurology, Amsterdam, Netherlands, 3University Hospital Basel, Department of Biomedicine, Basel, Switzerland
P258
Orbitrap proteomics analysis of cerebrospinal fluid to identify novel markers for progression after a first attack of demyelination
1Erasmus MC, Neurology, Rotterdam, Netherlands
P259
Metabolomics of cerebrospinal fluid from progressive MS patients
1Tisch MS Research Center of New York, New York, NY, United States
P260
Biomarkers in cerebrospinal fluid (Tau, phospho-Tau (181) and neurofilament light) in clinically isolated syndrome patients and healthy controls
1Aristotle University, AHEPA Hospital, 1st Department of Neurology, Thessaloniki, Greece, 2Aristotle University, Papanikolaou Hospital, 3rd Department of Neurology, Thessaloniki, Greece
Neurofilament light (NFL) was analyzed and determined using the Elisa technique in 62 CSF samples of the same cohort. The group consisted of 49 MS patients (42±12) and 13 controls (41±12). MS patients were 40 females and 9 males, while the controls were 4 females and 9 males. 18 (36.7%) of the patients suffered from CIS, 21 (42.8%) from RRMS, 2 (4%) from PPMS, 4 (8%) from SPMS, 2 (4%) from RPMS.
We used the commercial available kits for the ELISA technique (Innogenetics, Belgium). Statistical analysis was performed using SPSS statistical package 17.0.
§ higher tTau concentration in CIS patients in comparison with the controls (U=69, z=−1.9, p=0.05)
§ significantly lower pTAU levels in CIS patients in comparison with the controls (U=230, z=−1.9, p=0,05) CIS patients demonstrated lower mean age (36.5+-11) than the controls (40+-12)
§ significantly higher concentrations of NFL in CIS patients when compared with the controls (Mann-Whitney: U=56, z=−2.4. p=0.014).
P261
Urine levels of 8-Isoprostane in relapsing-remitting and secondary progressive multiple sclerosis
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States, 2EMD Serono Inc., Billerica, MA, United States
P262
Potential biomarkers of BIIB033 activity in phase 1 clinical studies
1Biogen Idec, Inc., Cambridge, MA, United States
P263
Correlation of neurofilaments and nitrotyrosine with retinal nerve fiber layer thickness and disability in different phases of multiple sclerosis
C Uzunköprü1,
1Ege University Medical School of Hospital, Neurology, Izmir, Turkey, 2Ege University Medical School of Hospital, Physiology, Izmir, Turkey, 3Ege University Medical School of Hospital, Ophthalmology, Izmir, Turkey
P264
Correlation of mRNA expression in the blood with multiple sclerosis disease activity on MRI
1University of Texas Health Science Center at Houston, Neurology, Houston, TX, United States, 2University of Texas Health Science Center at Houston, Biomedical Informatics, Houston, TX, United States, 3University of Texas Health Science Center at Houston, Integrative Biology and Pharmacology, Houston, TX, United States
P265
Identification of multiple sclerosis cerebrospinal fluid biomarkers using nuclear magnetic resonance spectroscopy
1Poznan University of Medical Sciences, Department of Neurology and Cerebrovascular Disorders, Poznan, Poland, 2Adam Mickiewicz University, Faculty of Chemistry, Supramolecular Chemistry, Poznan, Poland, 3Adam Mickiewicz University, NanoBioMedical Centre, Poznan, Poland, 4Polish Academy of Sciences, Institute of Bioorganic Chemistry, Poznan, Poland, 5Adam Mickiewicz University, Department of Macromolecular Physics, Poznan, Poland
P266
Next generation sequencing of microRNA in the CD4+ T-cells of secondary progressive multiple sclerosis individuals
1Bond University, Faculty of Health Sciences and Medicine, Gold Coast, Australia, 2Hunter Medical Research Institute, Centre for Information-Based Medicine, Newcastle, Australia, 3John Hunter Hospital, Department of Neurology, Division of Medicine, Newcastle, Australia, 4Hunter Area Pathology Service, Division of Molecular Genetics, Newcastle, Australia
P267
MicroRNA-572 expression in serum of multiple sclerosis patients with different patterns of disease progression
1Don C. Gnocchi Foundation, Lab Molecular Medicine, Milano, Italy
P268
Uric acid levels are reduced in multiple sclerosis
1University Federico II, Department of Neurosciences, Napoli, Italy, 2Imperial College, Department of Primary Care and Public Health, London, United Kingdom, 3University Federico II, Department of Public Health, Napoli, Italy
Further investigations should be addressed to clarify the relationship between UA levels and MS activity with longitudinal models considering UA variability within subjects.
P269
Search of biomarkers associated with disability progression by means of gene expression profiling in patients with progressive multiple sclerosis
1Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain
P270
Neurofilament light subunit as an independent biomarker in clinically isolated syndromes
1Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain, 2Hospital Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Neurology and Immunology Department-Multiple Sclerosis Unit, Madrid, Spain, 3Vall Hebron University Hospital, Magnetic Resonance Unit, Neuroradiology Department, Barcelona, Spain
P271
Subanalysis of a multicentric cross-sectional study of CSF-GFAP in the diagnosis of inflammatory demyelinating diseases
1Tohoku University, Department of Neurology, Sendai, Japan, 2Tokyo Women’s Medical University, Department of Neurology, Tokyo, Japan, 3Juntendo University, Department of Neurology, Tokyo, Japan, 4Tenri Hospital, Department of Neurology, Tenri, Japan, 5Yonezawa National Hospital, Department of Neurology, Yonezawa, Japan, 6Tohoku Pharmaceutical University Hospital, Department of Neurology, Sendai, Japan, 7Konan Hospital, Department of Neurology, Sendai, Japan, 8Tohoku University, Department of Multiple Sclerosis Therapeutics, Sendai, Japan
P272
CSF fetuin-A is a biomarker of subclinical disease activity in progressive MS
1Tisch MS Research Center of New York, New York, NY, United States
P273
Lipidomics analysis reveals low levels of phosphatidylcholines and sphingomyelins in cerebrospinal fluid of multiple sclerosis patients
D Pieragostino1,2, M D’Alessandro1,2, M Di Ioia2,3, M Zucchelli2,4, A Lugaresi3, P Sacchetta1,2,
1University ‘G. d’Annunzio’, Experimental and Clinical Sciences, Chieti, Italy, 2Centre of Investigation on Aging (Ce.S.I.), Analytical Biochemistry and Proteomics Unit, Chieti, Italy, 3University ‘G. d’Annunzio’, Neurosciences and Imaging, Chieti, Italy, 4University “G. d’Annunzio”, School of Medicine and Health Sciences, Chieti, Italy
Lipids were analyzed by LC-MS/MS. Elution was obtained using a column Atlantis HILIC by a linear gradient of formic acid 0.1% and ACN. The LC system was coupled on-line with an ESI-triple quadrupole mass spectrometer. The profile of biological phosphatidylcholines (PCs) and sphingomyelins (SMs) in CSF was obtained by parent ion scan mode following the signal at m/z=184 Da corresponding to the polar head of this classes of phospholipids.
Partial least squares discriminant analysis using SIMCA-P+ was employed for data processing in order to find differential lipids in two analyzed groups. The significant metabolites were identified using Lipidmaps and Human Metabolome Database. Correlation analysis between clinical parameters and lipid levels were performed by using Statistica 7.0.
P274
Metabolomic profile of multiple sclerosis patients
1University of Cagliari, Cagliari, Italy, 2ASL8, Cagliari, Italy
Samples were analyzed with a 500 MHz Varian spectrometer; multivariate statistical techniques were used for data interpretation. Initially data analysis was conducted with principal component analysis (PCA) then a supervised analysis (orthogonal partial least squares discriminant analysis [OPLS-DA]) was applied. To evaluate the goodness of the models the variance and the predictive ability (R2X, R2Y, Q2) were calculated. Metabolites were identified and quantified using Chenomx software and data available in the literature.
Metabolomic analysis appears to be a promising non-invasive approach to study MS. Our results are preliminary and need to be replicated in other samples.
P275
Metabolomics analysis of cerebrospinal fluid reveals a distinctive biochemical alteration associated with multiple sclerosis
1G. d’Annunzio, Chieti, Italy
P276
Increased production of superoxide anion, antioxidative enzyme activity and oxidative damage in multiple sclerosis patients during relapse
1Military Medical Academy, Belgrade, Serbia
P277
Oxidation and axonal degeneration: early oxidation state can be a long term disability biomarker. Results from a 12-years study
1Hospital Virgen Macarena, Seville, Spain
P278
Elevated CSF lipocalin-2 levels at diagnosis predict faster disability progression in RRMS patients
AM Menezes1, S Xavier1, S Neves1,2,3, F Marques1,2,3,
1School of Health Sciences, University of Minho, Braga, Portugal, 2Life and Health Sciences Research Institute, University of Minho, Braga, Portugal, 3ICVS/3B’s Associated Laboratory, Braga, Portugal
P279
Expression of miRNAs in multiple sclerosis cerebrospinal fluid and their relation to MR activity
1Girona Biomedical Research Institute (IDIBGI), Neurodegeneration and Neuroinflamation Group, Girona, Spain, 2IDI MRI-Unit, Radiology Department, Dr. Josep Trueta University Hospital, Girona, Spain, 3University of Girona, Department of Computer Architecture and Technology (VICOROB Group), Girona, Spain, 4Neuroimmunology and Multiple Sclerosis Unit, Dr. Josep Trueta University Hospital, Department of Neurology, Girona, Spain, 5Endocrinology and Nutrition (UDEN), Girona Biomedical Research Institute (IDIBGI), and CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn, CB06/03), Department of Diabetes, Girona, Spain
Disease therapy
P280
Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
D Baroncini1,
1Centro Studi Sclerosi Multipla and H. San Raffaele, Gallarate-Milan, Italy, 2Centro Studi Sclerosi Multipla, Gallarate, Italy
In pts treated with NAT and FTY the ARR was 0.03±0.20 vs 0.3±0.7 (p< 0.001) after 1 year, and 0.04±0.15 vs 0.26±0.42 (p< 0.001) after 2 years of treatment respectively; the proportion of clinically active patients was 3% vs 22% (p< 0.001) after 1 year and 8% vs 32% (p=0.003) after 2 years of treatment respectively; the proportion of disease-free pts 97% vs 45% (p< 0.001) after 1 year and 93% vs 42% (p< 0.001) after 2 years of treatment respectively. The EDSS score was 2.1±1.4 vs 2.0±1.2 (p=0.971) after 1 year and 2.3±1.5 vs 2.1±1.2 (p=0.736) after 2 years of follow up.
P281
The influence of immunomodulatory treatment on the clinical course of multiple sclerosis
1Karolinska Institutet, Clinical Neuroscience, Stockholm, Sweden
Survival analysis adjusted for suspected confounders was performed with the outcome variable time in months from the baseline EDSS at diagnosis to EDSS ≥4 in a comparison of patients selected for treatment early or late after onset of disease.
Univariate Kaplan-Meier analysis showed a statistically significant difference for time to reach EDSS ≥4 between early and delayed treatment groups (p > 0.001) with those treated late doing worse (hazard ratio of 1.77 (95% CI: 1.15−2.73) to reach EDSS ≥4). The difference remained statistically significant after adjusting for covariates (age at onset, the baseline EDSS and gender).
However, further analysis revealed that the early and delayed treatment groups were very different at the mean of age at diagnosis (32.2 and 39.1 years respectively). When we chose to include age at diagnosis instead of age at onset in the Cox proportional hazard model, significance was lost (95% CI for hazard ratio to reach EDSS ≥4 were 0.94-2.35).
Interestingly, gender was not a significant covariate in either model while the baseline EDSS remained significant in both analyses.
P282
Mechanism of action and safety implications of differently manufactured glatiramer acetates: gene expression studies of a human monocyte cell line
SE Kolitz1, T Hasson2, F Towfic1, JM Funt1, S Bakshi2, KD Fowler1, D Laifenfeld2, MN Artyomov1, R Schwartz2, A Komlosh2, L Hayardeny2, D Ladkani2, MR Hayden2,
1Immuneering Corporation, Cambridge, MA, United States, 2Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel
P283
Rituximab following natalizumab withdrawal in relapsing remitting multiple sclerosis
1Southern California Permanente Medical Group, Los Angeles Medical Center, Neurology, Los Angeles, CA, United States, 2Kaiser Permanente Southern California, Research & Evaluation, Pasadena, CA, United States
P284
Comparison of fingolimod versus interferon beta/glatiramer acetate as second-line therapy in active multiple sclerosis
A He1, T Spelman1, V Jokubaitis2, A Lugaresi3, G Izquierdo4, M Trojano5, P Grammond6, J Lechner-Scott7, P Duquette8, M Girard8, E Pucci9, M Slee10, F Grand’Maison11, C Oreja-Guevara12, C Boz13, R Fernandez-Bolanos14, S Hodgkinson15, J Sanchez-Menoyo16, G Iuliano17, M Barnett18, F Moore19, H Butzkueven20,
1Royal Melbourne Hospital, Melbourne, Australia, 2University of Melbourne, Department of Medicine, Melbourne, Australia, 3University ‘G. d’Annunzio, Chieti, Italy, 4Hospital Universitario Virgen Macarena, Sevilla, Spain, 5University of Bari, Bari, Italy, 6Hotel-Dieu de Levis, Quebec, QC, Canada, 7John Hunter Hospital, Newcastle, Australia, 8Hôpital Notre Dame, Montreal, QC, Canada, 9Ospedale di Macerata, Macerata, Italy, 10Flinders University and Medical Centre, Adelaide, Australia, 11Hôpital Charles LeMoyne, Quebec, QC, Canada, 12University Hospital San Carlos, Madrid, Spain, 13Karadeniz Technical University, Trabzon, Turkey, 14Hospital Universitario Virgen de Valme, Sevilla, Spain, 15Liverpool Hospital, Liverpool, Australia, 16Galdakao Hospital, Vizcaya, Spain, 17Ospedali Riuniti di Salerno, Salerno, Italy, 18Brain and Mind Research Institute, Sydney, Australia, 19Jewish General Hospital, Montreal, QC, Canada, 20University of Melbourne, Melbourne, Australia, 21Royal Melbourne Hospital, Department of Neurology, Melbourne, Australia
P285
Clinical markers of long-term disability in RRMS patients treated with interferon beta
1Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain, 2Vall Hebron University Hospital, Preventive Medicine and Epidemiology Department, Barcelona, Spain
P286
Rituximab in the treatment of secondary-progressive multiple sclerosis
1University of Massachusetts Medical School, Worcester, MA, United States, 2Maine Medical Center, Portland, ME, United States
P287
Efficacy of Natalizumab extended dosing in multiple sclerosis: a retrospective multicenter analysis
1NYU Langone Medical Center, New York, NY, United States, 2Georgetown University Hospital, Neurology, Washington, DC, United States, 3Rocky Mountain MS Clinic, Salt Lake City, UT, United States, 4University of Buffalo, Neurology, Buffalo, NY, United States, 5Barnabas Health MS Center, Neurology, Livingston, NJ, United States, 6University of Texas Southwestern Medical Center, Neurology, Dallas, TX, United States, 7National Institute of Neurological Disease and Stroke, Bethesda, MD, United States, 8National Institute of Allergy and Immunology, Bethesda, MD, United States, 9University of Alabama at Birmingham, Birmingham, AL, United States
P288
Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
1University of Melbourne, Department of Medicine, Melbourne, Australia, 2Royal Melbourne Hospital, Department of Neurology, Melbourne, Australia, 3Charles University in Prague, Prague, Czech Republic, 4University of Bari, Bari, Italy, 5University ‘G. d’Annunzio, Chieti, Italy, 6Hospital Universitario Virgen Macarena, Sevilla, Spain, 7Jahn Ferenc Teaching Hospital, Budapest, Hungary, 8Hotel-Dieu de Levis, Quebec, QC, Canada, 9Amiri Hospital, Kuwait, Kuwait, 10Hôpital Notre Dame, Montreal, QC, Canada, 11Ospedale di Macerata, Macerata, Italy, 12John Hunter Hospital, Newcastle, Australia, 13Flinders University and Medical Centre, Adelaide, Australia, 14Hôpital Charles LeMoyne, Quebec, QC, Canada, 15Orbis Medical Center, Sittard, Netherlands, 16Groen Hart Ziekenhuis, Gouda, Netherlands, 17Liverpool Hospital, Liverpool, Australia, 18University Hospital San Carlos, Madrid, Spain, 19AORN San Giuseppe Moscati, Avellino, Italy, 20Brain and Mind Research Institute, Sydney, Australia, 2119 Mayis University, Samsun, Turkey, 22National Neurological Institute C. Mondino, Pavia, Italy, 23Royal Brisbane and Women’s Hospital, Brisbane, Australia, 24Galdakao Hospital, Vizcaya, Spain, 25Semmelweis University, Budapest, Hungary, 26University of Debrecen, Debrecen, Hungary, 27Petz A. County Hospital, Gyor, Hungary, 28Karadeniz Technical University, Trabzon, Turkey
P289
Persistence with fingolimod versus dimethyl fumarate in patients with multiple sclerosis: retrospective analysis of US open source pharmacy data
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States, 3IMS Health, Waltham, MA, United States
P290
Including threshold rates of brain volume loss in the definition of disease-activity-free in multiple sclerosis using fingolimod phase 3 data
1University of Siena, Department of Medicine, Surgery and Neuroscience, Siena, Italy, 2University Hospital Basel, Medical Image Analysis Centre, Basel, Switzerland, 3University Hospital Basel, Department of Neurology and Division of Neuroradiology, Basel, Switzerland, 4University of Ottawa and the Ottawa Hospital, Research Institute, Ottawa, ON, Canada, 5University of California San Francisco, Department of Neurology, San Francisco, CA, United States, 6University of Genoa, Biostatistics Unit, Department of Health Sciences, Genoa, Italy, 7Novartis Pharma AG, Basel, Switzerland, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States, 9University Hospital Basel, Basel, Switzerland
P291
Comparison of survival of interferon beta-1b treated MS patients across two populations: the limitation of using propensity score matching
1University of Aarhus, Dept. of Clinical Epidemiology, Aarhus, Denmark, 2The Danish MS Research Centre, The Danish Multiple Sclerosis Registry, Copenhagen, Denmark, 3Bayer HealthCare Pharmaceuticals, New Jersey, NJ, United States, 4University of Chicago Medical Center, Dept. of Neurology, Chicago, IL, United States
P292
A six-year clinical follow-up study of patients with multiple sclerosis who started natalizumab
1Sapienza University, Neurology and Psychiatry, Rome, Italy, 2S. Antonio Abate Hospital, Multiple Sclerosis Centre, Gallarate, Italy, 3San Luigi Gonzaga University-Hospital, Regional Multiple Sclerosis Centre, Orbassano, Italy, 4Tor Vergata University, Neurosciences, Rome, Italy, 5S. Camillo-Forlanini Hospital, Neurosciences, Rome, Italy
Disability worsening was observed in 8 (6%) continuing, 17 (23%) temporarily interrupting, and 66 (39%) discontinuing patients. Disability reduction was observed in 37 (30%) continuing, 15 (20%) temporarily interrupting, and 12 (7%) discontinuing patients.
Discontinuing and interrupting patients were 9.3 and 4.3 times more likely to experience disability worsening than continuing ones (p< 0.001 and p=0.001, respectively); discontinuation implied a 2.2-fold increased risk of disability worsening even respect to temporary interruption (p=0.015).
Discontinuing patients were less likely to experience disability reduction than continuing (OR=0.21, p< 0.001) and temporarily interrupting ones (OR=0.35, p=0.014). Finally, the odds of disability reduction did not differ between continuing and temporarily interrupting patients (p=0.21).
P293
Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry
1General Hospital Linz, Department of Neurology and Psychiatry, Linz, Austria, 2Medical University of Graz, Department of Neurology, Graz, Austria, 3Medical University of Vienna, Department of Neurology, Vienna, Austria, 4Paracelsus Medical University of Salzburg, Department of Neurology, Salzburg, Austria, 5Innsbruck Medical University, Clinical Department of Neurology, Innsbruck, Austria
P294
Comparison of dropout rates of disease modifying therapies in multiple sclerosis
1Istanbul University Istanbul Medical Faculty, Neurology, Istanbul, Turkey, 2Istanbul Bilim University, Neurology, Istanbul, Turkey
P295
Consensus opinion of US neurologists on practice patterns in radiologically and clinically isolated syndrome and relapsing-remitting MS
1Georgetown University, Washington, DC, United States, 2Baylor Research Institute, Dallas, TX, United States, 3Wayne State University, Detroit, MI, United States, 4Mount Sinai School of Medicine, New York, NY, United States, 5CVS Caremark Inc., Woonsocket, RI, United States
P296
Assessing tolerability of interferon beta-1a intramuscular injections with a 30 gauge needle
AC Neal1, LO Tuttle1, JA Ruiz1, BM Anderson1,
1Mount Sinai Rehabilitation Hospital, Mandell Center for Multiple Sclerosis, Hartford, CT, United States
P297
Influence of treatments on multiple sclerosis disability: a cohort study
1University of Cagliari, Cagliari, Italy, 2ASL8, Cagliari, Italy
P298
Safety and efficacy of treosulfan in 21 patients with active secondary progressive multiple sclerosis after treatment with mitoxantrone
1University of Würzburg, Department of Neurology, Würzburg, Germany, 2University of Münster, Department of Neurology, Münster, Germany
P299
Improving adherence in pediatric MS: feasibility of a randomized-control trial with a remote motivational interviewing intervention
1Hospital for Sick Children, Neurosciences and Mental Health, Toronto, ON, Canada, 2DeltaQuest Foundation, Concord, MA, United States, 3Tufts University Medical School, Boston, MA, United States, 4Oslo and Akershus University College of Applied Sciences, Oslo, Norway, 5Hospital for Sick Children, Neurology, Toronto, ON, Canada
P300
Comparative tolerability and efficacy of dimethyl fumarate and fingolimod in multiple sclerosis
1Cleveland Clinic Lerner College of Medicine, Cleveland, OH, United States, 2Cleveland Clinic Mellen Center, Cleveland, OH, United States
P301
Suboptimal response to therapy in disease-free MS patients: a paradox?
FFA Figueira1,
1Hospital São Francisco, Neurology, Rio de Janeiro, Brazil
P302
Patient-reported adverse events of high-dose intravenous methylprednisolone for relapse treatment in multiple sclerosis (FEEL study)
1to-BBB Technologies BV, Leiden, Netherlands, 2St Antonius Ziekenhuis, Utrecht, Netherlands, 3Viecuri Medisch Centrum, Venlo/Venray, Netherlands, 4Jeroen Bosch Hospital, Den Bosch, Netherlands, 5Sint Lucas Andreas Ziekenhuis, Amsterdam, Netherlands, 6Orbis Medical Center, Sittard, Netherlands, 7Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, 8Reinier de Graaf Groep, Delft, Netherlands, 9Canisius-Wilhelmina Ziekenhuis, Nijmegen, Netherlands, 10St. Elisabeth Ziekenhuis, Tilburg, Netherlands, 11Slingeland Ziekenhuis, Doetinchem, Netherlands, 12Westfriesgasthuis, Hoorn, Netherlands, 13Admiraal De Ruyter Ziekenhuis, Goes, Netherlands, 14Groene Hart Ziekenhuis, Gouda, Netherlands, 15Meander Medisch Centrum, Amersfoort, Netherlands, 16Tweesteden Ziekenhuis, Tilburg, Netherlands, 17MS4 Research Institute, Nijmegen, Netherlands
P303
Safety and efficacy of dimethyl fumarate in patients with multiple sclerosis - real world experience
1Lahey Clinic/Tufts University, Neurology, Lexington, MA, United States
P304
Time to relapse among propensity score matched patients receiving disease modifying therapy for multiple sclerosis
BH Johnson1, MM Bonafede1,
1Truven Health Analytics, Outcomes Research, Cambridge, MA, United States, 2Biogen Idec Inc., HE&OR, Global Market Access, Cambridge, MA, United States
P305
Adherence project with German MS-patients: can an approach of individualized patient counseling improve adherence?
M Mäurer1, R Voltz2, Y Begus-Nahrmann3, B Schmid4,
1Caritas Hospital, Department of Neurology, Bad Mergentheim, Germany, 2University Hospital of Cologne, Department of Palliative Medicine, Cologne, Germany, 3Konzept Pharma Service GmbH, Freden, Germany, 4Biogen Idec GmbH, Ismaning, Germany, 5Heinrich-Heine University, Department of Neurology, Düsseldorf, Germany
As of April 2014, 1701 DMF patients registered in the PCP. Approximately 75% of patients had experience with at least one therapy while the rest was newly diagnosed in both cohorts. The primary reason for transitioning to DMF in both groups was sensed ineffectiveness of prior therapy. Approximately a third of patients in the PCP reported adverse events (AE). Flushing was the most common AE, so far. Close contact between PCP and patients lead to effective AE management and most of the symptoms could be handled and improved. To retain adherence individual intake procedures were defined and the application with a reminder function was distributed.
P306
Reduced frequency and severity of injection site reactions with glatiramer acetate 40mg/mL three times weekly dosing
1University of Texas, Health Science Center at Houston, Houston, TX, United States, 2Teva Pharmaceutical Industries, Netanya, Israel, 3Teva Pharmaceutical Industries, Frazer, PA, United States, 4Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 5Teva Pharmaceutical Industries, Cleveland, OH, United States
P307
Real-world titration of disease modifying therapies in the treatment of multiple sclerosis: findings from a survey of neurologists
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States, 2Thomas Jefferson University, Jefferson School of Population Health, Philadelphia, PA, United States, 3Analysis Group, Inc., New York, NY, United States, 4Analysis Group, Inc., Boston, MA, United States
P309
Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing multiple sclerosis
1University of Texas Medical Branch, Central Texas Neurology Consultants, Round Rock, TX, United States, 2Suncoast Neuroscience Associates, St. Petersburg, FL, United States, 3Neurological Physicians of Arizona, Gilbert, AZ, United States, 4PharmStats, Ltd., Escondido, CA, United States, 5Biogen Idec, Inc., Cambridge, MA, United States
P310
A novel MIF inhibitor as therapy for multiple sclerosis and stroke
1Portland Veterans’ Affairs Medical Center, Neuroimmunology Research, R&D-31, Portland, OR, United States, 2Oregon Health & Science University, Portland, OR, United States
Identify the CD74-binding region within DR-α1 and develop an optimal CD74-binding DR-α1 construct;
Evaluate inhibitory effects of DR-α1 constructs on monocyte and T-cell activation; and
Determine efficacy of DR-α1 constructs for treatment of experimental autoimmune encephalomyelitis (EAE) and experimental stroke.
P311
Strategies to reduce adverse events related to oral dimethyl fumarate
1NYU Langone Multiple Sclerosis Care Center, Neurology, New York, NY, United States
P312
Monthly pulse methylprednisolone as an add-on therapy is effective in long-term treatment of multiple sclerosis
1Dokuz Eylul University, Dept. of Neurology, Izmir, Turkey, 2Giresun State Hospital, Giresun, Turkey, 3Dokuz Eylul University, Izmir, Turkey, 4Usak State Hospital, Usak, Turkey
P313
Patient demographics and disease-modifying therapy use in relapsing-remitting and secondary progressive multiple sclerosis in the United States
1Kantar Health, Princeton, NJ, United States, 2Biogen Idec Inc., Cambridge, MA, United States
P314
Comparative analysis of drop-out rates during the first year of fingolimod versus natalizumab treatment in the Swedish IMSE registry
T Frisell1, L Jonsson2, N Nordin2, C Holmén2, J Askling1, J Hillert2,
1Karolinska Institutet, Department of Medicine, Stockholm, Sweden, 2Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
P315
Clinical experience with rituximab in the treatment of refractory multiple sclerosis
1Hospital Clínico Universitario, Unit of Neuroimmunology - Neurology Department, Valencia, Spain, 2Hospital Universitari i Politècnic La Fe, MS Unit - Neurology Department, Valencia, Spain, 3Hospital Francesc De Borja De Gandia, Neurology Department, Gandia, Spain
P316
Tolerability, safety and efficacy of fingolimod in clinical practice, experience of multiple sclerosis health network in Alsace region
1Hôpital de Hautepierre, Strasbourg, France, 2alSacEP, Colmar, France
P317
Fingolimod effect on clinical and MRI disease activity in young adult patients with relapsing multiple sclerosis
1Partners Pediatric Multiple Sclerosis Centre, Massachusetts General Hospital, Boston, MA, United States, 2Novartis Pharma AG, Basel, Switzerland, 3Centro Studi Sclerosi Multipla, Gallarate, Italy, 4Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada
P318
Systematic literature review and network meta-analysis of peginterferon beta-1a and injectable therapies for relapsing-remitting multiple sclerosis
K Tolley1, M Hutchinson2, A Pachner3,
1Tolley Health Economics Ltd, Buxton, United Kingdom, 2St. Vincent’s University Hospital, Dublin, Ireland, 3Geisel School of Medicine at Dartmouth, Hanover, NH, United States, 4Biogen Idec Inc., Cambridge, MA, United States, 5HERON™ Commercialization - A Parexel® Company, Chandigarh, India
P319
Monitoring interferon beta treatment response with magnetic resonance spectroscopy in relapsing remitiıng multiple sclerosis
1Erciyes University, Neurology, Kayseri, Turkey, 2Erciyes University, Radiology, Kayseri, Turkey
P320
Can fingolimod reduce the occurrence of MRI proven black hole and cerebral atrophy burden in Hispanic population with multiple sclerosis?
1San Juan MS Center, Caribbean Center for Clinical Research, San Juan, Puerto Rico
P321
Challenges experienced by neurologists in the individualization of multiple sclerosis treatment: findings from an international study
1AXDEV Group, Brossard, QC, Canada, 2Colchester University Hospital, Colchester, United Kingdom
P322
Fingolimod (Gilenya) confers cognitive stability in active relapsing-remitting multiple sclerosis patients
1Abarbanel Mental Health Center, Psychogeriatrics, Bat-Yam, Israel, 2Sackler School of Medicine, Tel-Aviv, Israel, 3Sheba Medical Center, Multiple Sclerosis Center, Ramat Gan, Israel
P323
Efficacy and safety of Fingolimod in clinical practice
1CHOP-Complejo Hospitalario Pontevedra, Pontevedra, Spain, 2CHUVI-Complejo Hospitalario Universitario Vigo, Vigo, Spain, 3CHUS- Complejo Hospitalario Santiago, Santiago de Compostela, Spain, 4HULA- Hospital Universitario Lucus Augusti, Lugo, Spain, 5POVISA, Vigo, Spain, 6CHUAC-Complejo Hospitalario Universitario A Coruña, Coruña, Spain, 7Complejo Hospitalario Arquitecto Marcide, Ferrol, Spain, 8Hospital de Monforte, Monforte de Lemos, Spain
Fingolimod was prescribed as first-line agent in 7 patients, as second-line drug in 51 patients, as third-line in 29 patients and as a fourth/fifth-line agent in 14 patients. Natalizumab was the previous treatment in 30% of patients. Fingolimod demonstrated efficacy in the 94% of patients; only six of them (5,9%) had more relapses and/or disability progression.
Fingolimod was discontinuated in 4% of patients, due to inefficacy (n=2) and to side effects (n=2); symptomatic bradycardia during the first-dose observation time in one, and an abnormal liver function test at another one (x5 normal value). Another side effects were: macular edema (n=1), self-limited leukopenia (n=7); arterial hypertension (n=2); self-limited liver enzyme elevation (n=2) and urinary infection (n=2).
P324
Efficacy of second-line treatments in multiple sclerosis patients: a multicenter experience in clinical practice
1University of L’Aquila, Department of Neurology, L’Aquila, Italy, 2Ospedali Riuniti Foggia, Department of Neurology, Foggia, Italy, 3IRCCS Meuromed, Department of Neurology, Pozzilli, Italy
The ARR in the year preceding the start of treatment was 1.9±0.4 in the natalizumab group and 1.2±0.5 in the fingolimod group.
Proportion of patients with new T2 or Gd+ lesions at MRI prior treatment starting was 90% in natalizumab group and 78% in fingolimod group.
Mean EDSS score at the start of treatment was 2.9±0.9 in natalizumab group and 2.6±0.8 in fingolimod group.
At 1-year treatment follow-up, the proportion of patients free from relapse was 87% in natalizumab and 93% in fingolimod group.
The proportion of patients free from EDSS progression was 98% in natalizumab group and 99% in fingolimod group. The proportion of patients free from MRI activity was 93% in patients treated with natalizumab and 75% in those treated with fingolimod. The proportion of patients free from any disease activity was 79% in natalizumab group and 70% in fingolimod group.
P325
Multiple sclerosis treatment practices in women of child-bearing age in Switzerland: results of the women with MS online survey
H Sorribas1,
1Merck (Schweiz) AG, Merck Serono, Zug, Switzerland, 2Hôpitaux Universitaires et Faculté de Médecine, Médecin Adjoint Agrégé Service de Neurologie/Unité de Neuroimmunologie et SEP - HUG, Service de Médecine de Laboratoire - HUG, Département de Pathologie et Immunologie - CMU, Geneva, Switzerland
P326
Spanish Registry of patients with multiple sclerosis treated with fingolimod (GILENYA Registry): safety and effectiveness after one year on treatment
A Rodriguez-Antigüedad1, C Oreja-Guevara2, X Montalban3, J Meca4, D Muñoz5, JC Álvarez-Cermeño6, J Olascoaga7, L Ramió8, V Meca9, A Saiz10, JM Prieto11, MÁ Hernández12, B Casanova13, ME Marzo14, N Téllez15, R Villaverde16, RC Ginestal17, J Gracia18, A Escartín19, S Martínez-Yélamos20, L Landete21, J Mallada22, J Benito-León23, L Brieva24, M Garcia-Garcia25,
1Hospital de Basurto, Neurology Department, Bilbao, Spain, 2Hospital Clínico San Carlos, Neurology Department, Madrid, Spain, 3Hospital Universitari Vall d’Hebron, Neurology Department, Barcelona, Spain, 4Hospital Universitario Virgen de la Arrixaca, Neurology Department, Murcia, Spain, 5Hospital Xeral de Vigo, Neurology Department, Vigo, Spain, 6Hospital Universitario Ramón y Cajal, Neurology Department, Madrid, Spain, 7Hospital Universitario Donostia, Neurology Department, Donostia, Spain, 8Dr. Josep Trueta University Hospital, Multiple Sclerosis and Neuroimmunology Unit, Girona Biomedical Research Institut (IDIBGI), Girona, Spain, 9Hospital Universitario de la Princesa, Neurology Department, Madrid, Spain, 10Hospital Clínic de Barcelona, Neurology Department, Barcelona, Spain, 11Complejo Hospitalario Universitario de Santiago de Compostela, Neurology Department, Santiago, Spain, 12Hospital Universitario Nuestra Señora de Candelaria, Neurology Department, Sta. Cruz Tenerife, Spain, 13Hospital Universitari i Politècnic La Fe, Neurology Department, Valencia, Spain, 14Hospital San Pedro, Neurology Department, La Rioja, Spain, 15Hospital Clínico Universitario de Valladolid, Neurology Department, Valladolid, Spain, 16Hospital General Universitario Morales Meseguer, Neurology Department, Murcia, Spain, 17Hospital Universitario Fundación Jiménez Díaz, Neurology Department, Madrid, Spain, 18Complejo Hospitalario Universitario de Albacete, Neurology Department, Albacete, Spain, 19Hospital de la Santa Creu i San Pau, Neurology Department, Barcelona, Spain, 20Hospital Universitari de Bellvitge, Neurology Department, Barcelona, Spain, 21Hospital Universitario Doctor Peset, Neurology Department, Valencia, Spain, 22Hospital General de Elda, Neurology Department, Elda, Spain, 23Hospital Universitario 12 de Octubre, Neurology Department, Madrid, Spain, 24Hospital Universitari Arnau de Vilanova, Neurology Department, Lleida, Spain, 25Adknoma Health Research, Project Management, Barcelona, Spain, 26Hospital Regional Universitario de Málaga, Neurology Department, Málaga, Spain
P327
Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab
1Cantonal Hospital of St. Gallen, Department of Neurology, St. Gallen, Switzerland
P328
A monocentric, prospective, observational study to assess the satisfaction of patients treated with monthly natalizumab
1Edith Cavell Hospital/Multiple Sclerosis Clinic/ULB, Neurology, Uccle, Belgium, 2ULB/Erasmus Hospital, Neurology, Brussels, Belgium
P329
Effectiveness of natalizumab in extended dosing interval
1Hospital Universitari Germans Trias i Pujol, Neurosciences, Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Pharmacy, Barcelona, Spain
Epidemiology
P330
In utero 25-hydroxyvitamin D and risk of multiple sclerosis among offspring in the Finnish Maternity Cohort
1Harvard School of Public Health, Boston, MA, United States, 2University Hospital of Turku, Turku, Finland, 3National Institute for Health and Welfare, Oulu, Finland
P331
Timing of cod liver oil use as a vitamin D source and multiple sclerosis risk in Norway: the EnvIMS study
1KG Jebsen Centre for MS-Research, University of Bergen, Department of Clinical Medicine, Bergen, Norway, 2University of Bergen, Department of Global Public Health and Primary Care, Bergen, Norway, 3Harvard School of Public Health, Department of Nutrition, Boston, MA, United States, 4Haukeland University Hospital, The Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Bergen, Norway, 5University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway, 6Akershus University Hospital, Department of Neurology, Lørenskog, Norway, 7University of Tromsø, Department of Clinical Neurology, Tromsø, Norway, 8University Hospital of North Norway, Department of Neurology, Tromsø, Norway, 9McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montréal, QC, Canada, 10University of Sassari, Department of Clinical and Experimental Medicine, Sassari, Italy, 11Research Institute of the McGill University Health Centre, Montréal, QC, Canada
It is still unclear whether this suggested effect is related to specific age periods prior to disease.
Based on a self-administered questionnaire previously assessed for acceptability, feasibility and reliability a total of 953 MS patients and 1717 healthy controls reported whether they had used cod liver oil during childhood, adolescence and adulthood. Additionally, frequency and quantity of cod liver oil consumption during age 13-19 was explored. The associations between exposure and disease were estimated using logistic regression. All estimates were adjusted for age and sex. Further, the estimates were adjusted for possible confounders such as sun exposure, infectious mononucleosis and smoking.
P332
Potential impact of air pollutants on multiple sclerosis incidence in Tehran, Iran: role of vitamin D
P Heydarpour1, H Amini2, S Khoshkish1, H Seidkhani3, M Yunesian4,
1Tehran University of Medical Sciences, Department of Neurology, Tehran, Iran, Islamic Republic of, 2Kurdistan University of Medical Sciences, Kurdistan Environmental Health Research Center, Sanandaj, Iran, Islamic Republic of, 3Tehran University, Lab of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics (IBB), Tehran, Iran, Islamic Republic of, 4Tehran University of Medical Sciences, Center for Air Pollution Research (CAPR), Institute for Environmental Research (IER), Tehran, Iran, Islamic Republic of
P333
Temporal effects on the presentation and evolution of multiple sclerosis
1Cardiff University, Institute for Psychological Medicine and Clinical Neuroscience, Cardiff, United Kingdom, 2University Hospital of Wales, Neurology, Cardiff, United Kingdom
P334
The association of multiple sclerosis prevalence and the soil heavy metal in Isfahan, Iran: one step closer to understanding etiology
M Etemadifar1, R Kiani2, B Mehrabi3,
1Isfahan University of Medical Science, Isfahan, Iran, Islamic Republic of, 2Isfahan Research Commitee of Multiple Sclerosis, Isfahan, Iran, Islamic Republic of, 3Tarbiat Modares University, Tehran, Iran, Islamic Republic of
P335
Exploring early life sun exposure and MS risk using alternative life course epidemiology hypotheses: the EnvIMS study
1McGill Univeristy, Epidemiology, Biostatistics and Occupational Health, Montreal, QC, Canada, 2University of Bergen, Department of Global Public Health and Primary Care, Bergen, Norway, 3Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, Department of Neurology, Bergen, Norway, 4University of Bergen, The KG Jebsen Centre for MS-Research, Department of Clinical Medicine, Bergen, Norway, 5University of Sassari, Sassari, Italy, 6McGill University Health Centre Research Institute, Montreal, QC, Canada
P336
Neonatal vitamin D status and risk of multiple sclerosis
1Karolinska Institutet, Department of Clinical Neuroscience and Center for Molecular Medicine, Stockholm, Sweden, 2Karolinska Institutet, Internal Medicine Department, Karolinska University Hospital, Stockholm, Sweden, 3Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden, 4The University of Queensland, Queensland Centre for Mental Health Research, Queensland Brain Institute, Brisbane, Australia
P337
Multiple sclerosis in Møre and Romsdal, Western Norway 1960-2013. Time trends of incidence and prevalence through more than five decades
1Molde Hospital, Helse Møre and Romsdal Health Trust, Department of Neurology, Molde, Norway, 2Norwegian University of Science and Technology (NTNU), Unit for Applied Clinical Research, Department of Cancer Research and Molecular Medicine, Trondheim, Norway
We have traced every patient diagnosed with MS in the county and all MS patients living in Møre and Romsdal on Prevalence day 1 January 2013. The primary source for MS patients was the case files at the Department of Neurology and Clinical Neurophysiology at Molde Hospital. However, we have searched all available local, regional and national sources for incident and prevalent cases. Only patients diagnosed before prevalence day are included. An experienced neurologist has examined all patients, the majority several times, during the course of illness.
P338
High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010)
1University of British Columbia, Vancouver, BC, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3Dalhousie University, Halifax, NS, Canada, 4McGill University, Montreal, QC, Canada, 5University of Alberta, Edmonton, AB, Canada, 6University of Calgary, Calgary, AB, Canada
P339
35 years of mortality due to multiple sclerosis in Canada, 1975-2009: no decrease in mortality rates despite shift to older age at death
S Warren1,
1University of Alberta, Edmonton, AB, Canada
P340
Seasonal variation of relapse rate in MS is latitude-dependent
1University of Melbourne, Melbourne Brain Centre, Parkville, Australia, 2Craigavon Area Hospital, Portadown, United Kingdom, 3University of Bari, Department of Basic Medical Sciences, Neuroscience and Sense Organs, Bari, Italy, 4Kommunehospitalet, Arhus C, Denmark, 5Hospital Universitario Virgen Macarena, Sevilla, Spain, 6University ‘G. d’Annunzio’, MS Center, Department of Neuroscience and Imaging, Chieti, Italy, 7Orbis Medical Centre, Sittard-Geleen, Netherlands, 8Neurological Institute IRCCS Mondino, Pavia, Italy, 9Hôpital Notre Dame, Montreal, QC, Canada, 10Center de Réadaptation Déficience Physique Chaudière-Appalache, Levis, QC, Canada, 11Ospedale di Macerata, Macerata, Italy, 12Karadeniz Technical University, Trabzon, Turkey, 13Groene Hart Ziekenhuis, Gouda, Netherlands, 14University Hospital San Carlos, Madrid, Spain, 15Brain and Mind Research Institute, Sydney, Australia, 16Neuro Rive-Sud, Hôpital Charles LeMoyne, Greenfield Park, QC, Canada
P341
Risk of multiple sclerosis related to month of birth changes over time
1Oslo University Hospital, Ullevål, Dep. of Neurology, Oslo, Norway, 2University Of Oslo, Faculty of Medicine, Oslo, Norway
P342
The changing face of MS: does ARR vary by epoch?
1Brigham and Women’s Hospital, Neurology, Partners MS Center, Brookline, MA, United States, 2EMD Serono, Inc., Rockland, MA, United States
P343
The incidence of multiple sclerosis in New Zealand, 2013: a population- based study
1University of Otago, School of Medicine, Christchurch, New Zealand, 2New Zealand Brain Research Institute, Christchurch, New Zealand, 3University of Otago, Deans Department, Christchurch, New Zealand, 4University of Canterbury, Public Health, Christchurch, New Zealand, 5Christchurch Public Hospital, Department of Neurology, Christchurch, New Zealand
P344
Genes and environment in multiple sclerosis (GEMS) study: enabling the prospective study of individuals at risk of multiple sclerosis
1Brigham and Women’s Hospital, Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Boston, MA, United States, 2Harvard Medical School, Boston, MA, United States, 3National Institute of Neurological Disorders and Stroke, Translational Neuroradiology Unit, Neuroimmunology Branch, Bethesda, MD, United States
P345
Prevalence and incidence of multiple sclerosis estimated in European Register for Multiple Sclerosis (EUReMS): study protocol of the Epi-1d study
1University of Sassari, Sassari, Italy, 2University Medical Center, Georg-August Universität, Göttingen, Germany, 3Multiple Sclerosis Centre of Catalonia (Cemcat), Valld’Hebron University Hospital, Barcelona, Spain, 4Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, Dept. of Neurology, Bergen, Norway, 5KG Jebsen Centre for MS Research, University of Bergen, Dept. of Clinical Medicine, Bergen, Norway, 6Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany, 7University of Sassari, Dept. of Clinical and Experimental Medicine, Sassari, Italy, 8University of Sassari, Dept. of Biomedical Sciences, Sassari, Italy, 9State University of Medicine and Pharmacy ‘Nicolae Testemitanu’, Chisinau, Moldova, Republic of, 10Hospital Universitari Josep Trueta, Neurologia, Girona, Spain, 11Hospital Santa Caterina, Neurologia, Girona, Spain, 12Fundació Salut Empordà, Neurology Dept., Figueres, Spain, 13European Multiple Sclerosis Platform, EMSP, Brussels, Belgium
P346
Vitamin D in multiple sclerosis; clinical and immunological implications
1Copenhagen University Hospital Rigshospitalet, Danish Multiple Sclerosis Center, Copenhagen, Denmark
P347
Impact of wGRS on familial aggregation and clinical phenotypes in Italian multiple sclerosis patients
1Scientific Institute San Raffaele, Department of Neurology, Milan, Italy, 2Scientific Institute San Raffaele, Laboratory of Genetics of Neurological Complex Disorders, Milan, Italy
P348
A prospective case-control study of dietary salt intake and risk of pediatric MS
1UCSF Regional Pediatric MS Center, San Francisco, CA, United States, 2University of Pennsylvania, Department of Neurology, Philadelphia, PA, United States, 3SUNY Stony Brook, Department of Neurology, Stony Brook, NY, United States, 4UT Southwestern, Department of Neurology, Dallas, TX, United States, 5SUNY Buffalo, The Pediatric MS Center at the Jacobs Neurological Institute, Buffalo, NY, United States, 6Loma Linda University, Department of Child Neurology, Loma Linda, CA, United States, 7Mayo Clinic, Department of Neurology, Rochester, MN, United States, 8Alabama Pediatric MS Center, Birmingham, AL, United States, 9Northwestern Feinberg School of Medicine, Department of Neurology, Chicago, IL, United States, 10Massachusetts General Hospital, Partners Pediatric MS Center, Boston, MA, United States, 11University of Utah, Department of Pediatrics, Salt Lake City, UT, United States, 12University of Utah, Department of Neurology, Salt Lake City, UT, United States
Dietary sodium intake was assessed using the Block Kids Food Screener (NutritionQuest), a validated, self-report questionnaire that evaluates the frequency and portion of beverages/foods consumed. Sodium intake was compared between cases and controls and adjusted for age, gender, race and ethnicity in logistic regression models.
There was no significant difference in unadjusted mean sodium intake between cases (1965 mg/d) and controls (2072 mg/d) and the proportion of subjects exceeding the adequate intake was similar between cases and controls (62% vs. 68%). Among male subjects, both cases (2349 mg/d) and controls (2435 mg/d) exceeded the Tolerable Upper Limit (2300 mg/d) for sodium intake.
A non-significant trend towards increased odds of MS (1.015) for each 100 mg increase in sodium (95% CI 0.992, 1.038; p=0.19) was observed in the analyses adjusted for age, gender, race and ethnicity. Adjusted analyses including socioeconomic status and body mass index are pending.
P349
Increasing prevalence and stable incidence of multiple sclerosis in Western Norway, 1953-2013
1National Multiple Sclerosis Competence Centre, Department of Neurology, Bergen, Norway, 2Norwegian MS Registry & Biobank, Department of Neurology, Bergen, Norway
P350
The spectrum of idiopathic inflammatory demyelinating diseases in South America: a multicenter study
1UNIRIO, Neurology, Rio de Janeiro, Brazil, 2Hospital da Lagoa, Rio de Janeiro, Brazil, 3Hospital Britânico, Buenos Ayres, Argentina, 4Hospital de Paraguay, Assuncion, Paraguay, 5Instituto de Previzion Social, Assuncion, Paraguay, 6Hospital Universítário de Maracaibo, Maracaibo, Venezuela, 7Hospital Ofir Loyola, Belem, Brazil, 8Santa Casa, Belo Horizonte, Brazil, 9Rede Sarah, Brasilia, Brazil, 10Centro de Reabilitação, Cuiabá, Brazil, 11Universidade Federal de Mato Grosso, Cuiabá, Brazil, 12H C Cetom, Florianópolis, Brazil, 13Hospital da Restauração, Recife, Brazil, 14Centro Neurológico do Litoral Paulista, Santos, Brazil, 15Centro Neurológico do Litoral Paulista, Santoss, Brazil, 16Hospital Santa Marcelina, São Paulo, Brazil, 17Universidade Sul Fluminense, Vassouras, Brazil, 18Centro Neurologico de Volta Redonda, Volta Redonda, Brazil, 19Santa Casa, Rio de Janeiro, Brazil, 20Universidade de Joinville, Joinville, Brazil, 21Clinica de Curitiba, Curitiba, Brazil, 22INCA, Rio de Janeiro, Brazil
P351
Sodium intake in multiple sclerosis patients
1Raúl Carrea Institute for Neurological Research (FLENI), Neurology, Buenos Aires, Argentina, 2Center for Neurologic Diseases - Brigham and Women’s Hospital, Boston, MA, United States
P352
Body mass index and baseline vitamin D status modify the response to vitamin D supplementation in multiple sclerosis patients and healthy controls
1Johns Hopkins University School of Medicine, Neurology, Baltimore, MD, United States, 2University of California San Francisco, San Francisco, CA, United States, 3University of California San Francisco, Neurology, San Francisco, CA, United States
P353
Epidemiology of multiple sclerosis in the Republic of Moldova: an incidence and prevalence study in the northern and central regions
1State University of Medicine and Pharmacy ‘N.Testemiţanu’, Chisinau, Moldova, Republic of, 2Institute of Neurology and Neurosurgery, Dept. of Neurology, Chisinau, Moldova, Republic of, 3Dept. of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, 4District Hospital of Riscani, Riscani, Moldova, Republic of, 5Ospedale Maggiore della Carità, Novara, Italy, 6University of Sassari, Dept. of Clinical and Experimental Medicine, Sassari, Italy
P354
Increasing incidence of multiple sclerosis among women in Buenos Aires: a 21-year health maintenance organization based study
1Centro de Esclerosis Múltiple de Buenos Aires, Buenos Aires, Argentina, 2Hospital Italiano, Buenos Aires, Argentina
P355
eQTL discovery in MS patients elucidates functional mechanisms associated with disease susceptibility and treatment
1Brigham and Women’s Hospital, Department of Neurology, Boston, MA, United States, 2Broad Institute, Program in Medical and Population Genetics, Cambridge, MA, United States, 3Harvard Medical School, Boston, MA, United States, 4San Raffaele Scientific Institute, Milan, Italy
P356
The use of valproic acid and multiple sclerosis
1Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark, 2University of Southern Denmark, Institut of Regional Health Research, Odense, Denmark, 3Rigshospitalet, Danish Multiple Sclerosis Registry, Copenhagen, Denmark, 4Multiple Sclerosis Clinic of Southern Jutland, Department of Neurology, Sønderborg, Denmark, 5Danish Multiple Sclerosis Research Centre, Department of Neurology, Neuroscience Center, Rigshospitalet, Copenhagen, Denmark, 6University of Aarhus, Department of Clinical Epidemiology, Clinical Institute, Aarhus, Denmark, 7Rigshospitalet, The Danish Multiple Sclerosis Registry, Copenhagen, Denmark
P357
Vitamin D levels and antibody titers against Epstein-Barr virus and human herpesvirus 6 in multiple sclerosis patients: a one-year follow-up study
I Ortega-Madueño1, L Lopez-Lozano1, M Garcia-Montojo1, MI Dominguez-Mozo1, AM Arias-Leal1, MA Garcia-Martinez1, I Casanova1, MJ Torrejon1, R Arroyo1,
1Hospital Clinico San Carlos, Madrid, Spain
P358
Early-onset multiple sclerosis in Isfahan, Iran: a report of the demographic and clinical features of 221 patients
1Isfahan University of Medical Science, Isfahan, Iran, Islamic Republic of
True childhood-onset MS (onset age ≤ 10) and
Juvenile MS (10 < onset age ≤ 16).
Regarding our True childhood-onset MS group, the mean age at MS onset was 9.1 ± 1.2. All 11 patients had experienced the RRMS pattern. The most common presentation was cerebellar sign and symptom in this group.
P359
Using patient-derived multiple sclerosis severity score to demonstrate differences in MS severity across racial groups in an urban MS center
1NYU School of Medicine, Neurology, New York, NY, United States, 2University of Alabama at Birmingham, Epidemiology, Birmingham, AL, United States
P360
Disease progression in multiple sclerosis after age 65
1EHESP School of Public Health, Epidemiology, Rennes, France, 2INSERM CIC-P 1414, Rennes, France, 3Pontchaillou Hospital, Neurology Department, Rennes, France, 4AP-HP - Salpetriere Hospital, Neurology Department, Paris, France, 5AP-HP - Salpetriere Hospital, Infectious Diseases Department, Paris, France
For the second analysis, 101 old patients were compared to 951 patients younger than 60 years. The follow-up duration from MS onset was longer in the old patients group than in the younger patients’ group (27 y vs 14 y, p< .0001). Comparisons of times remaining at each EDSS step have not been analyzed yet.
P361
Age at disease onset in familial and sporadic multiple sclerosis in Argentina
1Centro de Esclerosis Múltiple de Buenos Aires, Buenos Aires, Argentina, 2Neurosciences Institute of Buenos Aires, Buenos Aires, Argentina, 3Multiple Sclerosis Section Hospital E.Tornú, Buenos Aires, Argentina, 4Private Office, Buenos Aires, Argentina, 5Private Office, Cordoba, Argentina, 6Department of Neurology, Institute for Neurological Research Dr. Raúl Carrea, FLENI, Buenos Aires, Argentina, 7Hospital Britânico, Buenos Aires, Argentina, 8Hospital General de Agudos Carlos G Durand, Buenos Aires, Argentina, 9Hospital Aleman, Buenos Aires, Argentina
P362
Vitamin D, latitude and sunshine hours in Scotland
1University of Edinburgh, Center for Population Health Sciences, Edinburgh, United Kingdom
P363
Prevalence, demographics and clinical characteristics of multiple sclerosis in the city of Tlemcen, Algeria
1CHU Dr T. Damerdji, Service de Neurologie, Tlemcen, Algeria, 2CHU Dr T. Damerdji, Service d’Epidemiologie, Tlemcen, Algeria, 3CHU Frantz Fanon, Service de Neurologie, Blida, Algeria
Results, a total of 202 patients fulfilled the McDonald diagnostic criteria(2005- 2010).
P364
Large scale epidemiological survey of disability progression in Japanese multiple sclerosis patients
1Tohoku University School of Medicine, Department of Neurology, Sendai, Japan, 2Biogen Idec Japan Ltd, Tokyo, Japan
P365
Highly active multiple sclerosis and Epstein-Barr virus reactivation
1Mayo Clinic, Neurology, Rochester, MN, United States
Patient 1 - A 29-year-old man was admitted to hospital for subacutely worsening gait ataxia, blurred vision and headache. MRI revealed extensive gadolinium-enhancing lesions within the cerebral, posterior fossa and spinal cord white matter. Serologies returned positive for EBNA-1 IgG, VCA IgG and VCA IgM. Evaluation was consistent with MS, he improved following IV methylprednisolone, and interferon beta-1a was initiated. He remained without clinical relapse at follow up the next year and VCA IgM had become negative. MRI showed a few enhancing lesions and he transitioned to fingolimod. A few months later he returned with multifocal neurologic symptoms and examination findings. MRI showed extensive MS activity and VCA IgM was again positive. He improved with acute therapy and was transitioned to dimethyl fumarate. MS activity was quiet and VCA IgM negative at last follow up.
Patient 2 - A 45-year-old man was admitted to hospital for subacutely worsening myelopathy. MRI showed numerous gadolinium-enhancing lesions within the cerebral and spinal cord white matter. Serologies returned positive for EBNA-1 IgG, VCA IgG and VCA IgM. Evaluation was consistent with MS and he improved with acute therapy.
P366
Residential distance from main roads, air pollution, and multiple sclerosis disability in Southern California
1University of Southern California, Neurology, Los Angeles, CA, United States, 2UAW, Public Health, Dhaka, Bangladesh, 3University of Southern California, Preventive Medicine, Los Angeles, CA, United States
P367
Comparison of factors impacting vitamin D status in childhood & adult-onset demyelinating disease
1University of Virginia, Pediatric Neurology, Galloway, OH, United States, 2University of Virginia, Charlottesville, VA, United States
P368
Vitamin D level and its clinical correlation in Thai patients with central nervous system demyelinating diseases
1Faculty of Medicine Siriraj Hospital, Mahidol University, Department of Medicine, Bangkok, Thailand, 2Buddachinaraj Hospital, Department of Medicine, Phitsanulok, Thailand, 3Bumrungrad International Hospital, Bangkok, Thailand
P369
Clinical characteristics and outcome measures associated with disease progression in a prospective cohort of early diagnosed MS patients
1Jacobs Comprehensive MS Treatment and Research Center, Buffalo, NY, United States, 2New York State MS Consortium, Buffalo, NY, United States, 3SUNY University of Buffalo School of Medicine and Biomedical Sciences, Department of Neurology, Buffalo, NY, United States, 4MS Center of Northeastern New York, Latham, NY, United States, 5SUNY-Stony Brook MS Comprehensive Care Center, Neurology, Stony Brook, NY, United States, 6New York University Langone Medical Center, MS Comprehensive Care Center, New York, NY, United States, 7University of Rochester Medical Center, Department Neurology, Rochester, NY, United States, 8SUNY Upstate Medical University, Neurology, Rochester, NY, United States, 9Winthrop University Hospital, Winthrop Comprehensive MS Care Center, Mineola, NY, United States, 10Alpha Neurology, Staten Island University Hospital, Staten Island, NY, United States, 11Albany Medical College, Neurology, Albany, NY, United States, 12Buffalo Neuroimaging Analysis Center, Buffalo, NY, United States, 13SUNY - Buffalo Pharmaceutical Sciences, Neuroscience, Buffalo, OK, United States
P370
Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis
1CHU Carémeau, Neurology Department, Nimes, France, 2Institut de Génomique Fonctionnelle, UMR 5203, Université Montpellier 1 et 2, Montpellier, France, 3University Institute of Clinical Research, Université Montpellier 1, Laboratory of Biostatistics, Epidemiology and Public Health, Montpellier, France, 4CHU Gui de Chauliac, Neurology Department, Montpellier, France, 5INSERM U 1051, Université Montpellier 1, Montpellier, France
P371
Vitamin D and multiple sclerosis: a comparison of serum 25-hydroxyvitamin D with demographic findings and paraclinical outcomes
V Nykvist1,
1Glostrup Hospital, University of Copenhagen, Neurology, Glostrup, Denmark
P372
Is relapsing-remitting MS a benign disease?
1Marshfield Clinic, Marshfield, WI, United States
P373
Specific clinical phenotypes of relapsing multiple sclerosis based on disease activity
1Allegheny General Hospital, Neurology, Pittsburgh, PA, United States, 2University of South Carolina, Columbia, SC, United States, 3Drexel University College of Medicine, Pittsburgh, PA, United States
Experimental models
P374
The CNS barriers differentially regulate the migration of B-cells
1CRCHUM, Neurosciences, Montréal, QC, Canada, 2Notre Dame Hospital, Neurology, Montréal, QC, Canada, 3Mc Gill University, Neurology and Neurosurgery, Montréal, QC, Canada, 4Toronto University, Immunology, Toronto, ON, Canada
Trans-endothelial migration assays revealed that BBB tend to be less permissive to B cell migration when compare to the BMB (10.8% (BMB) vs. 7.1% (BBB)) (n=6 HVs). Interestingly, the use of anti-ALCAM blocking antibodies induced a 25% reduction in the number of migrated B lymphocytes across the BMB (n=3 HVs).
P375
B7-H1 limits T-cell-mediated brain endothelial cell dysfunction and endothelial barrier disruption in a spontaneous model of CNS autoimmunity
I Kuzmanov1, V Posevitz1, S Hucke1, D Chudyka1,
1University Hospital Münster, Department of Neurology, Münster, Germany
In our spontaneous model of CNS autoimmunity, lack of B7-H1 resulted in earlier disease onset and significantly increased disease severity, although cytokine responses were not altered. Intriguingly, we observed that Devic mice lacking B7-H1 not only exhibited characteristic spinal cord infiltrates but frequently displayed meningeal and parenchymal T cell infiltrations in the brain and cerebellum - CNS areas typically spared in this model, thus indicating that the propensity of encephalitogenic T cells to break through the BBB is enhanced in these mice.
P376
Serpine1 is a negative regulator of experimental autoimmune encephalomyelitis
1Centre de Recherche du CHU de Québec, Quebec, QC, Canada, 2Stony Brook School of Medicine, Stony Brook, NY, United States, 3Brigham & Women’s Hospital, Boston, MA, United States
P377
MR molecular Imaging of VCAM-1 in EAE mice treated by statin: a new perspective for diagnosis and therapeutic management
M Gauberti1, A Montagne2, D Vivien1, G Defer1,3, F Docagne1,
1Inserm U 919, University of Caen, Caen, France, 2University of Southern California, Los Angeles, CA, United States, 3University Hospital of Caen, Neurology, Caen, France
P378
ATX-MS-1467 reduces MRI lesions and prevents disease progression in a humanized mouse model of multiple sclerosis
1EMD Serono Research and Development Institute, Inc., Neurology eTIP, Translational & Biomarker Research Group, Billerica, MA, United States, 2Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, United States
P379
Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune encephalomyelitis
R Kim1, N Itoh1, A Hoffman1, R Spence1, Y Ao1, M Sofroniew1,
1University of California, Los Angeles, CA, United States
P380
Beneficial effects of short chain fatty acids on the course of experimental autoimmune encephalomyelitis
1Ruhr-University Bochum, Department of Neurology, Bochum, Germany
P381
Laquinimod prevents disability progression in a model of spontaneous chronic EAE and interferes with the development of follicular helper T-cells
1University of California, Neurology, San Francsico, CA, United States, 2Stanford University, Pathology, Stanford, CA, United States
P382
Oxysterols regulate T lymphocytes trafficking during experimental autoimmune encephalomyelitis
1Geneva University, Department of Pathology and Immunology, Geneva, Switzerland, 2Geneva University Hospitals, Division of Neurology, Geneva, Switzerland
P383
Development of a cortical lesion in a new rat model of focal inflammatory demyelination in serial MRI
1Medical University Graz, Department of Neurology, Graz, Austria, 2Joanneum Research, Graz, Austria, 3Karolinska Institute, Center for Molecular Medicine, Stockholm, Sweden
P384
Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mouse
1Neuroscience Institute Cavalieri Ottolenghi (NICO), University Hospital S. Luigi Gonzaga (CReSM), Orbassano, Italy, 2Experimental Neurology Institute (INSPE), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy, 3Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland
P385
Neuroanatomical organization and global transcriptome analyses of c-Fos activated astrocytes in EAE lesions, altered by administration of fingolimod
A Groves1,2, Y Kihara1, M Mayford1,
1Scripps Research Institute, La Jolla, CA, United States, 2University of California San Diego, Neuroscience, La Jolla, CA, United States
P386
The lesion localization of passive transfer NMO-IgG model in Lewis rats
1Tohoku University Graduate School of Medicine, Department of Multiple Sclerosis Therapeutics, Sendai, Japan, 2Tohoku University Graduate School of Medicine, Department of Neurology, Sendai, Japan
P387
Laquinimod prevents NMOIg-induced disease exacerbation in a model of neuromyelitis optica
AT Argaw1,2,3, L Asp1,2,3, J Zhang1,2,3, VJ Cogliani1,2,3, P Waters4, P Hayardeny5, M Levy6,
1Icahn School of Medicine at Mount Sinai, Corinne Goldsmith Dickinson Center for MS, New York, NY, United States, 2Icahn School of Medicine at Mount Sinai, Friedman Brain Institute, New York, NY, United States, 3Icahn School of Medicine at Mount Sinai, Neurology, New York, NY, United States, 4John Radcliffe Hospital, Neuroimmunology Group, Oxford, United Kingdom, 5Teva Pharmaceuticals, Netanya, Israel, 6Johns Hopkins Hospital, Neurology, Baltimore, MD, United States
P388
Anti-murine CD52 therapy provides anti-inflammatory and neuroprotective effects in EAE
1Neuroimmunology Research, Genzyme, a Sanofi Company, Framingham, MA, United States
P389
Therapeutic testosterone administration ameliorates clinical disability and cortical atrophy in EAE
RD Spence1, N Itoh1, CRL Mongerson1, SH Wailes1, AJ Wisdom1, RR Voskuhl1,
1University of California, Department of Neurology, Los Angeles, CA, United States
P390
Chondroitin 6-O-sulfate ameliorates experimental autoimmune encephalomyelitis
1Kinki University School of Medicine, Neurology, Osaka-Sayama, Japan, 2Nagoya University School of Medicine, Biochemistry, Nagoya, Japan, 3Kobe Pharmaceutical University, Biochemistry, Kobe, Japan
P391
Adaptive angioplasticity promotes recovery in experimental autoimmune encephalomyelitis
1Wayne State University, Detroit, MI, United States
P392
Bringing CLARITY to EAE
RD Spence1, F Kurth1, N Itoh1, CRL Mongerson1, SH Wailes1, MS Peng1,
1University of California, Department of Neurology, Los Angeles, CA, United States
P393
The role of glatiramer acetate in mitochondrial dynamics and biogenesis in EAE
1University of Maryland Baltimore, Neurology, Baltimore, MD, United States, 2MS Center of Excellence-EAST, VA Maryland Health Care System, Baltimore, MD, United States
P394
Superior efficacy of glucocorticoid treatment of experimental autoimmune encephalomyelitis in macrophage migration inhibitory factor deficient mice
1University of Texas at San Antonio, San Antonio, TX, United States, 2University of Texas at San Antonio, Biology, San Antonio, TX, United States
P395
Modulation of ARNT2 expression as an indicator of neuronal responses in models of MS
1University of British Columbia, Pathology and Laboratory Medicine, Vancouver, BC, Canada
P396
The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis
1High Point Pharmaceuticals, LLC, Biology, High Point, NC, United States, 2High Point Pharmaceuticals, LLC, Chemistry, High Point, NC, United States
P397
Characterization of GALT derived lymphocyte with regulatory properties from mice treated with murine antiCD52 antibody
1Geisel School of Medicine at Dartmouth, Department of Microbiology/Immunology, Hanover, NH, United States
P398
Plovamer acetate causes a more pronounced increase in eosinophils and CCL22 in naïve and EAE mice compared with glatiramer acetate
A Savinainen1,
1EMD Serono Research & Development Institute, Inc., Billerica, MA, United States
P399
Therapeutic effect and mechanisms of antigen-specific tolerogenic dendritic cells in experimental autoimmune encephalomyelitis
1Hospital Universitari Germans Trias i Pujol, Immunology, Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Neurosciences, Barcelona, Spain
A total of 1·10^6 generated TolDC-MOG cells, unpulsed TolDC or PBS (sham control) were administrated pre-clinically (on days 5 and 9 pi) or therapeutically (on days 15, 19, 23 and 33pi) on C57BL/6 mice immunized with MOG40-55. Clinical and immunological parameters were evaluated.
P400
Diffusion tensor imaging (DTI) reveals cortical structure and axon circuit alterations in a chronic demyelinating mouse model of multiple sclerosis
N Harris1, A Khalaj2, R Mofrad-Babapour2, L Martinez-Torres2, Z Winchester2,
1School of Medicine at University of California, Neurosurgery, Los Angeles, CA, United States, 2School of Medicine at University of California, Los Angeles, CA, United States, 3School of Medicine at University of California at Riverside, Riverside, CA, United States
P401
Visual evoked potentials and MRI reveal optic nerve involvement in a relapsing remitting model of multiple sclerosis
1Scientific Institute and University Hospital San Raffaele, Neurology and INSPE-Institute of Experimental Neurology, Milan, Italy
P402
Spectroscopic determination of chelating properties and uptake in the cuprizone multiple sclerosis model
1University of Akron, Chemistry, Akron, OH, United States, 2Indiana University Northwest, Chemistry, Gary, IN, United States, 3University of Akron, Biology, Akron, OH, United States
Quantification of cellular uptake was determined in MO3.13 cells, a human oligodendrocyte cell line using a copper-dependent colorimetric assay based on the strong absorbance at 600 nm for the copper-cuprizone complex. These levels were confirmed by selected reaction monitoring (SRM) with liquid chromatography mass spectrometry (LC-MS).
The colorimetric assay displayed a loss of cuprizone in the cell media indicating that is compound can cross the cell membrane. This uptake was associated with loss of viability. Selected reaction monitoring quantified the cellular level of cuprizone to be approximately 30 nM.
P403
Well-defined functional deficits and protracted course of EAE in rats with intraspinal injection of VEGF after low-dose immunization with MOG
1University Hospital Zurich, Neurology, Zurich, Switzerland, 2University Zurich, Balgrist Hospital, Zurich, Switzerland, 3University Zurich, Brain Research Institute, Zurich, Switzerland
P404
Clinical outcome of experimental autoimmune encephalomyelitis in semaphorin 7A-deficient mice
1Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain
P405
Gender-specific neuregulin1 modulation of experimental autoimmune encephalomyelitis
1University of Illinois at Chicago, Neurology and Rehabilitation, Chicago, IL, United States, 2Columbia University, Psychiatry, New York, NY, United States
P406
Oleanolic acid controls oxidative stress to protect against optic nerve degeneration in an experimental model of multiple sclerosis
C Cordova1, B Gutierrez2, R Martin3, M Hernandez2, N Tellez4,
1IBGM-CSIC/Uva, I3U, Valladolid, Spain, 2IBGM-CSIC/UVa, I3U, Valladolid, Spain, 3Hospital Clinico Universitario, Valladolid, Spain, 4Hospital Clinico Universitario, Neurologia, Valladolid, Spain
P407
Relative protection of H.
M Boziki1, E Kofidou1, E Kesidou1, R Lagoudaki1, O Touloumi1, E Nousiopoulou1, N Delivanoglou1, K-N Poulatsidou1, K Papadakos2, D Sgouras2, E Panagiotopoulou2, A Mentis2, G Deretzi3, N Taskos4, D Karacostas4, J Kountouras5,
1Aristotle University of Thessaloniki, Laboratory of Experimental Neurology and Neuroimmunology, B’ Neurological Department, AHEPA General Hospital, Thessaloniki, Greece, 2Hellenic Pasteur Institute, Laboratory of Medical Microbiology, Athens, Greece, 3’G. Papageorgiou’ General Hospital, Neurology Clinic, Thessaloniki, Greece, 4Aristotle University of Thessaloniki, B’ Department of Neurology, Thessaloniki, Greece, 5Aristotle University of Thessaloniki, B’ Pathology Clinic, Thessaloniki, Greece
P408
B cell antigen presentation is sufficient to drive neuro-inflammation in an animal model of multiple sclerosis
CR Parker1, AS Archambault1, J Sim2, JH Russell2,
1Washington University in St. Louis, Neurology, St. Louis, MO, United States, 2Washington University in St. Louis, Developmental Biology, St. Louis, MO, United States
P409
Antigen-specific myeloid-derived suppressor cells ameliorate experimental autoimmune encaphalomyelitis
1Vall d’Hebron Institut de Recerca, Gene and Cell Therapy Lab, Barcelona, Spain, 2Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain
P410
TGM6 is highly expressed by reactive astrocytes in the murine spinal cord during EAE and its levels correlate with the disease course
1Tisch MS Research Center of New York, New York, NY, United States
Genetics and epigenetics
P411
Genetic modification of 25(OH)D levels in MS
1Harvard School of Public Health, Boston, MA, United States, 2Bayer Pharma AG, Berlin, Germany, 3University of Chicago Surgery Brain Research Institutes, Department of Neurology, Chicago, IL, United States, 4VU University Medical Center, Amsterdam, Netherlands, 5Università Vita-Salute San Raffaele, Department of Neurology and Institute of Experimental Neurology, Milan, Italy, 6Rutgers, The State University of New Jersey, Deptartment of Neurology and Neurosciences, Newark, NJ, United States, 7CHU-Hopital Pontchaillou, Rennes, France, 8Neuroimaging Research Unit, Division of Neuroscience, Scientific Institute and University Hospital San Raffaele, Milan, Italy, 9University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, 10University of California, Department of Neurology, San Francisco, CA, United States, 11Heinrich-Heine University, Department of Neurology, Düsseldorf, Germany, 12Wake Forest University School of Medicine, Winston-Salem, NC, United States, 13University Hospital Basel, Basel, Switzerland, 14UCL Institute of Neurology, London, United Kingdom, 15Hospital Universitari Vall d’Hebron, Barcelona, Spain, 16Division of Neurology, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, 17Technische Universität München, Munich, Germany, 18Max Planck Institute of Psychiatry, Munich, Germany, 19Bayer HealthCare Pharmaceuticals, Whippany, NJ, United States, 20University Hospital of Bonn, Department of Neurology, Bonn, Germany
P412
Multiple quantitative trait loci for anti-EBNA-1 IgG titres are associated with risk of multiple sclerosis
1Menzies Research Institute Tasmania, Hobart, Australia, 2Queensland Institute of Medical Research, Genetic Epidemiology, Molecular Epidemiology and Neurogenetics Laboratories, Queensland, Australia, 3Brigham & Women’s Hospital, Program in Translational NeuroPsychiatric Genomics, Institute for the Neuroscience, Department of Neurology, Boston, MA, United States, 4Monash University, Monash Antibody Technologies Facility, Melbourne, Australia, 5Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 6Texas Biomedical Research Institute, Department of Genetics, San Antonio, TX, United States
P413
A tumor necrosis factor beta NcoI polymorphism is associated with inflammatory and metabolic markers in multiple sclerosis patients
1State University of Londrina, Londrina, Brazil
P414
Impact of genetic risk loci in multiple sclerosis on expression of proximal genes
T James1, M Lindén1, M Huss2, M Brandi3, M Khademi1, J Tegnér4, D Gomez-Cabrero4,
1Karolinska Institutet, Clinical Neuroscience, Stockholm, Sweden, 2Stockhom Univiersity, Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm, Sweden, 3Royal Institute of Technology, Science for Life Labratory, Stockholm, Sweden, 4Karolinska Institutet, Department of Medicine, Stockholm, Sweden
We validated our findings in public RNA-seq data from lymphoblastic cell lines (LCLs) from 248 individuals with genotypes from the 1000 Genomes Project, and in sorted CD4+, CD8+, CD19+ and CD14+ cells from 57 individuals.
We confirmed previously observed eQTL effects, such as rs1021156 affecting FAM164A expression. We also report several new eQTLs such as rs1920296 that affects IQCB1 and rs4794058 that affects TBKBP1 and MRPL45P2. We further show that rs12946510 affects ORMDL3 transcription in CD19+ cells, and rs7595717 affects PLEK expression in CD4+ cells.
P415
Multiple sclerosis susceptibility genes are associated with cervical cord atrophy and may explain disability status
DA Akkad1, B Bellenberg2, S Esser1, JT Epplen1, R Gold3, C Lukas2,
1Ruhr-University Bochum, Department of Human Genetics, Bochum, Germany, 2Ruhr-University Bochum, Department of Radiology, Bochum, Germany, 3Ruhr-University Bochum, Department of Neurology, Bochum, Germany
P416
A genome-wide copy number variation study identified T-cell receptor as a susceptibility gene for multiple sclerosis and neuromyelitis optica
1Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Department of Neurology, Fukuoka, Japan, 2Research Center for Transomics Medicine, Medical Institute of Bioregulation, Kyushu University, Division of Genomics, Fukuoka, Japan, 3Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Department of Neurological Therapeutics, Fukuoka, Japan
P417
Genetic interaction analysis of multiple sclerosis risk loci
M Lindén1, I Lima Bomfim1, J Hillert1, L Alfredsson2, T Olsson1,
1Karolinska Institutet, Clinical Neuroscience, Stockholm, Sweden, 2Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
P418
Non-HLA risk genes in Dutch MS multiplex families
1Erasmus MC, Neurology, Rotterdam, Netherlands, 2University Medical Centre Groningen, Groningen, Netherlands
P419
Susceptibility variants for multiple sclerosis in the Japanese population
1Kyushu University, Neurology, Fukuoka, Japan, 2Medical Institute of Bioregulation, Kyushu University, Research Center for Transomics Medicine, Fukuoka, Japan, 3University of California, Neurology, San Francisco, CA, United States
P420
Genetic predictors of multiple sclerosis
1Ospedale Regionale Civico Lugano, Lugano, Switzerland, 2Queen Mary University of London, London, United Kingdom, 3University of Oxford, Oxford, United Kingdom
P421
The PhenoGenetic Project: a biobank with which to investigate the genetic and environmental architecture of immune variation in multiple sclerosis
1Brigham and Women’s Hospital, Center for Neurologic Diseases, Boston, MA, United States, 2Harvard Medical School, Boston, MA, United States, 3Brigham and Women’s Hospital, Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology and Psychiatry, Boston, MA, United States
P422
SNPs within genes for cytokines and their receptors modulate IFN-γ and TNF-α associations with relapse in multiple sclerosis
1Menzies Research Institute Tasmania, Hobart, Australia
P423
Age at onset and disease severity in primary progressive multiple sclerosis: a genome-wide association study, pathway and network analysis
1San Raffaele Scientific Institute, Institute of Experimental Neurology (INSPE), Milan, Italy, 2University of Eastern Piedmont, Department of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), Novara, Italy, 3AOU Maggiore della Carità, MS Centre, SCDU Neurology, Novara, Italy
P424
Evaluation of interlukin 18 gene polymorphism and plasma concentration of IL-18 and IL-36 in relapsing remitting multiple sclerosis patients
1Isfahan University of Medical Sciences, Molecular Biology Department, Isfahan, Iran, Islamic Republic of, 2Isfahan University of Medical Sciences, Isfahan MS and Neuroimmunology Reseach Center, Immunology Department, Isfahan, Iran, Islamic Republic of, 3Isfahan University of Medical Sciences, Isfahan MS and Neuroimmunology Reseach Center, Neurology Department, Isfahan, Iran, Islamic Republic of
P425
Magnetic resonance imaging findings in healthy, genetically characterized, asymptomatic first-degree relatives of multiple sclerosis patients
1Translational Neuroradiology Unit, NINDS, NIH, Bethesda, MD, United States, 2Program in Translational NeuroPsychiatric Genomics, Departments of Neurology, Brigham and Women’s Hospital, Boston, MA, United States, 3Harvard Medical School, Boston, MA, United States, 4National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, United States
P426
Target resequencing of regions associated with multiple sclerosis in the Italian population
N Barizzone1, S Anand2,3, M Sorosina4, E Mangano2, R Bordoni2, F Clarelli4, F Esposito4, O Raymkulova5, G Predebon6, V Martinelli4, G Comi4, M Leone4, G De Bellis2, F Martinelli Boneschi4,
1A. Avogadro University, IRCAD, Health Sciences, Novara, Italy, 2Institute for Biomedical Technologies (ITB) National Research Council (CNR), Milan, Italy, 3University of Sannio, Department of Science and Technology, Benevento, Italy, 4San Raffaele Scientific Institute, Milan, Italy, 5MS Centre, SCDU Neurology, AOU Maggiore della Carità, Novara, Italy, 6A. Avogadro University, Health Sciences, Novara, Italy
P427
Human Aquaporin 4 gene polymorphisms in Chinese patients with neuromyelitis optica spectrum disorders
1Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2School of Mathmatics and Computational Science, Sun Yat-sen University, Guangzhou, China, 3Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 4Fifth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
P428
Defining the functional role of a novel MS susceptibility gene, IL7R alpha chain
L Bergamaschi1, G Galarza-Muñoz2, F Briggs3, S Arvai1, L Barcellos4, M Garcia-Blanco5,
1Duke Molecular Physiology Institute, Medicine, Durham, NC, United States, 2Duke University, Molecular Gnetics and Microbiology, Durham, NC, United States, 3Case Western Reserve University, Epidemiology and Biostatistics, Cleveland, OH, United States, 4University of California, School of Public Health, Berkeley, CA, United States, 5Duke University Medical Center, Molecular Gnetics and Microbiology, Durham, NC, United States
P429
Progranulin gene variability influences recovery and residual disability after relapses in multiple sclerosis
1AOU Città della Salute e della Scienza di Torino, Torino, Italy, 2IRCSS Ospedale Maggiore Policlinico di Milano, Milano, Italy
Imaging-1
P430
White matter abnormalities and gray matter atrophy measurements in long disease duration multiple sclerosis: prediction of a benign course
1VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, Netherlands, 2Neuroscience Campus Amsterdam, Amsterdam, Netherlands, 3VU University Medical Center, Department of Anatomy and Neurosciences, Amsterdam, Netherlands, 4VU University Medical Center, Department of Physics and Medical Technology, Amsterdam, Netherlands, 5VU University Medical Center, Department of Neurology, Amsterdam, Netherlands, 6VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam, Netherlands
P431
Regional distribution and evolution of grey matter changes in different MS phenotypes: a 5-year longitudinal study
1University Hospital of Verona, Dept. of Neurological and Movement Sciences, Verona, Italy, 2Imperial College, Division of Brain Sciences, Faculty of Medicine, London, United Kingdom, 3Istituto Superiore di Sanità, Dept. of Cell Biology and Neuroscience, Rome, Italy, 4University of Padova, Dept. of Information Engineering, Padova, Italy, 5Imperial College, Neuroscience Dept., London, United Kingdom, 6Swansea University, Institute of Life Science ‘ILS’, Swansea, United Kingdom, 7Euganea Medica, Neuroradiology Unit, Padova, Italy, 8University of Padova, Dept. of Biology, Padova, Italy
P432
The association of thoracic spinal cord gray matter atrophy with disability and disease type in multiple sclerosis
1UCSF, Neurology, San Francisco, CA, United States, 2University Hospital Basel, University of Basel, Neurology, Basel, Switzerland, 3UCSF, Opthalmology, San Francisco, CA, United States, 4Bioengineering Graduate Group, University of California San Francisco & Berkeley, San Francisco & Berkeley, CA, United States, 5UCSF, Radiology and Biomedical Imaging, San Francisco, CA, United States
P433
Brain parenchymal fraction in the healthy - determined by MRI in an age stratified population and via a systematic review of the literature
1Umeå University, Dept. of Pharmacology and Clinical Neuroscience, Umeå, Sweden, 2Umeå University, Dept. of Radiation Sciences, Diagnostic Radiology, Umeå, Sweden
P434
The rate of GM lesion development is similar in all MS disease subtypes
1University of Nottingham, Division of Clinical Neurosciences, Nottingham, United Kingdom, 2University of Nottingham, Sir Peter Mansfield MR Centre, Nottingham, United Kingdom, 3Queen Elizabeth Hospital, London, United Kingdom, 4University of Nottingham, School of Psychology, Nottingham, United Kingdom
Measure the rate of cortical lesions accumulation at 14 months using more sensitive ultra high field imaging (7T).
Assess the association between the rate of cortical and white matter lesion (WML) accumulation with the disability progression.
P435
Motor network global and local efficiency changes across the MS spectrum
1UCL Institute of Neurology, NMR Research Unit, Queen Square MS Center, London, United Kingdom, 2University of Genoa, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Genoa, Italy, 3University Hospital Basel, Department of Neurology, Basel, Switzerland, 4Cardiff University, Department of Psychology, Cardiff, United Kingdom, 5Xuanwu Hospital of Capital Medical University, Beijing, China, 6National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London, United Kingdom
P436
The link between subpial and diffuse white matter pathology in MS: a multimodal 7T and 3T MRI study using a surface-based and a tract-based analysis
1AA Martinos Center for Biomedical Imaging, Charlestown, MA, United States, 2Harvard University, Boston, MA, United States, 3Ecole Polytechnique de Montréal, Montreal, QC, Canada, 4Beth Israel Deaconess Medical Center, Boston, MA, United States
the relationship between subpial pathology and juxta-cortical WM injury using a surface-based method,
the relationship between subpial pathology and “long distance” WM injury in tractographically connected tracts as a function of distance from the cortex,
the relative contribution of subpial and WM damage to clinical metrics.
T1-weighted images optimized for cortical surface reconstruction using FreeSurfer,
diffusion tensor images (DTI, 1.85 mm iso, 60 directions). T2* maps were registered to cortical surfaces, and sampled along the cortex at 25%, 50%, 75% depth from pial surface.
WM tracts of interest (cingulum, corticospinal tract, CST, thalamic radiation, longitudinal fasciculus) were reconstructed using probabilistic tractography. The relationship between DTI metrics at each voxel along the tracts and laminar T2* in the projection cortex was tested with a multi-linear regression model. The relationship between T2* at each cortical depth and juxta-cortical WM pathology (DTI metrics sampled at 2mm below the cortex) was tested vertex-wise using a General Linear Model (GLM).
P437
Multiple sclerosis lesion fingerprint using quantitative MRI multicontrast analysis
1University of Lausanne, Lausanne, Switzerland, 2Advanced Clinical Imaging Technology Group, Siemens-EPFL, Lausanne, Switzerland, 3Ecole Polytechnique Federale Lausanne, STI / IEL / LTS5, Lausanne, Switzerland, 4Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Department of Clinical Neurosciences, Lausanne, Switzerland, 5Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Department of Radiology, Lausanne, Switzerland, 6University of Verona, Department of Computer Science, Verona, Italy, 7Max Planck Institute for Biophysical Chemistry, Biomedizinische NMR Forschungs GmbH, Goettingen, Germany, 8Siemens Schweiz AG, Healthcare Sector IM&WS S, Renens, Switzerland
P438
Texture of deep gray matter areas relates to disability in multiple sclerosis
1University Hospital Basel, Department of Neurology, Basel, Switzerland, 2Centre for Addiction and Mental Health, Kimel Family Translational Imaging-Genetics Research Laboratory, Research Imaging Centre, Toronto, ON, Canada, 3University of Toronto, Department of Psychiatry and Institute of Biomaterials and Biomedical Imaging, Toronto, ON, Canada, 4University Hospital Basel, Medical Image Analysis Center, Basel, Switzerland, 5University Hospital Basel, Department of Radiology, Division of Diagnostic and Interventional Neuroradiology, Basel, Switzerland
P439
Sustained low rate of brain volume loss under long-term fingolimod treatment in relapsing multiple sclerosis: results from the LONGTERMS study
1Medical Image Analysis Center (MIAC), Basel, Switzerland, 2VU University Medical Center, Amsterdam, Netherlands, 3Cleveland Clinic, Neurological Institute, Cleveland, OH, United States, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States, 6University Hospital, Department of Neurology, Basel, Switzerland
Results up to month (M) 72 are presented for those patients who received continuous fingolimod 0.5 mg throughout core and extension and those who switched from placebo to fingolimod (placebo-fingolimod).
P440
Iron in multiple sclerosis lesions can be detected by larger volumes on quantitative susceptibility mapping than on T2 weighted imaging
1Cornell University, Ithaca, NY, United States, 2Weill Medical College, New York, NY, United States, 3Yale University, New Haven, CT, United States, 4Yale University, New Haven, NY, United States
P441
Grey matter abnormalities in mesial temporal lobe characterize patients with multiple sclerosis and epilepsy
1University Hospital of Verona, Dept. of Neurological and Movement Sciences, Verona, Italy, 2University of Naples Federico II, Department of Pharmacology, Napoli, Italy, 3University of Padova, Department of Information Engineering, Padova, Italy, 4Euganea Medica, Neuroradiology Unit, Padova, Italy, 5Multiple Sclerosis Centre, ULSS 6, Vicenza, Italy
P442
OASIS and SuBLIME software for MS lesion segmentation
1Johns Hopkins, Department of Biostatistics, Baltimore, MD, United States, 2University of Pennsylvania, Department of Biostatistics and Epidemiology, Philadelphia, PA, United States, 3Johns Hopkins, Institute of Genetic Medicine, Baltimore, MD, United States, 4National Institute of Neurological Disorders and Stroke, Translational Neuroradiology Unit, Bethesda, MD, United States
P443
Myelin water MRI reveals long-term demyelination in normal appearing white matter from relapsing remitting multiple sclerosis
1University of British Columbia, Radiology, Vancouver, BC, Canada, 2University of British Columbia, Physics and Astronomy, Vancouver, BC, Canada, 3University of British Columbia, Medicine, Vancouver, BC, Canada, 4University of British Columbia, Pathology and Laboratory Medicine, Vancouver, BC, Canada
P444
Extended cortical lesion determining acute relapses in multiple sclerosis
M Puthenparampil1, D Poggiali1, P Perini1, F Rinaldi1, G Rolma1, F Causin1,
1University of Padova, Department of Neuroscience SNPSRR, Padova, Italy
Wernicke’s aphasia,
agraphia with acalculia not associated to motor deficit or linguistic disturbance,
hyposthenia of the left arm followed by muscle twitching of the hand, spreading to arm and face,
acute onset of left lower limb paroxysmal hypertonia,
temporal lobe status epilepticus with psychotic symptoms mimicking encephalitis.
DIR and PSIR disclosed large, snake-like, inflammatory lesions in the corresponding cortex. The symptoms completely recovered after high-dose steroid therapy.
P445
Brain positron emission tomography scanning can be used to image pathological determinants of progressive multiple sclerosis
1Turku University Hospital, Turku, Finland, 2Turku PET Centre, Turku, Finland
P446
In vivo characterization of axonal damage in multiple sclerosis using high-gradient diffusion magnetic resonance imaging
1Massachusetts General Hospital, Department of Radiology, Boston, MA, United States, 2Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Boston, MA, United States, 3Massachusetts General Hospital, Department of Neurology, Boston, MA, United States, 4Stanford University, Richard M. Lucas Center for Imaging, Department of Radiology, Stanford, CA, United States
Sagittal 2-mm diffusion-weighted stimulated-echo echo planar images were acquired with 17 diffusion gradient increments (30-272 mT/m) and 5 diffusion times (11-96 ms) (b-values 400-10,000 s/mm2). Diffusion gradients were applied in the z-direction, perpendicular to the callosal fibers. Total acquisition time was 52 minutes.
The AxCaliber model of diffusion in intra- and extra-axonal compartments was used to estimate axon diameter and density in the mid-sagittal corpus callosum within regions of interest (ROIs) drawn in T2 hyperintense lesions in MS subjects, normal-appearing white matter (NAWM) of the genu, body and splenium in MS subjects and similar locations in HCs. Mean axon diameter and density were compared between MS lesion ROIs and NAWM ROIs in the same MS subjects using the Wilcoxon matched-pair sign-rank test and between groups using the Mann-Whitney U test.
P447
Bi-directional trans-synaptic degeneration in the visual pathway in multiple sclerosis
1VU University Medical Centre, Amsterdam, Netherlands
P448
Evidence of resting-state fMRI functional connectivity abnormalities in pediatric-onset MS and the relation to structural damage and cognition
1The Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Institute of Medical Science, Toronto, ON, Canada, 3York University, Psychology, Toronto, ON, Canada, 4Rotman Research Institute, Baycrest, Toronto, ON, Canada, 5Montreal Neurological Institute, Montreal, QC, Canada, 6Children’s Hospital of Philadelphia, Philadelphia, PA, United States
P449
Improved white matter integrity with natalizumab treatment in multiple sclerosis
1VU University Medical Center, Radiology and Nuclear Medicine, Amsterdam, Netherlands, 2VU University Medical Center, Anatomy and Neurosciences, Amsterdam, Netherlands, 3VU University Medical Center, Neurology, Amsterdam, Netherlands, 4VU University Medical Center, Physics & Medical Technology, Amsterdam, Netherlands
P450
Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis
1VU University Medical Center, Dept of Radiology and Nuclear Medicine, Amsterdam, Netherlands, 2VU University Medical Center, Dept of Anatomy and Neurosciences, Amsterdam, Netherlands, 3VU University Medical Center, Dept of Physics and Medical Technology, Amsterdam, Netherlands, 4VU University Medical Center, Dept of Neurology, Amsterdam, Netherlands
P451
Attenuated BOLD hemodynamic response predicted by degree of white matter insult, slows cognition in multiple sclerosis
1University of Texas at Dallas, Dallas, TX, United States, 2University of Texas Southwestern Medical Center, Dallas, TX, United States
To examine the extent to which functional magnetic resonance imaging (fMRI) activity within executive brain regions differs during cognition for patients with MS (MSPs) compared to healthy controls (HCs).
To examine if differences in activity in MSPs are predicted by their degree of white matter insult.
To examine if brain activity or white matter insult mediate cognitive slowing in MSPs.
MSPs were slower than HCs on processing speed performance, t(49) = 2.31, p = .025. Further, MSPs had a significantly attenuated BOLD-hemodynamic response compared to HCs in DLPFC during processing speed performance t(49) = −3.42, p = .001.
In MSPs increasing white matter insult significantly decreased the BOLD-hemodynamic response, r = −.52, p < .0011.
Using multivariate regression, we found that the BOLD-hemodynamic response in DLPFC significantly predicted processing speed performance when controlling for white matter insult, partial r = −.464, p = .0191.
1Two multivariate outliers (x > 95% UCL) were excluded from these analyses.
Cognitive slowing and accompanying decreased DLPFC BOLD-hemodynamic response for patients with relapsing-remitting MS compared HCs were confirmed in the present study.
Decreased BOLD-hemodynamic activity was predicted by increased individual differences in white matter insult in patients with relapsing-remitting MS.
Although, the degree of white matter integrity predicted DLPFC BOLD-hemodynamic activity, it did not mediate the relationship between activity and cognitive slowing. Such a difference suggests that MS-related cognitive slowing might be related to the break down of functional neural mechanisms, rather than structural.
P452
Disrupted distant functional connectivity within the temporoparietal junction is linked to impaired attention in multiple sclerosis
1Massachusetts General Hospital, Harvard Medical School, Neurology, Boston, MA, United States, 2Massachusetts General Hospital, Harvard Medical School, Psychiatry, Boston, MA, United States, 3Massachusetts General Hospital, Harvard Medical School, Radiology, Boston, MA, United States
P453
The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis
1University of Colorado School of Medicine, Department of Neurology, Aurora, CO, United States, 2Analysis Group, Inc., Boston, MA, United States, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
P454
Multivoxel MR spectroscopy in a pilot crossover study of natalizumab to dimethyl fumerate therapy
1LDS Hospital and Intermountain Health Care, Radiology, Salt Lake City, UT, United States, 2Rocky Mountain MS Research Group, Salt Lake City, UT, United States
P455
Normal appearing white matter injury in MS is affected by the distance to the nearest cortical lesion
1University of Nottingham, Division of Clinical Neurosciences, Nottingham, United Kingdom, 2University of Nottingham, Sir Peter Mansfield MR Centre, Nottingham, United Kingdom, 3Leicester Royal Infirmary, Leicester, United Kingdom, 4University of Nottingham, Nottingham, United Kingdom, 5University of Nottingham, School of Psychology, Nottingham, United Kingdom
A one sample Wilcoxon signed rank showed that the regression slopes were significantly positive (p < 0.0123), suggesting a significant linear dependence of NAWM MTR values on the distance to GM lesions.
P456
Dynamics of brain iron accumulation differ between clinically isolated syndrome and definite multiple sclerosis: a longitudinal 3T MRI study
1Medical University of Graz, Graz, Austria
P457
Region of interest based grey matter volumetry identifies clinically meaningful atrophy in early relapsing forms of multiple sclerosis
R Opfer1, A Tewes1,
1Jung Diagnostics GmbH, Hamburg, Germany, 2University Medical Center Hamburg Eppendorf, Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (INIMS), Hamburg, Germany, 3University Hospital Zurich, Neuroimmunology and Multiple Sclerosis Research Section (nims), Department of Neurology, Zurich, Switzerland
P458
Comparison of spinal cord area between spinal cord measurements using different coils in multiple sclerosis patients with 3.0T MRI
1Vall Hebron University Hospital, Magnetic Resonance Unit, Neuroradiology Dept., Barcelona, Spain, 2Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Dept., Barcelona, Spain
P459
Increased gray matter lesion detection in MS with 7 Tesla MRI: a post-mortem verification study
1VU University Medical Center, Anatomy and Neurosciences, Amsterdam, Netherlands, 2VU University Medical Center, Radiology, Amsterdam, Netherlands, 3University Medical Center Utrecht, Radiology, Utrecht, Netherlands, 4University Medical Center Utrecht, Neurology, Utrecht, Netherlands, 5VU University Medical Center, Physics and Medical Technology, Amsterdam, Netherlands
*Both authors contributed equally to this work
P460
Thalamus structure and function determines severity of cognitive impairment in multiple sclerosis
1VU University Medical Center, Anatomy and Neurosciences, Amsterdam, Netherlands, 2VU University Medical Center, Radiology, Amsterdam, Netherlands, 3VU University Medical Center, Neurology, Amsterdam, Netherlands
P461
Regional white matter abnormalities and cognitive impairment in MS: a multicenter TBSS study
1San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Neuroimaging Research Unit, Institute of Experimental Neurology, Milan, Italy, 2San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Department of Neurology, Milan, Italy, 3VU Medical Centre, Radiology and Image Analysis Centre (IAC), Amsterdam, Netherlands, 4Institute of Neurology, UCL, Department of Brain Repair and Rehabilitation, London, United Kingdom, 5University of Siena, Dept. of Medicine, Surgery & Neuroscience, Siena, Italy, 6Medical University of Graz, Department of Neurology, Graz, Austria, 7Second University of Naples, Department of Neurology, Naples, Italy
global cognitive and attention Z score vs FA/MD abnormalities of most of the damaged areas described above;
visual memory Z score vs FA of the corpus callosum and right inferior fronto-occipital fasciculus;
verbal memory Z score vs MD abnormalities of most of the damaged areas; and
WCST scores vs MD of the corticospinal tract, superior longitudinal fasciculus, left inferior fronto-occipital fasciculus, forceps major, fornix, anterior thalamic radiation and left cingulum.
P462
Thalamic tract integrity changes are associated with cognition and disinhibition in multiple sclerosis
1VU University Medical Center, Anatomy and Neurosciences, Amsterdam, Netherlands, 2University at Buffalo State University of New York, Department of Neurology, School of Medicine and Biomedical Sciences, Buffalo, NY, United States, 3VU University Medical Center, Radiology, Amsterdam, Netherlands, 4University at Buffalo State University of New York, Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, Buffalo, NY, United States, 5Don Gnocchi Foundation, IRCCS, Milan, Italy, 6MRI Clinical Translational Research Center, School of Medicine and Biomedical Sciences, Buffalo, NY, United States
P463
Multimodal quantitative magnetic resonance imaging of thalamus in multiple sclerosis and neuromyelitis optica
J Wang1,
1Hangzhou Normal University, Hangzhou, China, 2Xuanwu Hospital, Beijing, China, 3VU Medical Center, Amsterdam, Netherlands
P464
Memory impairment in multiple sclerosis: relevance of hippocampal activation and hippocampal connectivity
1VU University Medical Center, Anatomy and Neurosciences, Amsterdam, Netherlands, 2VU University Medical Center, Neurology, Amsterdam, Netherlands, 3VU University Medical Center, Radiology, Amsterdam, Netherlands
P465
Volumetric imaging of grey and white matter in the human brain
1McMaster University, School of Biomedical Imaging, Hamilton, ON, Canada, 2Wayne State University, MR Research Facility, Detroit, MI, United States, 3Royal Victoria Regional Health Center, Barrie, ON, Canada, 4MRI Institute of Biomedical Research, Detroit, MI, United States
P466
Brain sodium MRI in multiple sclerosis: a promising tool to monitor disability
1CRMBM UMR 7339 CNRS Aix-Marseille Universite, Marseille, France, 2Computer Assisted Clinical Medicine, Heidelberg University, Mannheim, Germany
Patients with progressive MS showed diffuse sodium accumulation only in the grey matter, and especially in regions involved in motor and cognitive functions predominantly altered in this form of MS (primary motor cortices, premotor cortices, cerebellum, thalami, limbic and frontal networks).
Interestingly, higher was the level of disability in patients whatever the stage of MS, higher was the local sodium concentration inside the following grey matter regions: right primary motor area, right middle frontal gyrus, left premotor cortex, bilateral superior frontal gyri and the bilateral cerebellum.
P467
Measurement of cortical thickness and volume of subcortical structures in multiple sclerosis: agreement between 2D and 3D T1-weighted images
1Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain, 2Vall Hebron University Hospital, Magnetic Resonance Unit, Neuroradiology Department, Barcelona, Spain
P468
Diffusion tensor imaging reveals distinct patterns of white matter changes in pediatric monophasic demyelinating disorders and multiple sclerosis
1San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience and Department of Neurology, Milano, Italy, 2McGill University, Montreal Neurological Institute, McConnell Brain Imaging Centre, Montreal, QC, Canada, 3McGill University, Centre for Intelligent Machines, Montreal, QC, Canada, 4Children’s Hospital of Philadelphia, University of Pennsylvania, Division of Neurology, Philadelphia, PA, United States
As expected, FA decreased and MD increased more steeply over time in MS compared to children with mADS; nonetheless, FA and MD trajectories in both groups significantly differed from those expected from their age-dependent baseline trajectories.
FA trajectories were similar between mADSp (n=11) and MS, both decreasing significantly faster than ADEM (n=18) and baseline trajectories.
Longitudinal FA and MD were not significantly different between mADST2+ (n=17) and MS; in both groups, longitudinal FA decreased more steeply than mADST2-, and differed significantly from the baseline trajectory.
P469
Effective connectivity of the default mode network in MS patients: increased self-inhibition of the posterior cingulate cortex
1University of Verona, Department of Neurological and Movement Sciences, Verona, Italy, 2University of Padova, Department of Information Engineering, Padova, Italy
P470
Evolution of gadolinium-enhancing lesions into chronic black holes in patients treated with subcutaneous interferon β-1a in PRISMS and SPECTRIMS
1University of British Columbia, Vancouver, BC, Canada, 2EMD Serono, Inc., Rockland, MA, United States, 3University Hospital Basel, Basel, Switzerland
P471
Ultra-high field MRI of intra- and extra-cellular sodium concentration in multiple sclerosis
1Mount Sinai School of Medicine, Neurology, New York, NY, United States, 2Federico II University, Neuroscience, Naples, Italy, 3Mount Sinai School of Medicine, Radiology, New York, NY, United States, 4New York University, Radiology, New York, NY, United States, 5New York University, Neurology, New York, NY, United States, 6Mount Sinai School of Medicine, Neuroscience, New York, NY, United States
To measure TSC, ISC and ESC in MS patients using triple-quantum sodium MRI at 7 Tesla (7T);
to investigate the associations between TSC, ISC and ESC and measures of lesion and brain volume;
to assess the clinical significance of ISC and ESC.
Between groups comparison was performed with an ANCOVA test controlling for age, gender and intra-cranial volume. The correlation between sodium MRI-derived parameters, proton MRI-derived measures and clinical scores were assessed using Spearman’s rank correlation coefficient.
ISC resulted significantly higher and ISVF lower in thalamus, frontal middle gyrus, precentral gyrus and superior longitudinal fasciculus bilaterally, in the left insula and cortico-spinal tract and in the forceps minor (p< 0.05, Ke=10). Global GM ISVF showed a correlation trend with EDSS (r=−0.47, p=0.054) and global GM ISC showed a correlation with T2 lesion volume (r=0.50, p< 0.05).
P472
Cervical cord area measurement using volumetric brain magnetic resonance imaging
Z Liu1,2,
1Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom, 2Xuanwu Hospital of Capital Medical University, Department of Neurology, Beijing, China, 3University of Genoa, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Genoa, Italy, 4National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London, United Kingdom
to determine if an active surface model frequently used to measure cord cross-sectional area at C2/3 could be reliably used at to measure the cord area at higher levels in short (0.5cm) segments; and
to explore whether cord area measures at these higher levels would be a plausible alternative to the area obtained at the standard C2/3 level.
P473
Natural evolution of gadolinium-enhancing lesions into chronic black holes in multiple sclerosis: analysis of PRISMS and SPECTRIMS placebo arms
1University of British Columbia, Vancouver, BC, Canada, 2EMD Serono, Inc., Rockland, MA, United States, 3University Hospital Basel, Basel, Switzerland
P474
Unraveling the neuroimaging markers of motor dysfunction in long-standing multiple sclerosis
1VU University Medical Center, Radiology and Nuclear Medicine, Amsterdam, Netherlands, 2VU University Medical Center, Anatomy and Neurosciences, Amsterdam, Netherlands, 3VU University Medical Center, Neurology, Amsterdam, Netherlands
P475
MRI correlates of disability: neuroimaging substudy at 20-years in the ongoing US glatiramer acetate open-label extension study
1Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI, United States, 2Sastry Foundation Advanced Imaging Laboratory, Wayne State University School of Medicine, Detroit, MI, United States, 3Wayne State University School of Medicine, Department of Diagnostic Radiology, Detroit, MI, United States, 4Teva Pharmaceutical Industries, Netanya, Israel, 5Teva Pharmaceutical Industries, Cleveland, OH, United States
P476
MS cortex-study: the association of cortical thickness and cortical lesions with clinical symptoms in multiple sclerosis
1University Hospital Zurich, Department of Neurology, Zurich, Switzerland, 2Luzerner Kantonsspital, Department of Internal Medicine, Centre of Neurology and Neurorehabilitation, Luzern, Switzerland, 3University of Zurich, Institute of Psychology, Division of Neuropsychology, Zurich, Switzerland, 4Medizinisch Radiologisches Institut, Zurich, Switzerland
P477
Tissue-specific brain volume changes on natalizumab: a 36-month follow-up study using VBM
1Vall Hebron University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona, Spain, 2Vall Hebron University Hospital, Magnetic Resonance Unit, Neuroradiology Department, Barcelona, Spain
P478
Slowly expanding lesions in MS: a histopathological mirage?
1NINDS, NIH, Translational Neuroradiology Unit, Neuroimmunology Branch, Bethesda, MD, United States
P479
MRI reveals connectivity of cortical lesions to deep white matter lesions in multiple sclerosis
1Mayo Clinic, Neurology, Rochester, MN, United States, 2Mayo Clinic, Biomedical Statistics and Informatics, Rochester, MN, United States, 3Mayo Clinic, Radiology, Rochester, MN, United States, 4Mayo Clinic, Biomedical Engineering and Medical Physics, Rochester, MN, United States
P480
Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study
1VU University Medical Center, Anatomy and Neurosciences, Amsterdam, Netherlands, 2VU University Medical Center, Radiology, Amsterdam, Netherlands, 3VU University Medical Center, Pathology, Amsterdam, Netherlands
P481
Corpus callosum atrophy is associated with cognitive impairment in multiple sclerosis: results of a 17-year longitudinal study
1Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Stockholm, Sweden, 2Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
P482
Functional and structural connectivity abnormalities underlying clinical disability in multiple sclerosis
1University Sapienza, Neurology and Psychiatry, Rome, Italy, 2Santa Lucia Fundation, Rome, Italy, 3FMRIB Centre, Oxford, United Kingdom
P483
Longitudinal DMN changes in cognitively preserved MS patients
1Second University of Naples, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Naples, Italy, 2MRI Research Centre SUN-FISM - Neurological Institute for Diagnosis and Care ‘Hermitage Capodimonte’, Naples, Italy, 3University of Salerno, Department of Medicine and Surgery, Salerno, Italy
To compare DMN functional connectivity (FC) between CP-MS and HC at baseline (BL) and at 2-year follow-up (FU).
The HC group was matched for age, sex and education.
Both groups were re-assessed after 2 years and only persistent CP subjects - 12 out of 16 MS patients and 12 out of 13 HC - were retained in the study for the analysis.
The MRI data were acquired by a 3 Tesla GE scanner equipped with a 8-channel coil.
The preprocessing of resting state-fMRI (rs-fMRI) data, statistical analysis and visualization were performed by BrainVoyager QX. The individual and group-level ICA analysis was carried out on functional time series preprocessed by fast-ICA and sog-ICA algorithms.
CP-MS compared to HC at each time-point showed: at BL, a reduced FC in the anterior node (AN), as well as an increased FC in the peripheral PN of the DMN; at FU no differences within the AN, and a persistent increased FC in the peripheral PN of the DMN.
P484
White matter lesion central veins: an interscanner comparison of patients with multiple sclerosis and ischemic lesions at 3-Tesla MRI
1University of Nottingham, Division of Clinical Neuroscience, Nottingham, United Kingdom, 2Nottingham University Hospitals NHS Trust, Department of Medical Physics, Nottingham, United Kingdom, 3University of Nottingham, Division of Radiological and Imaging Sciences, Nottingham, United Kingdom, 4University of Nottingham, Sir Peter Mansfield Magnetic Resonance Centre, Nottingham, United Kingdom
Intralesional vein numbers in the MS group differed between scanners despite the same core gradient echo sequence being used. The mean number identified using scanner A, standard T2* was 15.3 (range 2-36) vs 5.5 (range 0-11) using scanner B. T2* with EPI factor allowed the most number of veins to be identified (mean 45.6, range 5-101) compared to the standard T2* gradient echo on the same scanner. WM lesion numbers differed between scanners. The mean lesion number in the MS group on scanner A, standard T2* being 49.7 vs 14 using scanner B. T2* with EPI factor allowed higher lesion counts (mean 71.2). FLAIR allowed the highest lesion counts but numbers differed between scanners (78.7 vs 46.6, MS group). Similar findings were seen in the ischemic group.
P485
Inflammation does not cause chronic global neurodegeneration in NMO? A longitudinal multimodel quantitative MRI study comparing NMO and MS
1University of Oxford, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom, 2Oxford University Hospitals NHS Trust, Department of Neurology, Oxford, United Kingdom, 3University of British Columbia, Vancouver, BC, Canada, 4University of Bristol, Clinical Research and Imaging Centre, Bristol, United Kingdom
Longitudinal: Reduction in brain volume over the year was greatest in the RRMS group but did not reach statistical significance. Significant atrophy of the temporal lobes and thalami along with areas of progressive change in DTI and MWI metrics were found in the RRMS only.
P486
Functional >changes in default mode network activity - the most sensitive resting state fMRI parameter for short-term longitudinal changes in MS
1Medical University Graz, Graz, Austria, 2Radboud University Nijmegen, Nijmegen, Netherlands, 3University of Oxford, Oxford, United Kingdom
P487
Functional MRI encoding task for faces in multiple sclerosis
1San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Neuroimaging Research Unit, Institute of Experimental Neurology, Milan, Italy, 2San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Department of Neurology, Milan, Italy, 3San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Department of Neuroradiology, Milan, Italy
P488
Brain atrophy quantification in multiple sclerosis
1icoMetrix, Leuven, Belgium, 2VU University Medical Center, Amsterdam, Netherlands, 3Antwerp University Hospital, Antwerp, Belgium
20 multiple sclerosis patients participated in a study at VU University Medical Center, Amsterdam, the Netherlands. They were scanned on a 3T whole body scanner (GE Signa HDxt, Milwaukee, WI, USA). Expert lesion identification and manual segmentation was performed based on the FLAIR images by a highly trained neuroradiological team.
WM, GM and CSF percentages within the expert-segmented lesions are compared between the segmentation of the 3D T1-weighted images before and after lesion filling using unpaired t-tests.
P489
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in MS lesions via conventional clinical imaging
1National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, United States, 2University of British Columbia, Statistics, Vancouver, BC, Canada, 3University of Florence, Neurology and Radiology, Florence, Italy, 4Myelin Repair Foundation, Saratoga, CA, United States
P490
The value of MRS, a novel MRI technique, as a predictor of disability: analysis at 20-years of RRMS patients treated long-term with glatiramer acetate
1Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI, United States, 2Sastry Foundation Advanced Imaging Laboratory, Wayne State University School of Medicine, Detroit, MI, United States, 3University of New Mexico Health Sciences Center, Albuquerque, NM, United States, 4Teva Pharmaceutical Industries, Cleveland, OH, United States, 5Teva Pharmaceutical Industries, Netanya, Israel
Footnotes
Underlining of author represents the presenting author in each abstract